CHAPTER 138

Androgen Physiology, Pharmacology, and Abuse

David J. Handelsman

CHAPTER OUTLINE

KEY POINTS

- Understanding androgen physiology is essential to making the best use of androgen pharmacology.
- Testosterone is the major circulating androgen in males, secreted by testicular Leydig cells, with its biological effects manifest by binding and stimulation of androgen receptors.
- The full spectrum of testosterone effects also depends on indirect effects manifest via pre-receptor activation of testosterone's bioactive metabolites, dihydrotestosterone and estradiol, acting on androgen receptor and estrogen receptors, respectively.
- Androgen pharmacology consists of (1) androgen replacement therapy that employs testosterone at physiologic doses to rectify pathologic androgen deficiency, and (2) pharmacologic androgen therapy that utilizes any androgen and dosage that is safe and cost-effective regardless of gonadal status.
- Nonpathological (functional) causes of androgen deficiency require sound evidence of safety, efficacy, and cost-effectiveness to justify pharmacological androgen therapy.
- Numerous testosterone products are available allowing for individual optimization of replacement regimens to achieve maximal convenience and long-term compliance for lifelong testosterone replacement therapy.

An androgen, or male sex hormone, is defined as a substance capable of developing and maintaining masculine characteristics in reproductive tissues (notably the genital tract, secondary sexual characteristics, and fertility) and contributing to the anabolic status of somatic tissues.

Testosterone is the principal androgen in the circulation of mature male mammals. It includes a characteristic four-ring C18 steroid structure and is synthesized mainly by Leydig cells, located in the interstitium of the testis between the seminiferous tubules. Leydig cell secretion

creates a high local concentration of testosterone in the testis as well as a steep downhill concentration gradient into the bloodstream, maintaining circulating testosterone levels that exert characteristic androgenic effects on distant androgen-sensitive target tissues. The classic biological effects of androgens are primarily mediated by binding to the androgen receptor, a member of the steroid nuclear receptor superfamily encoded by a single gene located on the X chromosome, which then leads to characteristic patterns of gene expression by regulating the transcription of an array of target genes. This physiologic definition of an androgen in the whole animal is now complemented by a biochemical and pharmacologic definition of an androgen as a chemical that effectively competes with testosterone binding to the androgen receptor (AR)[1] to stimulate postreceptor functions in isolated cells or cell-free systems. In addition, nongenomic mechanisms of androgen action involving rapid, membrane-mediated nontranscriptional processes in the cytoplasm have been described but not yet fully characterized.[2-4]

Testosterone is used clinically at physiologic doses for androgen replacement therapy, and, at typically higher doses, testosterone, or more usually synthetic androgens based on its structure, is also used for pharmacologic androgen therapy. The principal goal of androgen replacement therapy is to restore a physiologic pattern of androgen exposure to all the body's tissues. Such treatment is usually restricted to the major natural androgen, testosterone, aiming to replicate physiologic circulating testosterone levels and the full spectrum (including prereceptor androgen activation) of endogenous androgen effects on tissues and recapitulating the natural history of efficacy and safety.[5] By contrast, pharmacologic androgen therapy exploits the anabolic or other effects of androgens on muscle, bone, and other tissues as hormonal drugs, which are judged on their efficacy, safety, and relative cost effectiveness similar to any other therapeutic agents. Insight into the physiology of testosterone is a prerequisite for understanding and making the most effective use of androgen pharmacology.[6,7]

TESTOSTERONE PHYSIOLOGY

Biosynthesis

Testosterone, synthesized by an enzymatic sequence of steps from cholesterol[8,9] (Fig. 138-1) within the 500 million Leydig cells located in the interstitial compartment of the testis between the seminiferous tubules, constitutes approximately 5% of mature testis volume (see Chapter 136 for details).[10] The cholesterol is predominantly formed by de novo synthesis from acetate, although preformed cholesterol either from intracellular cholesterol ester stores or extracellular supply from circulating low-density lipoproteins also contributes.[9] Testosterone biosynthesis involves two multifunctional cytochrome P-450 complexes involving hydroxylations and side-chain scissions (cholesterol side-chain cleavage [CYP11A1,P450c11 or P450scc, which produces C20 and C22 hydroxylation and C20,22 lyase activity] and 17-hydroxylase/17,20 lyase [which hydroxylates the C17 and then excises two carbons (20 and 21) converting a 21- to a 19-carbon structure]) together with 3 and 17β-hydroxysteroid dehydrogenases and $\Delta^{4,5}$ isomerase. The highly tissue-selective regulation of the 17,20 lyase activity (active in gonads but inactive in adrenals) independently of 17-hydroxylase activity (active in all steroidogenic tissues) is a key branch-point in steroidogenic pathways. Both activities reside in a single, multifunctional protein with the directionality of pathway flux determined by enzyme cofactors, notably electron supply from NADPH via the P450 oxidoreductase (POR), a membrane-bound flavoprotein serving diverse roles as a reductase and cytochrome b_5.[11] In addition, some extragonadal biosynthesis of testosterone and dihydrotestosterone from circulating weak adrenal androgen precursor DHEA within specific tissues has been described[12]; however, the net contribution of adrenal androgens to circulating testosterone in men is minor,[13,14] although it makes a much larger proportional contribution to circulating testosterone in women.[15,16]

Testicular testosterone secretion is principally governed by luteinizing hormone (LH) through its regulation of the rate-limiting conversion of cholesterol to pregnenolone within Leydig cell mitochondria by the cytochrome P-450 cholesterol side-chain cleavage enzyme (CYP11A1) complex located on the inner mitochondrial membrane. Cholesterol supply to mitochondrial steroidogenic enzymes is governed by proteins including sterol carrier protein 2.[17] This facilitates cytoplasmic transfer of cholesterol to mitochondria together with steroidogenic acute regulatory protein[18] and peripheral benzodiazepine receptor,[19] which govern cholesterol transport across the mitochondrial membrane. All subsequent enzymatic steps are located in the Leydig cell endoplasmic reticulum. The high testicular production rate of testosterone creates both high local concentrations (up to 1 μg/g tissue, ~100 times higher than blood concentrations) and rapid turnover (200 times per day) of intratesticular testosterone[20]; however, the precise physical state in which such high concentrations of intratesticular testosterone and related steroids exist in the testis remains to be clarified.

Secretion

Testosterone is secreted at adult levels during three epochs of male life: transiently during the first trimester of intrauterine life (coinciding with masculine genital tract differentiation), during early neonatal life as the perinatal androgen surge (with still undefined physiologic significance), and continually after puberty to maintain virilization. The dramatic somatic changes of male puberty are the consequence of striking increases in testicular secretion of testosterone, rising ~thirtyfold over levels that prevail in prepubertal children and in women or castrate men originating from extratesticular sources. After middle age, there are gradual decreases in circulating testosterone as well as increases in gonadotrophin and sex hormone–binding globulin (SHBG) levels[21,22] with these trends being absent until late old age among men who remain in excellent health[23,24] but exaggerated by the coexistence of chronic illness[22,25-27] as well as temporal trends including increasing prevalence of obesity[28,29] and immunoassay-derived artifacts from substitutions of assay reagents.[30,31] These age-related changes from



Figure 138-1 **Pathways of testosterone biosynthesis and action.** In men, testosterone biosynthesis occurs almost exclusively in mature Leydig cells by the enzymatic sequences illustrated. Cholesterol originates predominantly by de novo synthesis pathway from acetyl-CoA with luteinizing hormone regulating the rate-limiting step, the conversion of cholesterol to pregnenolone within mitochondria, whereas remaining enzymatic steps occur in smooth endoplasmic reticulum. The Δ^5 and Δ^4 steroidal pathways are on the left and right, respectively. Testosterone and its androgenic metabolite, dihydrotestosterone, exert biological effects directly through binding to the AR and indirectly through aromatization of testosterone to estradiol, which allows action via binding to the ER. The androgen and ERs are members of the steroid nuclear receptor superfamily with highly homologous structure differing mostly in the C-terminal ligand-binding domain. The LH receptor has the structure of a G-protein linked receptor with its characteristic seven transmembrane spanning helical regions and a large extracellular domain that binds the LH molecule, which is a dimeric glycoprotein hormone consisting of an α subunit common to other pituitary glycoprotein hormones and a β subunit specific to LH. Most sex steroids bind to sex hormone–binding globulin (SHBG), which binds tightly and carries the majority of testosterone in the bloodstream.

the accumulation of chronic disease states are functionally attributable to impaired hypothalamic regulation of testicular function,[32-35] as well as Leydig cell attrition[10] and dysfunction[36-38] and atherosclerosis of testicular vessels.[39] As a result, the aging hypothalamic-pituitary-testicular axis exhibits reactive changes to concomitant systemic disorders as well as multilevel functional defects that, in concert, lead to reduced circulating testosterone levels during male aging.[40,41]

Testosterone, like other lipophilic steroids secreted from steroidogenic tissues, leaves the testis by diffusing down a concentration gradient across cell membranes into the bloodstream, with smaller amounts appearing in the lymphatics and tubule fluid. After male puberty, >95% of circulating testosterone is derived from testicular secretion with the remainder arising from extragonadal conversion of precursors with minimal intrinsic androgenic potency, such as dehydroepiandrosterone and androstenedione. These weak androgens, predominantly originating from the adrenal cortex, constitute a large circulating reservoir of precursors for conversion to bioactive sex steroids in extragonadal tissues including the liver, kidney, muscle, and adipose tissue. Endogenous adrenal androgens contribute negligibly to direct virilization of men,[13] and residual circulating and tissue androgens after medical or surgical castration result in minimal biologic effect on androgen-sensitive prostate cancer.[42] Conversely, adrenal androgens in women are a major source of biologically active androgen precursors making a proportionately larger contribution to the

much lower (~5% of men) circulating testosterone concentrations. In women, circulating testosterone is derived approximately equally from direct gonadal secretion and indirectly from peripheral interconversion of adrenal androgen precursors.[15,16] Exogenous dehydroepiandrosterone at physiologic replacement doses of 50 mg/day orally[15] is incapable of providing adequate blood testosterone for androgen replacement in men but produces dose-dependent increases in circulating estradiol in men[43,44] and hyperandrogenism in women.[14]

Hormone production rates can be calculated either from estimating metabolic clearance rate (from bolus injection or steady-state isotope infusion using high specific-activity tracers) and mean circulating testosterone levels[45,46] or by estimation of testicular arteriovenous differences and testicular blood flow rate.[47] These methods provide consistent estimates of a testosterone production rate of 3 to 10 mg/day using tritiated[48,49] or nonradioactive deuterated[50] tracers with interconversion rates of ~4% to dihydrotestosterone (DHT)[49,51] and 0.2% to estradiol[52] under the assumption of steady-state conditions (hours to days). These steady-state methods are a simplification that neglects diurnal rhythm,[53,54] episodic fluctuation in circulating testosterone levels during shorter periods (minutes to hours) entrained by pulsatile LH secretion,[55] and postural influence on hepatic blood flow.[48] The major known determinants of testosterone metabolic clearance rate are circulating SHBG concentration,[56] diurnal rhythm,[50] and postural effects on hepatic blood flow.[48,50] Circulating testosterone levels are influenced by genetic effects on circulating SHBG[57-60] and other mechanisms[49] as well as environmental factors.[28,29,50]

Transport

Testosterone circulates in blood at concentrations greater than its aqueous solubility by binding to circulating plasma proteins. The most important is SHBG, a high-affinity but low-capacity binding protein, and other low-affinity but higher-capacity binding proteins include albumin, corticosteroid-binding globulin,[61] and α_1 acid glycoprotein.[62] Testosterone binds avidly to circulating SHBG, a homodimer of two glycoprotein subunits each comprising 373 amino acids with 3 glycosylation sites, 2 N-linked and 1 O-linked, and containing a single high-affinity steroid-binding site.[63] The affinity of SHBG for binding testosterone is subject to a genetic polymorphism[58] but is not altered in liver disease,[64] but whether it is influenced by other chronic diseases or pregnancy (when circulating levels increase) is not known. SHBG is secreted into the circulation by human, but not rodent, liver as well as into the seminiferous tubules of the testis by rodent, but not human, Sertoli cells where it is known as testicular androgen-binding protein.[65] SHBG is also secreted by placenta thereby contributing to the rise in blood SHBG during pregnancy.[66] As a product of hepatic secretion, circulating SHBG levels are particularly influenced by first-pass effects on the liver of oral drugs including sex steroids. Circulating SHBG (and thereby total testosterone) concentrations are characteristically decreased (androgens, glucocorticoids) or increased (estrogens, thyroxine) by supraphysiologic hormone concentrations at the liver, such as produced by oral administration or by high-dose androgen injections. In contrast, endogenous sex steroids and parenteral (nonoral) administration, which maintain physiologic hormone concentrations (transdermal, depot implants), result in minimal effects on blood SHBG levels. Other modifiers of circulating SHBG levels include upregulation by acute or chronic liver disease and androgen deficiency and downregulation by obesity, protein-losing states,[63] and, rarely, genetic SHBG deficiency.[67] Under physiologic conditions, 60% to 70% of circulating testosterone is SHBG bound, with the remainder bound to lower affinity, high-capacity binding sites (albumin, α_1 acid glycoprotein, corticosteroid-binding protein), with 1% to 2% remaining nonprotein bound.

Transfer of hydrophobic steroids into tissues is presumed to occur passively according to physicochemical partitioning between the hydrophobic protein-binding sites on circulating binding proteins, the hydrophilic aqueous extracellular fluid, and the lipophilic cellular plasma membranes. According to the free hormone hypothesis,[68-70] the free (nonprotein bound) fraction of testosterone is the most biologically active, with the loosely protein-bound testosterone constituting a less accessible but mobilizable fraction, with the largest moiety tightly bound to SHBG constituting only an inactive reservoir. As the free and/or bioavailable fractions would also have enhanced access to sites of testosterone inactivation by degradative metabolism that terminates androgen action, the free fractions may equally be considered the most evanescent and least active. Consequently, a theoretical basis for the free hormone hypothesis is questionable. Furthermore, empirical evidence indicates that, rather than being biologically inert, SHBG participates actively in cellular testosterone uptake via specific SHBG membrane receptors, uptake mechanisms, and signaling via G protein and cyclic AMP.[71-75] These mechanisms include the megalin receptor, which is a multivalent low-density lipoprotein endocytic receptor located on cell surface membranes that can mediate receptor-mediated cellular uptake of SHBG loaded with testosterone by endocytosis[76,77] and may influence tissue androgen action.[78,79] Consequently, the biological significance and clinical utility of partitioning circulating testosterone into these derived fractions remain to be firmly established.

Measurement

Measuring blood testosterone concentration is an important part of the clinical evaluation of androgen status, and it is important for confirming a clinical and pathological diagnosis of androgen deficiency. The circulating testosterone concentration is a surrogate measure for whole body testosterone production rate and the inferred impact of androgens on tissues. However, the reliance on a spot measurement of blood testosterone concentration neglects changes in the whole body metabolic clearance rate as well as other factors influencing net androgen effects at tissue levels. These include the efficiency of blood testosterone transfer into adjacent tissues during capillary transit as well as prereceptor, receptor, and postreceptor factors influencing the testosterone activation, inactivation, and

action in that tissue. Circulating testosterone levels are also dynamic and feature distinct circhoral and diurnal rhythms. Circhoral LH pulsatility entrains some pulsatility in blood testosterone levels,[35] although the buffering effects of the circulating steroid-binding proteins dampen the pulsatility of blood testosterone concentrations. This is strikingly illustrated in the more strikingly pulsatile patterns of circulating testosterone in rodents, which lack any circulating SHBG because of a lack of hepatic expression of the SHBG gene in those species.[80,81] Diurnal patterns of morning peak testosterone levels and nadir levels in the midafternoon are evident in younger and in healthy older men,[53] but they are lost in some aging men.[54] Consequently, it is a conventional practice to standardize testosterone measurements to morning blood samples on at least 2 different days.

The advent of steroid radioimmunoassay in the 1970s made it feasible to measure blood testosterone concentrations affordably with speed and sensitivity. However, cross-reacting steroids and nonspecific matrix effects are limitations on testosterone immunoassays relative to the high specificity of mass spectrometry-based methods, also known as the reference method.[82] The steep rise in demand for testosterone measurements in clinical practice and research led to method simplifications to integrate steroid immunoassays into automated immunoassay platforms. These changes, notably eliminating preparative solvent extraction and chromatography as well as introducing bulky nonauthentic tracers, undermine the specificity of unextracted testosterone immunoassays,[83] particularly at the low circulating testosterone levels such as in women and children.[84] Even at the higher testosterone concentrations in men, commercial testosterone immunoassays demonstrate wide method-specific discrepancies.[31] New generation, bench-top mass spectrometers with higher sensitivity and throughput now overcome these limitations of testosterone immunoassays.

Based on the speculative free hormone hypothesis, assays to measure blood "free" testosterone levels directly in serum samples were developed using reference tracer methods of equilibrium dialysis,[85,86] or ultrafiltration,[87,88] or various formulae calculated based on immunoassay measurement of total testosterone and SHBG.[89,90] Similarly, another derived testosterone measure, "bioavailable" testosterone, is defined as the non-SHBG–bound testosterone (in effect the combination of albumin-bound plus unbound testosterone), and this testosterone can also be measured directly (by ammonium sulfate precipitation) or can be calculated by a formula from total testosterone and SHBG and albumin measurements. Some estimates of "free" testosterone, notably the direct analogue assay[91,92] and the free testosterone index,[93] are invalid for use in men. Because the measurement of "free" or "bioavailable" testosterone is laborious, calculational formulae with limited validation[89,90,94] have been widely used; however, these estimates for "free"[95-97] or "bioavailable"[98,99] testosterone are not accurate in large-scale evaluation. Overall, the clinical utility of various derived ("free," "bioavailable") measures of testosterone arising from the unproven free hormone hypothesis remain to be established; consequently, they contribute little genuine enlightenment to clinical decision making, and the recourse to such estimates in consensus clinical androgen deficiency diagnosis is minimal.

Metabolism

After testicular secretion, a small proportion of testosterone undergoes activation to two bioactive metabolites, that is, estradiol and DHT, whereas the bulk of secreted testosterone undergoes inactivation by hepatic phase I and phase II metabolism to inactive oxidized and conjugated metabolites for urinary and/or biliary excretion.[100]

The amplification pathway converts ~4% of circulating testosterone to the more potent, pure androgen, DHT.[49,51] DHT has a higher binding affinity[101] and 3 to 10 times greater molar potency in transactivation[102-104] of the AR relative to testosterone. Testosterone is converted to the most potent natural androgen DHT by the 5α-reductase enzyme that originates from two distinct genes (I and II).[105] Type 1 5α-reductase is expressed in the liver, kidney, skin, and brain, whereas type 2 5α-reductase is characteristically expressed strongly in the prostate but also at lower levels in the skin (hair follicles) and liver.[105] Congenital 5α-reductase deficiency resulting from mutation of the type 2 enzyme protein[106] leads to a distinctive form of genital ambiguity causing undermasculinization of genetic males, who may be reared as females, but in whom puberty leads to marked virilization including phallic growth, normal testis development, normal spermatogenesis,[107] and normal bone density,[108] as well as, occasionally, masculine gender reorientation.[109] Prostate development remains rudimentary,[110] and sparse body hair without balding is characteristic.[111] This remarkable natural history reflects the dependence of urogenital sinus derivative tissues on strong expression of 5α-reductase as a local androgen amplification mechanism for their full development. This amplification mechanism for androgen action was exploited in developing azasteroid 5α-reductase inhibitors.[112] As the type 2 5α-reductase enzyme results in >95% of testosterone entering the prostate being converted to the more potent androgen DHT,[113] blockade of that isoenzyme (the expression of which is largely restricted to the prostate) confines the inhibition of testosterone action to the prostate (and other urogenital sinus tissue derivatives) without blocking extraprostatic androgen action. DHT circulates at ~10% of blood testosterone concentrations because of spillover from the prostate[114,115] and nonprostatic sources.[116] Whereas genetic mutations disrupting type 2 5α-reductase produce disorders of urogenital sinus-derived tissues in men and mice,[117] genetic inactivation of type 1 5α-reductase includes no male phenotype in mice, and no mutations of the human type 1 enzyme have been reported. Whether this reflects the type I enzyme having an unexpected phenotype or an evolutionarily conserved vital function remains unclear. An important issue is whether eliminating intraprostatic androgen amplification by inhibition of 5α-reductase can prevent prostate disease. Two major randomized, placebo-controlled studies of men at high risk of (but without diagnosed) prostate cancer have both shown that oral 5α reductase inhibitors (finasteride,

dutasteride) reduced the incidence of low-grade prostate cancer as well as the prevalence of lower urinary tract symptoms from benign prostate hyperplasia.[118,119] The Prostate Cancer Prevention Trial (PCPT) was a major 10-year chemoprevention study randomizing 18,882 men, >55 years of age without known prostate disease, to daily treatment with 5 mg finasteride (inhibitor of type 2 5α reductase) or placebo, and the researchers observed a cumulative 25% reduction after 7 years of treatment in early-stage, organ-confined, low-grade prostate cancer. Another study randomized >8231 men aged 50 to 75 years with serum PSA <10 ng/mL and negative prostate biopsy to either daily treatment with 0.5 mg dutasteride (inhibitor of both type 1 and 2 5α reductases) or placebo for 4 years; a 23% reduction in the incidence of biopsy-proven prostate cancer was observed. Although neither study was designed to determine mortality benefit, both showed no reduction in higher-grade, but still organ-confined, cancers. Although this stage selectivity may be explained by diagnostic biases because of drug effects on prostate size and histology,[120,121] registration for chemoprevention of prostate cancer was refused by the FDA.[122] Whether or not preventive use of prostatic 5α-reductase inhibition in men with high prostate cancer risk proves warranted, novel synthetic androgens refractory to 5α-reductive amplification may have advantages for clinical development.

The diversification pathway of androgen action involves testosterone being converted by the enzyme aromatase[123] to estradiol to activate ERs. Although this involves only a small proportion (~0.2%) of testosterone output, the higher molar potency of estradiol (~100-fold higher vs. testosterone) makes aromatization a potentially important mechanism to diversify androgen action via ER-mediated effects in tissues where aromatase is expressed.[124] The diversification pathway is governed by the cytochrome P-450 enzyme (CYP19) aromatase.[123,125] In eugonadal men, most (~80%) circulating estradiol is derived from extratesticular aromatization.[52] The biological importance of aromatization in male physiology was first recognized in the early 1970s[126] when the local conversion of testosterone to estradiol within the neural tissues was identified and was subsequently shown to have an important role in mediating testosterone action, including negative feedback as well as activational and organizational effects, on the brain.[127] More recently, the importance of local aromatization in testosterone action has been reinforced by the striking developmental defects in bone and other tissues of men and mice, with genetic inactivation of aromatase leading to complete estrogen deficiency resulting from genetic inactivation of the aromatase.[128] This phenotype is also strikingly similar to that of a man[129] and mice[129] with genetic mutations inactivating ERα. Furthermore, men with aromatase deficiency treated with exogenous estradiol or other estrogens also demonstrated significant bone maturation. By contrast, genetic inactivation of ERβ has no effect on male mice[130] and no human mutations have been reported. Aromatase expression in tissue such as bone[131] and brain[127] may influence development and function by variation in aromatization that modulates local tissue-specific androgen action. By contrast, other tissues, such as mature liver and muscle, express little or no aromatase. Nevertheless, despite the importance of aromatization for male bone physiology, other observations indicate that androgens acting via ARs have important additional direct effects on bone. These include the greater mass of bone in men despite very low circulating estradiol concentrations compared with young women,[132] the failure of androgen insensitive rats lacking functional ARs but normal estradiol and ERs to maintain bone mass of normal males,[133] and the ability of nonaromatizable androgens to increase bone mass in estrogen-deficient women.[134,135] Testosterone action on bone and in the brain are not accounted for solely as a prohormone for local estradiol production (and action via estrogen receptors α and/or β), and AR-mediated effects are required to manifest the full spectrum of testosterone effects on bone[136,137] and in the brain.[138] In healthy men, fat mass is primarily, and sexual function partially, dependent on aromatization-dependent circulating estradiol, whereas muscle mass and strength are solely androgen dependent.[124] Further studies are needed to understand fully the significance of aromatization in maintaining androgen action in mature male animals.

Testosterone is metabolized to inactive metabolites in the liver, kidney, gut, muscle, and adipose tissue. Inactivation is predominantly by hepatic oxidases (phase I metabolism), notably cytochrome P-450 3A family,[139] leading ultimately to oxidation of most oxygen moieties followed by hepatic conjugation to glucuronides (phase II metabolism), which are rendered sufficiently hydrophilic for renal excretion. Uridine diphospho (UDP) glucuronosyl transferase (UGT) enzymes UGT2B7, UGT2B15, and UGT2B17 catalyze most phase II metabolisms (glucuronidation) of testosterone, with 2B17 being quantitatively the most important.[140] A functional polymorphism of UGT 2B17, a deletion mutation several times more frequent in Asian than in European populations,[141] explains the concordant population difference in the testosterone to epitestosterone (T/E) ratio,[142] thanks to a World Anti-Doping Agency (WADA)-approved urine screening test for testosterone doping in sport, which constitutes an ethnic-specific, false negative in surveillance for exogenous testosterone doping.[143]

The metabolic clearance rate of testosterone is reduced by increases in circulating SHBG levels[56] or decreases in hepatic blood flow (e.g., posture)[48] or liver function. Theoretically, drugs that influence hepatic oxidase activity could alter metabolic inactivation of testosterone, but empirical examples of sufficient magnitude to influence clinical practice are rare. Rapid hepatic metabolic inactivation of testosterone leads to both low oral bioavailability[144,145] and short duration of action when injected parenterally.[146] To achieve sustained androgen replacement, these limitations dictate the need to deliver testosterone via parenteral depot products (e.g., injectable testosterone esters, testosterone implants, transdermal testosterone) or oral delivery systems that either bypass hepatic portal absorption (buccal,[147,148] sublingual,[147,149] gut lymphatic[150,151]) or use synthetic androgens with substituents rendering them resistant to first-pass hepatic inactivation.[152]

Regulation

During sexual differentiation in early intrauterine life, fetal Leydig cells secrete the testosterone required for masculine sexual differentiation. The regulation of this fetal Leydig cell testosterone secretion appears to differ among species. Higher primate and equine placenta secrete a chorionic gonadotropin during early fetal life,[153] which may drive fetal human Leydig cell steroidogenesis[154] at the relevant time. By contrast, in subprimate mammals male sexual differentiation occurs without expression of any placental gonadotropin and occurs before the time when pituitary gonadotropin secretion starts so that fetal Leydig cell testosterone secretion may be autonomous of gonadotropin stimulation during the fetal development of most mammalian species.[155]

Puberty is initiated by a still mysterious suprahypothalamic process involving a developmental clock and multiple permissive processes,[156] which lifts the central neuroendocrine restraint on the final common pathway driving reproductive function in the mature male; that is, the episodic secretion of gonadotropin-releasing hormone (GnRH) from hypothalamic neurons.[55] Various explanatory theories, including the gonadostat, somatometer,[157] neurally driven changes in GABAergic inhibition and glutaminergic stimulation,[158] and triggering by kisspeptin-1 secretion and activating its receptor GPR54,[159,160] are proposed to explain the restraint and resurgence of the hypothalamic GnRH pulse generator without a comprehensive picture having yet emerged. Hypothalamic GnRH neurons are functional at birth but, after the perinatal androgen surge, remain tonically suppressed during infantile life. A maturation process that awakens the dormant hypothalamic GnRH neurons to unleash mature circhoral patterns of pulsatile GnRH secretion, which in turn entrains pulsatile LH secretion from pituitary gonadotropes, initiates puberty. Initially this resurgence of pulsatile GnRH and LH secretion occurs mainly during sleep[161] but eventually extends throughout the day with a persisting underlying diurnal rhythm. The timing and tempo of male puberty is under tight genetic control, encompassing nutrition influences on body weight and composition,[162] with a correspondingly growing number of genetic causes of delayed puberty identified.[163] Environmental factors that optimize growth (e.g., high socioeconomic status with better nutrition and health care) may explain secular trends toward earlier puberty with increased statural growth,[164,165] whereas claims that exposure to hormonally active chemical pollution contributes to earlier puberty[166] remain speculative.[167]

After birth, testicular testosterone output is primarily regulated by the pulsatile pattern of pituitary LH secretion. The episodic secretion of GnRH from hypothalamic neurons into the pituitary portal bloodstream drives this, providing a direct short-circuit route to pituitary gonadotropes. Under this regular but intermittent GnRH stimulation, pituitary gonadotrophs secrete LH in high amplitude pulses at ~60- to 90-minute intervals with minimal intervening LH secretion between pulses, with the net effect that circulating LH levels are distinctly pulsatile. This pulsatile pattern of trophic hormone exposure maintains Leydig cell sensitivity to LH to maintain mature male patterns of testicular testosterone secretion.[168]

LH stimulates Leydig cell steroidogenesis via increasing substrate (cholesterol) availability and activating rate-limiting steroidogenic enzyme as well as cholesterol transport proteins. LH is a dimeric glycoprotein consisting of an α subunit common to the other glycoprotein hormones (human chorionic gonadotropin [hCG], follicle-stimulating hormone, and thyrotropin-stimulating hormone) and a β subunit providing distinctive biologic specificity for each dimeric glycoprotein hormone by dictating its specific binding to the LH/hCG rather than the follicle-stimulating hormone or thyroid stimulating hormone receptors.[169,170] These cell surface receptors are highly homologous members of the heptahelical, G protein–linked family of membrane receptors. LH receptors are located on Leydig cell surface membranes and use signal transduction mechanisms primarily involving cyclic AMP as well as calcium as second messengers to cause protein kinase–dependent protein phosphorylation and DNA transcription, ultimately resulting in testosterone secretion.[171] Functionally, hCG is a natural, long-acting analogue of LH because they both bind to the same LH/hCH receptor and their β subunits are nearly identical. The longer duration of action of hCG is a result of its C-terminal extension of 31 amino acids containing four O-linked, sialic acid–capped carbohydrate side chains. These confer the greater resistance to degradation, which prolongs circulating residence time and biologic activity compared with LH,[172,173] a feature that has been exploited to engineer a longer-acting analogue of other circulating hormones such as FSH,[174] TSH,[175] and erythropoietin.[176]

Additional fine-tuning of Leydig cell testosterone secretion is provided by paracrine factors originating within the testis.[177] These include cytokines, inhibin, activin, follistatin, prostaglandins E_2 and $F_{2\alpha}$, insulin-like and other growth factors as well as still uncharacterized factors secreted by Sertoli cells. LH also influences testicular vascular physiology by stimulating Leydig cell secretion of vasoactive and vascular growth factors.[178]

Testosterone is a key element in the negative testicular feedback cycle through its inhibition of hypothalamic GnRH and, consequently, pituitary gonadotropin secretion. Such negative feedback involves both testosterone effects via ARs as well as aromatization to estradiol within the hypothalamus.[179,180] These culminate in the reduction of GnRH pulse frequency in the hypothalamus together with reductions in amplitude of LH pulses resulting from both reduced quantal secretion of GnRH as well as gonadotropin response to GnRH stimulation.[168] By contrast, the minority (~20%) of circulating estradiol directly secreted from the testes means that blood estradiol levels are under minimal physiologic regulation and are unlikely to be a major influence on negative feedback regulation of physiologic gonadotropin secretion in men.

Action

Androgen action involves prereceptor, receptor, and postreceptor mechanisms that are centered on the binding of testosterone (or an analogue) to the AR. Testosterone undergoes prereceptor activation by conversion to potent

bioactive metabolites, DHT, and estradiol. The steroidogenic enzyme 5α-reductase has two isozymes, types 1 and 2, which form a local androgen amplification mechanism converting testosterone to the most potent natural androgen, DHT.[181] The two isozymes, although homologous genes,[105] have different chromosomal locations and distinct biochemical features. This local androgen amplification mechanism is exemplified in urogenital sinus derived tissues, notably external and internal genitalia and the prostate, which characteristically express high levels of 5α-reductase type 2.[105] Other tissues such as nongenital skin and liver express 5α-reductase type 1.

The other form of prereceptor androgen activation is conversion of testosterone to estradiol by the enzyme aromatase,[182] which diversifies androgen action by facilitating effects mediated via ERs.[124] Consequently, whereas DHT may be considered a pure androgen because its bioactivity is solely mediated via AR, testosterone has a wider spectrum of action that includes diversification by aromatization and ER-mediated effects. These prereceptor mechanisms provide testosterone with a versatile and subtle range of regulatory mechanism before receptor-mediated effects depending on the balance between direct AR mediated versus indirect actions and/or ER-mediated mechanisms. Probably as a result, tissues vary in their androgenic thresholds and dose-response characteristics to testosterone and its bioactive metabolites.

ANDROGEN RECEPTOR

The AR is required for masculine sexual differentiation and sexual maturation, which ultimately leads to the development of a mature testis capable of supporting the spermatogenesis and testosterone production that form the basis for male fertility. The human AR is specified by a single X chromosome encoded gene located at Xq11-12 that specifies a protein of 919 amino acids,[1] a classic member of the large nuclear receptor superfamily[183] that includes receptors for the 5 mammalian steroid classes (androgen, estrogen, progesterone, glucocorticoid, mineralocorticoid) as well as for thyroid hormones, retinoic acid, and vitamin D, as well as numerous orphan receptors where the ligand was originally not identified.[184] AR expression is not confined to reproductive tissues and it is ubiquitously expressed, although levels of expression and androgen sensitivity of nonreproductive tissues vary.

The AR gene includes 8 exons specifying a protein of 919 amino acids with the characteristic structure of mammalian steroid receptors. It has an N-terminal domain (NTD) that specifies a long transactivating functional domain (exon 1), with a middle region specifying a DNA-binding domain (DBD) consisting of two zinc fingers (exons 2 and 3) separated by a hinge region from the C-terminal ligand-binding domain (LBD), which specifies the steroid-binding pocket (exons 4 to 8).

The NTD (exon 1) is relatively long, comprising more than half (535/919) the overall length of the AR. It has the least conserved sequence compared with other steroid receptors with a flexible and mobile tertiary structure harboring a transactivation domain (AF-1) that interacts with AR coregulator proteins and target genes.[185] Its loose, naturally disordered structure[186] also contains three homopolymeric repeat sequences (glutamine, glycine, proline) with the most important being the CAG triplet (glutamine) repeat polymorphism.[187] The less variable glycine (usually 24 residues) and proline (9 residues) repeat polymorphisms exhibit little apparent independent pathophysiologic significance, although linkage dysequilibrium between the glutamine and glycine repeat polymorphisms requires analysis of their effects as a coupled haplotype.[187] Among healthy people, where the glutamine repeat polymorphism has alleles of lengths between 5 and 35 (population mean 21), the length of the glutamine repeat is inversely proportional to AR transcriptional efficiency so that this polymorphism dictates genetic differences between individuals in the androgen sensitivity of their target tissues.[188,189] This genetic variation in tissue androgen sensitivity, although modest in magnitude, influences physiologic responses to endogenous testosterone in prostate size[190] and erythropoiesis[191] in carefully controlled studies. Wider epidemiologic implications of population variation in the genetic androgen sensitivity as specified by the polyglutamine repeat have been studied in a variety of potentially androgen-sensitive disorders,[187] including reproductive health disorders and hormone-dependent cancers in men and women as well as nongonadal disorders in which there are significant gender disparities in prevalence. In men, these include prostate[192] and other male preponderant cancers (liver, gastrointestinal, head, and neck), prostate hypertrophy, cryptorchidism and hypospadias, and male infertility,[193] whereas in women they include reproductive health disorders (polycystic ovary syndrome, premature ovarian failure, endometriosis, uterine leiomyoma, preeclampsia) and hormone-dependent cancers (breast, ovary, uterus). In addition, researchers have also performed studies examining the risks of obesity and cardiovascular disease, and mental and behavioral disorders including dementia, psychosis, migraine, and personality disorders.[187] However, as in many large-scale genetic association studies,[194] the findings remain mostly inconsistent, reflecting methodological limitations notably in recruitment, participation, and publication bias, as well as multiple hypothesis testing, all of which tend to inflate spurious associations.

Remarkably, the pathological elongation of the polyglutamine (CAG triplet) repeat to lengths of greater than 37 glutamines causes a neurodegenerative disease, spinal bulbar muscular atrophy (SBMA, also known as Kennedy's syndrome), a form of late-onset, slow progressing but ultimately fatal motor neuron disease,[195] one of several late-onset neurodegenerative polyglutamine repeat disorders.[196] Although the extreme length of the polyglutamine repeat does determine mild androgen resistance, these men usually have apparently normal reproductive function including fertility and virilization before diagnosis in midlife.[197] Furthermore, because complete AR inactivation in humans and other mammals does not cause motor neuron disease, and female carriers are protected from symptomatic neurodegeneration, SBMA, like other genetic polyglutamine repeat neurodegenerative diseases,[198] represents a toxic gain-of-function involving pathological protein aggregates of the mutant AR.[199]

Transgenic mouse models of SBMA suggest that testosterone deprivation by medical castration using a GnRH agonist may slow progression of neuropathy[199] and that genetic[200] or pharmacologic[201] administration of IGF-I may slow disease progression. However, the first major clinical trial of leuprolide, a GnRH analogue, failed to demonstrate a neuromuscular benefit in swallowing,[202] and further studies of selected subgroups and therapeutic targets are warranted.[203]

The DBD (exons 2 and 3) consists of ~70 amino acids with a high proportion of basic amino acids including 8 cysteines distributed as two sets of 4 cysteines, each forming a zinc coordination center for a single zinc atom, thereby creating two zinc fingers. The DBD is highly conserved between steroid receptors, reflecting its tightly defined function of forming the two zinc fingers that bind to DNA by intercalating between its grooves. The first zinc finger (exon 2) is directly involved with the major DNA groove of the androgen response element through a proximal (P-box) region, whereas the second zinc finger (exon 3) is also responsible for stabilizing hormone binding and enhancing receptor dimerization through its distal (D-box) region.

The hinge region (first half of exon 4) of ~40 amino acids between the DBD and LBD is considered a flexible linker region but may include additional functions involving interactions with DNA (nuclear localization, androgen response element) and protein (AR dimerization, coregulators) that influence AR transcriptional activity.

The LBD (midexon 4 to 8) of AR comprises ~250 amino acids that specify a steroid-binding pocket that creates the characteristic high-affinity, stable, and selective binding of testosterone, DHT, and synthetic androgens. Although the LBD's overall architecture is broadly conserved among nuclear receptors, the AR sequence diverges significantly to ensure the specificity of binding from other steroid classes and their different cognate ligands. Structural studies of the AR's LBD show that it has a tertiary conformation similar to other steroid receptors (most closely resembling PR) with 12 stretches of α helix interspersed with short β pleated sheets. The most C-terminal helix 12 seals the binding pocket and influences whether a bound ligand acts as an agonist or antagonist as well as forming a hydrophobic surface for binding of coregulator proteins that modify transcriptional activity of the androgen target genes. The LBD also participates in receptor dimerization, nuclear localization, and transactivation via its activation function (AF-2) domain.

The AR has a predominantly nuclear location in androgen target cells regardless of whether it is bound to its ligand or not, unlike other steroid receptors that are more often evenly distributed between cytoplasm and nucleus when not bound to their cognate ligands. Androgen binding to the C-terminal LBD causes a conformational change in the AR protein and dimerization to facilitate binding of the ligand-loaded receptor to segments of DNA featuring a characteristic palindromic motif known as an androgen-response element, located in the promoter regions of androgen target genes. Ligand binding leads to shedding of heat shock proteins 70 and 90 that act as a molecular chaperone for the unliganded AR.[204] Specific binding of the dimerized, ligand-bound AR complex to tandem androgen-response elements initiates gene transcription so that the AR acts as a ligand-activated transcription factor. AR transcriptional activation is governed by a large number of coregulators[205,206] whose tissue distribution and modulation of androgen action remain incompletely understood.

Androgen Insensitivity

Mutations in the AR are relatively common with >1000 different mutations recorded by 2012[207] in the McGill database (http://androgendb.mcgill.ca/), making androgen insensitivity the most frequent form of genetic hormone resistance. As the AR is an X chromosomal gene, functionally significant AR mutations are effectively expressed in all affected males because they are hemizygous. By contrast, women bearing these mutations (including the obligate heterozygote mothers of affected males) are silent carriers without any overt phenotype because they have a balancing allele, and in addition their circulating testosterone levels never rise to postpubertal male levels sufficient to activate AR-mediated effects.

AR mutations produce a wide spectrum of effects from functionally silent polymorphisms to androgen insensitivity syndromes that display phenotypes proportionate to the impairment of AR function and, thereby, the degree of deficit in androgen action.[1] These clinical manifestations extend from a complete androgen insensitivity syndrome (CAIS, formerly known as testicular feminization), which produces a well-developed female external phenotype with a spectrum spanning across all grades of undervirilized male phenotype, to, at the other extreme, a virtually normal male phenotype. The severity of androgen insensitivity can be categorized most simply as complete, partial, and mild, although a more detailed 7-stage Quigley classification based on degree of hypospadias, phallic development, labioscrotal fusion, and public/axillary hair is also described.[1,187] The degree of urogenital sinus derivative development together with testis descent provide clinical clues to the degree of androgen sensitivity.

CAIS caused by completely inactivating AR mutations results in a 46XY individual with a hormonally active testis that secretes abundant testosterone but that cannot activate AR-mediated action so no male internal or external genitalia or somatic features develop. However, testosterone aromatization to estradiol is unimpeded, leading to the development of normal female somatic features including breast and external genital development after puberty. The population prevalence of CAIS is estimated to be at least 1:20,000 male births or 1% to 2% among female infants with inguinal hernia.[1] The typical presentation of CAIS is a relatively tall, normally developed girl with delayed puberty and/or primary amenorrhea. The clinical features usually include well-developed breasts, hips, and female fat-pattern deposition, acne-free facial complexion with minimal axillary and pubic hair, with testes located within an inguinal hernia or in the abdominal cavity. The uterus and fallopian tubes are absent and the vagina is short and blind ending, reflecting unimpeded effects of testicular AMH secretion causing regression of Müllerian structures including the upper third of the

vagina. Earlier diagnosis is increasingly possible, where a prenatal 46XY karyotype is discrepant from a female phenotype on ultrasound or at birth or among female infants presenting with inguinal hernia.[208] The family history may be informative, with infertile maternal (but not paternal) aunts consistent with an X-linked inheritance. Laboratory investigations of postpubertal individuals show elevated blood LH, SHBG (at adult female levels), and testosterone (at adult male levels) before gonadectomy. The androgen sensitivity index, which is the product of LH and testosterone concentrations, is elevated.[209] These features reflect high amplitude and frequency LH pulses caused by the absence of effective negative androgenic feedback on the hypothalamus as well as by the increased LH drive to maintain high-normal male levels of testicular testosterone secretion. In untreated individuals, failure to suppress blood SHBG with short-term, high-dose androgen administration may be useful confirmation of androgen resistance.[210,211] After gonadectomy, blood LH and FSH increase to castrate levels but are partially suppressed by estradiol replacement therapy.

Long-term management includes: 1) reinforcing female gender identity with counseling to help the subject cope with eventual infertility and the acceptance of the genetic diagnosis, 2) postpubertal gonadectomy to prevent the risk of gonadoblastoma (especially if the gonad is impalpable) but allowing the completion of puberty, balancing the low risks of tumor at that age against the risk of unwanted virilization resulting from any residual AR function or mosaicism,[212] and 3) postgonadectomy estrogen replacement therapy to maintain bone density, breast development, and quality of life. Long-term bone density is often subnormal for age because of not only the deficit in androgen action but also the delayed or inadequate postgonadectomy estrogen replacement, often resulting from suboptimal adherence to medication.[108,213-215] Although the long-term outcomes for AR mutations based on large prospective studies of a consistent management approach remain limited, the clinical outcomes for individuals with CAIS reared as females are reported as successful,[216,217] although gender role and psychosexual functional outcomes remain suboptimal.[218-220]

Partial androgen insensitivity syndrome (PAIS) is characterized by a full range of external genital virilization and breast development from female to male phenotype, reflecting the functional severity of the AR mutation. The level of testis descent and phallic development provide simple clinical guides to the severity of the deficit in AR function. PAIS was originally recognized under a variety of eponymously named syndromes (Reifenstein, Gilbert-Dreyfus, Lubs, Rosewater) and only more recently was clearly distinguished from other developmental disorders of 46XY individuals with incomplete virilization, especially those resulting from steroidogenic enzyme defects. Severe forms of PAIS with minimal AR function produce a predominantly female phenotype with clitoromegaly, whereas PAIS with mutations displaying more functional AR are characterized by a male phenotype with various grades of labioscrotal formation (varying from minimal posterior partial labial fusion to labioscrotal fusion and bifid, ruggose scrotum) and hypospadias (urinary orifice ranging from perineal aperture to hypospadia with meatus at locations along penile shaft to the corona), micropenis, and gynecomastia, each in inverse proportion to the AR function. These features have been combined into an external masculinization score (EMS) ranging from 0 (female) to 12 (male) based on degree of scrotal fusion, phallic development, location of urethral meatus, and testis descent each scored 0 to 3.[221] The biochemical finding in PAIS are similar to those of CAIS but with a wide spectrum of severity from mildly virilized, predominantly female, to an undervirilized male phenotype. The increase in blood LH and testosterone are less severe and consistent, but the androgen sensitivity index[209] may help confirm the diagnosis of androgen resistance. Unlike CAIS, which usually presents during adolescence with failure of puberty, PAIS usually presents at birth with ambiguous genitalia requiring a crucial and decisive clinical judgment on sex of rearing to be made rapidly. The expert pediatric endocrinologist must balance the need for early genital surgery and vicarious decision-making against the risk of possible subsequent regret by the affected individual as an adult. This makes for inevitably complex, difficult, and contentious choices, as the available systematic prospective evidence from long-term follow-up of gender of rearing is still limited. Most individuals who are intersex because of PAIS, especially those with an EMS of 4 or more,[222] are reared as males.[221] Genital surgery for hypospadias is often required, and uncertainty usually remains about the adequacy of the potential for postpubertal virilization using either endogenous or exogenous testosterone. If pubertal progression is inadequate, exogenous testosterone may be useful, but a higher-than-usual dosage may be required to obtain satisfactory effects. Long-term follow-up of PAIS patients reared as males has shown apparently adequate psychosexual function despite phallic underdevelopment, limited somatic virilization, and dissatisfaction with outcomes by some patients as adults.[223] For those reared as females, the management is similar to that for CAIS and involves early genital surgery and prepubertal gonadectomy to prevent unwanted virilization.

Mild androgen insensitivity (MAIS) is the most minor form of androgen insensitivity displaying a near-normal male phenotype with only subtle changes in hair patterns relative to family norms (less body and facial hair, absence of temporal recession or balding) and/or minor defects restricted to spermatogenesis alone. The blood LH and testosterone concentrations are usually, but not always, elevated, although the androgen sensitivity index, which is the product of serum LH and testosterone concentrations, is more consistently raised. In common with mutations in many other genes, making a clear distinction between the most minor grades of clinical pathology and a silent, functionally insignificant polymorphism is challenging, and it depends on reproducing experimentally the functional consequences of the mutation in an authentic biological system. Ideally such verification is performed in vivo (e.g., in genetically modified mouse models) but, as this is laborious and expensive, it is rarely undertaken. The functional verification of putative mutations is usually undertaken either by in silico prediction

of functional effects of structural protein changes from sequence data or in vitro studies of cultured cells or cell-free systems aiming to characterize protein functions. Nevertheless, although informative, the biological fidelity of these surrogate endpoints relative to the in vivo effects on androgen action may remain questionable.

All types of mutations have been reported in the AR gene including disruption of the reading frame by deletions, insertions, splice-site interruption, and frame-shift, which usually produce major interference with function as well as the more common single base substitutions with effects ranging from nil to complete functional inactivation. In addition, mutation can produce less-common mechanisms of interrupting AR function, such as inefficient translation, unstable protein, or aberrant translational start sites, all leading to reduced expression of functional AR protein. Mutations occur throughout the AR gene, probably at random; however, those reported are distributed unevenly because the most important functional regions of the gene are sensitive even to minor changes in sequence, whereas the more variable regions may tolerate sequence changes without functional consequences. More than 90% of known mutations are single-base substitutions that have pathophysiologic consequences when they change the amino acid sequence in the functionally critical DBD or LBD regions, whereas sequence changes in other regions may not alter AR function, thereby constituting silent polymorphisms. For example, despite forming more than half the AR sequence, few functionally important mutations are reported in the NTD (exon1). Those described in exon 1 mostly represent major disruptions of the AR protein because of the creation of a premature stop codon, a major deletion or frame shift mutation causing mistranslation onward from exon 1, whereas point mutations are more likely to constitute functionally insignificant (silent) polymorphisms. Mutations in the LBD, comprising ~25% of AR sequence, constitute the majority (~60%) of reported mutations, whereas mutations in the DBD, representing ~7% of AR sequence, constitute ~14% of cases.[224] The functional effects of these two types of mutations generally differ in that LBD mutations demonstrate various degrees of reduced affinity and/or loosened specificity of ligand-binding characteristics, whereas DBD mutations demonstrate normal ligand binding but reduced or absent receptor binding to DNA. The profusion of AR mutations has created numerous experiments of nature, with multiple different mutations involving the same amino acid, and with the physiologic consequences depending generally on how conservative the amino acid substitution is. Nevertheless, there are exceptions to such categorization with mutations in regions other than the DBD or LBD sometimes unexpectedly affecting DNA or ligand-binding properties, presumably through physical interaction effects in the tertiary structure of the AR in its 3-dimensional topography.

The familial occurrence of androgen insensitivity resulting from the X-linked inheritance of mutated AR makes carrier detection and prenatal genetic diagnosis feasible. A carrier female has a 50% chance of having a child bearing the mutant AR allele, so the child would either be a carrier female or an affected male, and 50% of the woman's fertile daughters would also be carriers. A specific mutation detection test needs to be established, usually involving PCR-based genotyping for point mutations, although other mutational mechanisms may require more complex genotyping methods. For the prenatal genetic diagnosis that is now usually applied to chorionic villus samples, the genetic diagnosis must be rapid, reliable, and efficient. However, accurate genetic counseling relies on a consistent and predictable phenotype for any specific genotype. This is usually, but not invariably, true for AR mutations as the clinical manifestations for the same mutation are usually consistent in CAIS with rare exceptions,[225] whereas for PAIS the phenotype may vary even within a single family, which leads to significant implications for gender of rearing and/or the need for genital surgery, so that skilled genetic counseling is essential.[226] Discrepancies in the fidelity of phenotype within families, or between unrelated individuals bearing the identical mutation, is relatively common in PAIS and may be attributable to somatic mosaicism[227] or the effect of modifier genes that influence androgen action, such as 5α reductase.[228] An exotic, complex DNA breakage repair slippage mechanism has also been described to produce multiple mutations within a single family.[229] Wider population genetic screening for AR mutations is not currently cost effective, because, despite diminishing costs for increasingly facile genetic testing, the large number of different mutations that feature diverse mechanisms and variable phenotypes, which still mostly predict a normal life expectancy but a diminished quality of life, is difficult to cost or cure.[230]

Acquired androgen insensitivity during life can arise either through postnatal somatic or germ line AR mutations or by nongenetic, nonreceptor mechanisms that hinder androgen action. Among overt cases of androgen insensitivity, ~30% are absent in the mother's germ line so must arise as a de novo mutation in the postnatal maternal germ line[227] or in the fetal germ line soon after fertilization.[231] Somatic AR mutations, arising de novo postnatally in the stem cell pool of repopulating cells, are theoretically possible but have not been reported. Somatic AR mutations are relatively common in prostate cancer, usually arising in late-stage disease palliatively treated by androgen deprivation. The switch of highly androgen-dependent prostate cancer cells to an androgen-deplete milieu may encourage clonal selection of androgen insensitive sublines to proliferate in the terminal stage of the disease. Genetic instability of prostate cancer cells may also contribute to this process, although somatic AR mutations are rare in other cancers such as liver[232] or breast[233] cancer in the absence of androgen deprivation. Somatic AR mutation in prostate cancer cells is responsible for the paradoxical anti-androgen withdrawal syndromes observed with nonsteroidal (flutamide, bicalutamide, nilutamide) or steroidal (cyproterone, megestrol)[234,235] treatment. In this state, anti-androgen withdrawal or switchover[235] produces remission of worsening disease that is attributable to the occurrence of a de novo AR mutation in prostate cancer cells, which alters the ligand specificity that turns the nonsteroidal anti-androgens into

AR agonists.[236] The LNCaP prostate cell line widely used in cancer cell biology research harbors a mutated AR (T877A) that occurs relatively frequently in prostate cancer metastases and can cause the flutamide withdrawal syndrome.[237] Since the Nobel prize-winning discovery in the 1940s of androgen deprivation as palliative treatment of advanced prostate cancer,[238] targeting of AR for treatment of prostate cancer has focused on surgical or medical castration to eliminate AR's cognate endogenous ligand, testosterone. After transient remission following castration, however, prostate cancers resume growth in the apparently androgen-independent terminal, treatment-resistant stage of the disease. Although castration eliminates the major (>95%) contribution to overall androgen synthesis, ongoing production of androgens from other tissues expressing steroidogenic enzymes, such as the adrenal[239] and prostate tumors,[240] has been proposed to explain the late development of apparent androgen independence. Extensive clinical trials of maximum androgen blockade, which aim to ablate androgen action more thoroughly by adding anti-androgens to castration, however, have produced only minimal improvement in survival,[241] possibly because anti-androgens counter the deleterious initial "flare" effect of superactive GnRH analogues used for medical castration. A more effective approach has been the development of abiraterone, a rationally designed, mechanism-based inhibitor of CYP17A1 (17-hydroxylase/17,20 lyase) incorporating a 16 to 17 double bond to inhibit 17-hydroxylation. Abiraterone has proven effective and is well tolerated in treatment of late stage, apparently androgen-independent prostate cancer,[242] although the blockade of glucocorticoid and mineralocorticoid synthesis requires adrenal replacement therapy. In addition, newer AR blockers also provided promising new therapeutic approaches especially for castration-resistant advanced prostate cancer.[243]

Acquired androgen insensitivity may occur without AR mutations by mechanisms such as drugs including nonsteroidal (flutamide, bicalutamide, nilutamide) and steroidal (cyproterone acetate), drugs that block part of testosterone activation such as 5α reductase inhibitors (finasteride, dutasteride) or estrogen antagonists or aromatase inhibitors. In addition, drugs may have physiologic effects or pharmacologic actions that oppose various steps in androgen action such as LH and FSH suppression by estrogens or progestins or that cause an increase in circulating SHBG, which may influence testosterone transfer from blood into tissues to produce a functional phenocopy of androgen insensitivity.

Acquired androgen insensitivity in various disease states is reported with hormonal findings reflecting impeded androgen action, which may be reversible with alleviation of the underlying disease. The disease-related mechanisms that impede androgen action vary, but the most frequent is the increase in hepatic SHBG secretion that is caused by the underlying disease and/or its drug treatments. This impedes androgen action by reducing testosterone transport from blood to tissues as part of its overall reduction in the metabolic clearance rate of testosterone. For example, in hyperthyroidism, increased blood LH and testosterone concentrations with clinical features of androgen deficiency[244] are mediated by increased circulating SHBG caused by thyroid hormone-induced hepatic SHBG secretion,[245] whereas in hypothyroidism the reduced blood testosterone and SHBG are rapidly corrected by thyroid hormone replacement therapy.[244] In epilepsy, anticonvulsant-induced increase in hepatic SHBG secretion appears to be a common denominator in the near ubiquitous reproductive endocrine abnormalities in men with epilepsy.[246,247] The relative contributions of impaired tissue transfer of testosterone, reduced testosterone metabolic clearance rate,[248] or direct anti-androgenic effects of valproate[249] remain to be clarified. A similar mechanism of disease- and/or drug-induced increases in hepatic SHBG secretion may explain apparent acquired androgen insensitivity, often reversible with alleviation of the underlying disease, in various other conditions such as gluten enteropathy,[250,251] Wilson's disease,[252] relapsed acute intermittent porphyria,[253] acute alcoholism,[254] chronic liver disease, and transplantation.[64,255]

PHARMACOLOGY OF ANDROGENS

Indications for Androgen Therapy

Androgen therapy can be classified as physiologic replacement or pharmacologic therapy according to the dose and type of androgen objectives of treatment. Androgen replacement therapy aims to restore tissue androgen exposure in androgen-deficient men to levels comparable with those of eugonadal men. Using the natural androgen testosterone and a dose limited to one that maintains blood testosterone levels within the eugonadal range, androgen replacement therapy aims to restore the full spectrum of androgen effects while replicating the efficacy and safety experience of eugonadal men of similar age. Androgen replacement therapy is unlikely to prolong life because androgen deficiency, whether resulting from castration[256-260] or biological disorder,[261] has minimal effect in shortening life expectancy.[262] In contrast, pharmacologic androgen therapy uses androgens without restriction on androgen type or dose but aims to produce androgen effects on muscle, bone, brain, or other tissues. In this context, pharmacologic androgen therapy is a hormonal drug therapy evaluated for efficacy, safety, and cost-effectiveness by the same criteria as for other drugs. Many older uses of pharmacologic androgen therapy are now considered second-line therapies as more specific treatments are developed.[263] For example, erythropoietin has largely supplanted androgen therapy for anemia caused by marrow or renal failure, and improved first-line drug treatments for endometriosis, osteoporosis, and advanced breast cancer have similarly relegated androgen therapy to a last resort. Similarly, newer mechanism-based agents in development for hereditary angioedema may displace 17α-alkylated androgens.[264,265] Nevertheless in many clinical situations pharmacologic androgen therapy remains a cost-effective option with a long-established efficacy and safety profile.

Androgen Replacement Therapy

The main clinical indication for testosterone treatment is in replacement therapy for androgen-deficient men.

Establishing a pathological basis for androgen replacement therapy requires identifying well-defined pathological disorders of the hypothalamus, pituitary, or testis that lead to persistent deficiency in either hypothalamic-pituitary regulation of, or direct impairment of, testicular testosterone secretion. The prevalence of male hypogonadism requiring androgen replacement therapy in the general community can be estimated from the known prevalence of Klinefelter's syndrome (15.6 per 1000 male births in 33 prospective birth survey studies[266,267]), because Klinefelter's syndrome accounts for 25% to 35% of men requiring androgen replacement therapy. The estimated prevalence of ~5 per 1000 men in the general community makes androgen deficiency the most common hormonal deficiency disorder among men. Although life expectancy is not reduced by castration as an adult[256-260] or only minimally (1 to 2 years) shortened[261] by lifelong androgen deficiency, the hormonal deficit causes preventable morbidity and a suboptimal quality of life.[266] Because of its variable and often subtle clinical features, androgen deficiency remains significantly underdiagnosed, thus denying sufferers simple and effective medical treatment with often striking benefits. Only ~20% of men with Klinefelter's syndrome characterized by the highly distinctive tiny (<4 mL) testes, are diagnosed during their lifetime,[268] indicating that most men go through life without a single pelvic examination by any medical professional in striking contrast to standard reproductive health care for women.

The testis has two physiologic functions, spermatogenesis and steroidogenesis, either of which can be impaired independently, resulting in infertility or androgen deficiency, respectively, so the term *hypogonadism* is inherently ambiguous. However, hypogonadism of any cause may require androgen replacement therapy if the deficit in endogenous testosterone production is sufficient to cause clinical and biochemical manifestations of androgen deficiency. Androgen deficiency is a clinical diagnosis with a characteristic presentation and underlying pathological basis in hypothalamus, pituitary, or testis disorder, and it is confirmed by blood hormone assays (see Chapter 139 for details). The clinical features of androgen deficiency vary according to the severity, chronicity, and epoch of life at presentation. These include ambiguous genitalia, microphallus, delayed puberty, sexual dysfunction, infertility, osteoporosis, anemia, flushing, muscular ache, lethargy, lack of stamina or endurance, easy fatigue, or incidental biochemical diagnosis. For each androgen-deficient man, his leading clinical symptoms of androgen deficiency are distinctive, reproducible, and correspond to a specific blood testosterone threshold for any individual, but both the symptom(s) and threshold vary among men.[269] Because the underlying disorders are mostly irreversible, lifelong treatment is usually required. Androgen replacement therapy can rectify most clinical features of androgen deficiency apart from defective spermatogenesis.[270] When fertility is required in gonadotropin-deficient men, spermatogenesis can be initiated by treatment with pulsatile GnRH[271] (if pituitary gonadotroph function is intact[272]) or gonadotropins[273] to substitute for pituitary gonadotropin secretion. The short half-life of LH would require multiple daily injections rendering it unsuitable for gonadotrophin therapy.[274] Instead practical gonadotropin therapy uses hCG, a placental heterodimeric glycoprotein that has a much longer duration of action that allows it to be administered every two or three days. The chorionic gonadotropin hCG consists of an identical α subunit as LH (also the same as in FSH and TSH) combined with a distinct β subunit that is highly homologous to the LH β subunit except for a C-terminal extension of 22 amino acids, which includes four O-linked sialic acid-capped, carbohydrate side chains. This C-terminal extension markedly prolongs the circulating half-life of hCG relative to LH, thereby making it a naturally occurring long-acting LH analogue. Both endogenous LH and hCG act on the Leydig cell LH/hCG receptor to stimulate endogenous testosterone production. Pharmaceutical hCG, originally purified from pregnancy urine and more recently its recombinant form, can be administered 2 to 3 times weekly for several months. Where spermatogenesis remains persistently suboptimal, recombinant FSH may be added.[273] After an induced pregnancy has passed the first trimester, androgen replacement therapy usually reverts to the simpler and cheaper use of testosterone while preserving the ability subsequently to reinitiate spermatogenesis by gonadotropin replacement.[273] The potential value of hCG therapy in gonadotropin-deficient adolescents in producing timely testis growth replicating physiologic puberty,[275] rather than relying on exogenous testosterone as the standard management, which leaves a dormant testis, has yet to be evaluated.

The extension of testosterone replacement therapy to men with partial, subclinical, or compensated androgen deficiency states remains of unproven value. Biochemical features of Leydig cell dysfunction, notably persistently elevated LH with low to normal levels of testosterone constituting a high LH/testosterone ratio, are observed in aging men,[276-278] in men with testicular dysfunction associated with male infertility,[279] or in men after chemotherapy-induced testicular damage.[280-283] Although such features may signify mild androgen deficiency, substantial clinical benefits from testosterone replacement therapy remain to be demonstrated.[284,285] Furthermore, testosterone administration may have deleterious effects on spermatogenesis so that its potential adverse effect on men's fertility must be considered with regard to their marital and fertility status.

The prospect of ameliorating the problems of male aging by androgen therapy has long been of interest and has been subject of many observational and short-term interventional controlled clinical trials. The consensus from population-based cross-sectional[276,277] and longitudinal studies[27,286,287] is that circulating testosterone concentrations fall by up to ~1% per annum from midlife onward, an age-related decline that is accelerated by the presence of concomitant chronic disease[287] and is associated with decreases in tissue androgen levels[288,289] as well as numerous comorbidities of male aging.[278,290] Conversely, although excellent health persists without major comorbidities, older age is not associated with lowered circulating testosterone levels.[23,24] Numerous cross-sectional and longitudinal observational studies show

that low blood testosterone is associated with greater all-cause and/or cardiovascular mortality, and the results are summarized in several meta-analyses.[291-295] An observational study of older war veterans indicated that testosterone treatment was associated with better survival[296]; however, bias in the nonrandomized design allowing for preferential treatment of healthier men with testosterone may explain this finding.[297] Interventional studies have, however, remained too small and short-term to resolve this dilemma. Definitive evidence as to whether androgen supplementation ameliorates age-related changes in bodily function and improves quality of life requires high quality, randomized placebo-controlled clinical trials using testosterone,[298] DHT,[299,300] hCG,[301] or synthetic androgens[302]; however, thus far the only consistent changes observed in well controlled studies of at least 3 months duration have been small increases in lean (muscle) mass and decreases in fat mass.

The best available summary evidence from meta-analyses indicates no or only inconsistent benefits in bone,[303,304] muscle,[305] cardiovascular disease and risk factors,[291-295] sexual function,[306,307] and some adverse effects, notably polycythemia.[308] The 2004 Institute of Medicine report[309] recommended as a priority the acquisition of more convincing, target-defining feasibility evidence to justify a large-scale clinical trial to weight potential benefits against risks of accelerating cardiovascular and prostate disease.

The major hypothetical population risk from androgen therapy for male aging remains increased cardiovascular disease[262] as were the risks of estrogen replacement for menopause.[310] Cardiovascular disease occurs earlier and is of greater severity in men, resulting in a twofold to threefold higher age-specific risk of cardiovascular death compared with women.[311] Epidemiologic data from observational studies shows a consistent association of cardiovascular disease with low blood testosterone levels; however, this may be the consequence of nonspecific effects of chronic cardiovascular disease on the hypothalamic-pituitary-testicular axis and/or confounding by major cardiovascular risk factors such as diabetes and obesity. Prospective observational data remain conflicting, with low blood testosterone predicting subsequent cardiovascular death in some studies[312,313] but not in others.[314-316] Testosterone therapy for older, frail men may increase adverse cardiovascular events,[317] which are side-effects that may be underreported[318] in previous studies not reporting such hazards.[319] The male disadvantage in cardiovascular disease shows a complex pathogenesis, with androgens exhibiting apparently beneficial effects including in regulating cardiac ion channel fluxes that dictate QT interval length, cardiac ventricular repolarization, and lesser risk of arrthymia[320-328] as well as angiogenesis,[329] which must be integrated with other apparently deleterious effects.[262,330] Similarly, for the more feared but quantitatively less significant late-life prostate diseases, their androgen dependence is well established with lifelong androgen deficiency reducing the risk of fatal prostate cancer,[331] although prevailing endogenous testosterone levels in healthy men do not predict risk of subsequent prostate cancer.[332]

These epidemiologic observations are consistent with either circulating testosterone levels being a biomarker, that is, a nonspecific barometer of ill health, or else the observations indicate that restoring circulating testosterone to eugonadal levels could reduce age-related cardiovascular and prostate disease (the "andropause" hypothesis). Decisive testing of these alternatives requires an adequately powered, placebo-controlled randomized clinical trial.[309] As the decisive safety and efficacy evidence on testosterone supplementation for male aging remains distant, interim clinical guidelines have been developed by academic and professional societies[333-335] aiming to restrain the unproven testosterone prescribing, which nevertheless escalated throughout recent decades in Australia,[336] Europe,[337,338] and most dramatically in North America.[339-342]

At present, androgen treatment cannot be recommended as routine treatment for male aging (see also Chapter 139) because of both the lack of proven efficacy and the risk of adverse effects. Nevertheless, among older men with preexisting pathological pituitary-gonadal disorders causing androgen deficiency, androgen replacement therapy may be used cautiously if contraindications such as untreated prostate cancer are excluded. Increasing evidence supports the safety of resuming testosterone replacement therapy after successful completion of definitive surgical or radiotherapy treatment of organ-confined prostate cancer.[343]

Hormonal male contraception can be considered a form of androgen replacement therapy because all currently envisaged regimens aim to suppress spermatogenesis by inhibiting gonadotropin secretion using testosterone alone or, more effectively, together with a progestin or a GnRH antagonist[344] (see also Chapter 142). As a consequence, exogenous testosterone is required to replace endogenous testosterone secretion.

Pharmacologic Androgen Therapy

Pharmacologic androgen therapy uses androgens to maximal therapeutic efficacy within adequate safety limits but without regard to androgen class and dose. The objective is to use androgen effects to improve mortality and/or morbidity of an underlying disease. Mortality benefits require that androgens modify the natural history of an underlying disease, a goal not achieved in any nongonadal disorder. Morbidity benefits are more realistic in aiming to improve quality of life by enhancing muscle, bone, brain, or other androgen-sensitive function (including mood elevation) as an adjuvant therapy in nongonadal diseases. Such treatment is judged by the efficacy, safety, and cost-effectiveness standards of other drugs, but few studies fulfill the requirements of adequate study design (randomization, placebo control, objective end points, adequate power, and duration).[263] In most circumstances the role of androgen therapy is largely as an affordable but second-line, supportive, or adjunctive therapy.

The range of pharmacologic uses of androgens includes treatment of anemia because of marrow or renal failure; osteoporosis especially where estrogen therapy is contraindicated; advanced ER-positive breast cancer; hereditary angioedema (C1 esterase inhibitor deficiency);

and for immunologic, pulmonary, and muscular diseases (reviewed in detail[345]). In anemia resulting from renal or marrow failure, androgens have proven beneficial effects on morbidity by improving hemoglobin levels, reducing transfusion requirements, and improving quality of life. However, androgens do not characteristically improve mortality, as they do not change the natural history of the underlying disease. In renal anemia, androgens are equally effective with erythropoietin in maintaining hemoglobin levels and reducing the transfusion requirement.[346-348] However, their virilizing effects in women are limiting, so that the affordability and augmentation of erythropoietin effects by androgens provide an ongoing adjuvant role in older men or where erythropoietin is unavailable.[346-348] Similarly, in anemia resulting from marrow failure, androgens reduce transfusion dependence but do not improve survival from the underlying marrow disorders. They remain second-line, supportive therapy for men in whom marrow transplantation is not feasible or fails.

Although these traditional indications for pharmacologic androgen therapy are often superseded by more specific, effective but costly treatments, androgens usually persist as second-line, empirical therapies for which the lower cost and/or equivalent or synergistic efficacy may still favor androgen therapy in some settings. For historical reasons, pharmacologic androgen therapy has often involved synthetic, orally active 17α-alkylated androgens despite their hepatotoxicity, including cholestasis, hepatitis, adenoma, and peliosis.[349,350] Other than in treating angioedema, in which direct hepatic effects of 17α-alkyl androgens (rather than androgen action per se) may be crucial to increasing circulating C1 esterase inhibitor levels to prevent attacks,[351-353] safer (nonhepatotoxic) testosterone preparations should generally be favored for long-term clinical use, although the risk-benefit balance may vary according to prognosis. For hereditary angioedema, more specific and costly new therapies such as purified or recombinant C1 inhibitor and bradykinin or kallikrein antagonists may overtake the traditional role of androgens for long-term prophylaxis of hereditary angioedema.[264,265]

An important watershed was the proof via a well-designed, placebo-controlled randomized clinical trial that pharmacologic testosterone doses increase muscular size and strength even in eugonadal men,[354] overturning a previous belief to the contrary.[355] Testosterone has clear dose-dependent effects, ranging from below to well above the physiologic range, on muscle size and strength (but not performance function or fatigue) in young[356] and older[357] men with similar magnitude of ultimate effect.[358] Nevertheless, aging reduced the responsiveness of older muscle to testosterone as the same doses produced higher blood testosterone concentrations in older men. The higher blood testosterone concentrations are the result of decreased testosterone metabolic clearance rate caused by age-related higher blood SHBG concentrations.[359] Similarly, erythropoietic effects of testosterone are greater in older men who developed a higher rate of polycythemia.[360] Diverse androgen-sensitive effects including changes in metabolic function, cognition, mood, and sexual function were minimal at physiologic testosterone doses.[361,362] The wide dose-response to testosterone through and beyond the physiologic range suggests that androgens may provide beneficial effects in reversing the frailty observed in many medical settings. Whether such effects can be applied effectively and safely[317] to improve frailty and quality of life in chronic disease or in male aging remains an important challenge for the future.

Pharmacologic androgen therapy for human immunodeficiency virus (HIV) infection in the absence of classical hypogonadism has been investigated for its effects on disease-associated morbidity, notably AIDS wasting. However, pharmacologic androgen therapy does not alter the natural history of underlying disease, and the objective functional benefits remain modest, being confined to reversing some aspects of AIDS wasting. The rationale for pharmacologic androgen therapy in AIDS wasting is that body weight loss is an important determinant of survival in AIDS and other terminal diseases, with death estimated to occur when lean body mass reaches 66% of ideal.[363] This leads to the hypothesis that androgens may delay death by increasing appetite and/or body weight. Meta-analysis of randomized, placebo-controlled studies of pharmacologic androgen therapy in HIV-positive men with AIDS wasting indicates a modest increase in lean mass and decreased fat mass with additive effects from resistance training but inconsistent improvement in quality of life.[364,365] Among HIV-positive men without wasting there is less improvement in body composition and none in quality of life, although there is in the population in affluent countries a popular subculture of androgen abuse.[366] The oral progestin, megestrol acetate, used alone as an appetite stimulant, induces profound gonadotropin and testosterone suppression to castrate levels, and it predominantly increases fat mass rather than reversing the loss of muscle.[367,368]

A special application of pharmacologic androgen treatment is its use in women with estrogen-resistant menopausal symptoms such as loss of energy or libido. The similarity of blood testosterone in women, children, and orchidectomized men indicates that the term *female androgen deficiency* is not meaningful in women[369] with normal adrenal function.[370] In women with adrenal failure resulting from hypothalamic-pituitary or adrenal disease, DHEA replacement therapy[14] has significant but modest clinical benefits in some[370,371] but not all[372,373] studies, with relatively frequent, mild virilizing side-effects. Similar effects are observed using testosterone instead of DHEA.[374] Well-controlled studies of testosterone administration for menopausal symptoms or sexual hypofunction in women with normal adrenal function show strong placebo effects[375,376] but minimal or no consistent symptomatic benefits[377] even with supraphysiologic blood testosterone levels.[375] High-dose testosterone used at male androgen replacement therapy doses[378,379] produce markedly supraphysiologic blood testosterone levels and virilization, including voice changes and androgenic alopecia.[380-382] Lower but still supraphysiologic testosterone doses and blood levels increase bone density in menopausal women[383] but produce virilizing adverse effects (hirsutism, acne) in short-term studies,

whereas long-term safety risks for cardiovascular disease and hormone-dependent cancers (breast, uterus, ovary) remain unclear.[384] Studies of testosterone administration as a form of adjuvant pharmacologic androgen therapy in women with chronic medical disorders such as anorexia nervosa,[385] HIV,[386] and systemic lupus erythematosus[387] produce little consistent effect on disease activity or quality of life including sexual function beyond the effects of expectation.

Many important questions and opportunities remain for pharmacologic androgen therapy in nongonadal disease, but careful clinical trials are essential for proper evaluation.[345] Well-designed placebo-controlled clinical studies of pharmacologic androgen therapy in chronic disease have been reported. In men with severe chronic obstructive pulmonary disease, the therapy produces modest increases in muscle mass and strength with improved quality of life but no effect on underlying lung function,[388-390] whereas oral megestrol administration resulted in similar effects despite marked suppression of blood testosterone levels.[391] Similarly, although in an observational study chronic heart failure is associated with lower blood testosterone, which is proportional to the decrease in cardiac function and which predicts survival,[392] a placebo-controlled prospective study of testosterone administration showed improvement in effort-dependent exercise capacity but not in left ventricular function or survival.[393] This discrepancy suggests that the lowered blood testosterone is the consequence of a nonspecific adaptive reaction of the reproductive hormonal axis to chronic disease (ontogenic regression[394]) rather than a detrimental effect susceptible to being overcome by androgen supplementation. Both testosterone, and its nonaromatizable derivative nandrolone, produce increased bone density in men with glucocorticoid-induced osteoporosis with minimal short-term side-effects.[395,396] The best opportunities for future evaluation of adjuvant use of androgen therapy in men with nongonadal disease include steroid-induced osteoporosis; wasting resulting from AIDS or cancer cachexia; and chronic respiratory, rheumatologic, and some neuromuscular diseases. In addition, the role of pharmacologic androgen therapy in recovery and/or rehabilitation after severe catabolic illness such as burns, critical illness, or major surgery are promising,[397] but the therapy requires thorough evaluation because detrimental effects may occur.[398] Future studies of adjuvant androgen therapy require high-quality clinical data involving randomization and placebo controls as well as the need to find the optimal dose and authentic clinical, rather than surrogate, end points.

Androgen Misuse and Abuse

Misuse of androgens involves medical prescription without a valid clinical indication and outside of an approved clinical trial, and androgen abuse is the use of androgens for nonmedical purposes. Medical misuse includes prescribing androgens for male infertility[399] or sexual dysfunction in men without androgen deficiency,[306] where there are no likely benefits, or as a tonic for nonspecific symptoms in older men ("male menopause," "andropause," "late-onset hypogonadism")[309] or in women[369] where safe and effective use is unproven. Although there is no exact boundary that defines overuse, mass marketing and promotion to fend off aging in the absence of reliable evidence are hallmarks of systemic misuse of androgens. Androgens have a mystique of youthful virility, making them ideal for manipulative marketing to wealthy, worried well people as they grow older.

Androgen abuse originated in the 1950s as a product of the Cold War[400] whereby communist Eastern European countries could develop national programs to achieve short-term propaganda victories over the West in Olympic and international sports.[401] This form of cheating was readily taken up by individual athletes seeking personal rewards of fame and fortune in elite competitive sports. Throughout the decades, androgen abuse has become endemic in developed countries with sufficient affluence to support drug abuse subcultures. Androgen abuse is cultivated by underground folklore among athletes and trainers ("whatever it takes") particularly in power sports and bodybuilding, where the use of so-called "anabolic steroids" to enhance personal image and sports performance can be promoted. A lucrative illicit industry is fostered through wildly speculative underground publications touting the use of prodigious androgen doses in combination ("stacking") and/or in cycling regimens. The myotrophic benefits of supraphysiologic androgen doses in eugonadal men were long doubted[355] in the belief that alleged performance gains were attributable to placebo responses involving effects of motivation, training, and diet. This belief was overturned by a randomized, placebo-controlled clinical study showing decisively that supraphysiologic testosterone doses (600 mg testosterone enanthate weekly) for 10 weeks increases muscular size and strength.[354] In well-controlled studies of eugonadal young[402] and older[358] men, testosterone shows strong linear relationships of dose with muscular size and strength throughout and beyond the physiologic range. The additional dose-dependent increases in erythropoiesis[360] and mood[403] may also enhance the direct myotrophic benefits of supraphysiologic androgen dose. Although these studies prove the unequivocal efficacy of supraphysiologic androgen dosage to increase muscle size and strength even in eugonadal men, the specific benefits for skilled athletic performance depend on the sport involved, with the greatest advantages evident in power sports. The overall safety of the sustained supraphysiologic androgen exposure in these settings remains undefined, notably for cardiovascular and prostate disease as well as psychiatric sequelae.[404]

Progressively, the epidemic of androgen abuse has spread from elite power athletes so that the majority of abusers are no longer athletes but are recreational and cosmetic users wishing to augment bodybuilding or are occupational users working in security-related professions.[405] As an illicit activity, the extent of androgen abuse in the general community is difficult to estimate, although point estimates of prevalence are more feasible in captive populations such as high schools. The prevalence of self-reported lifetime ("ever") use is estimated to be 66 in the United States,[406] 58 in Sweden,[407] 32 in Australia,[408]

and 28 in South Africa[409] per 1000 boys in high school, with a much lower prevalence among girls. Predictors of androgen abuse in high schools are consistent across many cultures and include truancy, availability of disposable income, and minority ethnic or migrant status, and there is significant overlap with typical features of adolescent abuse of other drugs. Voluntary self-report of androgen abuse understates the prevalence of drug use among weight lifters[410] and prisoners.[411,412]

Abusers consume androgens from many sources including veterinary, inert, or counterfeit preparations, obtained mostly through illicit sales by underground networks with a small proportion obtained from compliant doctors. Highly sensitive urinary drug screening methods for detection of natural and synthetic androgens, standardized by the WADA for international and national sporting bodies as a deterrent, have contributed to the progressive elimination of known androgens from elite sporting events. The persistent demand for androgens as the most potent known ergogenic drugs has led to the production in unlicensed laboratories of illicit designer androgens such as norbolethone,[413] tetrahydrogestrinone,[414,415] and dimethyltestosterone[416] that are custom developed for elite professional athletes to evade doping detection. The rapid identification of these designer androgens has meant that they have been seldom, if ever, used.[417] Corresponding legislation has also been introduced by some governments to regulate the clinical use of androgens and to reduce the illicit supply of marketed androgens. Overall, although the community epidemic of androgen abuse driven by user demands shows few signs of abating,[418,419] rigorous detection is reducing the demand in elite sports, and similar trends have been reported in the long-running Monitoring the Future Project (http://www.monitoringthefuture.org/) whereby self-reported androgen abuse peaked in U.S. high schools around 2000 and is now abating.

Androgen abuse is associated with reversible depression of spermatogenesis and fertility,[420-424] gynecomastia,[425] hepatotoxicity caused by 17α-alkylated androgens,[426] HIV and hepatitis from needle sharing[427-431] (although the infectious risks are lower than among other intravenous drug users because of less needle and syringe sharing),[432] local injury and sepsis from injections,[433,434] overtraining injuries,[435] rhabdomyolysis,[436] popliteal artery entrapment,[437] cerebral[438] or deep vein thrombosis and pulmonary embolism,[439] cerebral hemorrhage,[440] convulsions,[441] as well as mood and/or behavioral disturbances.[442,443] The medical consequences of androgen abuse for the cardiovascular system have been reviewed,[444-448] but only few anecdotal reports are available relating to prostate diseases.[449-451] However, for both the cardiovascular system and prostate diseases, long-term consequences of androgen abuse based on anecdotal reporting are likely to be significantly underestimated because of underreporting of past androgen use and nonsystematic follow-up. Few well-controlled prospective clinical studies of the cardiovascular[452,453] or prostatic[358,402,454] effects of high-dose androgens have been reported. Most available clinical studies consist of nonrandomized, observational comparisons of androgen users compared with nonusers or discontinued users.[455-467] However, such retrospective observational studies suffer from ascertainment, participation, and other biases so that important unrecognized determinants of outcomes may not be measured. Given the low community prevalence of androgen abuse, well-designed, sufficiently powerful retrospective case-control studies are required to define the long-term risks of cardiovascular and prostate disease.[468] The best available evidence suggests that elite athletes experience a longer life expectancy because of reduced cardiovascular disease.[469,470] This benefit, however, is least evident among power athletes, the group with highest likelihood of past androgen abuse, and this is a finding confirmed by a small study showing a greater than fourfold increase in premature deaths (from suicide, cardiovascular disease, liver failure, and lymphoma) among 62 former power athletes compared with population norms.[471] More definitive studies are required, but at present, largely anecdotal information suggests that serious short-term medical danger is limited considering the extent of androgen abuse, that androgens are not physically addictive,[472,473] and that most androgen abusers eventually discontinue drug use. After cessation of prolonged use of high-dose androgens, recovery of the hypothalamic-pituitary-testicular axis may be delayed for months and up to 2 years,[424] creating a transient gonadotropin deficiency state.[474-476] This may lead to temporary androgen deficiency symptoms and/or oligozoospemia and infertility that eventually abate without requiring additional hormonal treatments. Although hCG can induce spermatogenesis,[422,477] like exogenous testosterone, it further delays recovery of the reproductive axis and perpetuates the drug-abuse cycle.[478] There remains anecdotal evidence from experienced observers that prolonged hypothalamic-pituitary suppression by high-dose exogenous androgens may not always be fully reversible after even a year off exogenous androgens, resembling the incomplete reversibility of GnRH analogue suppression of circulating testosterone in older men after the cessation of prolonged medical castration for prostate cancer.[479,480] An educational-program intervention resulted in modest success for deterring androgen abuse among secondary-school footballers,[481] and more effective interventions to prevent and/or halt androgen abuse capable of overcoming strong contrary social incentives of fame and fortune are yet to be defined.

Practical Goals of Androgen Replacement Therapy

The goal of androgen replacement therapy is to replicate the physiologic actions of endogenous testosterone, usually for the remainder of life, as the pathological basis of hypogonadism usually involves irreversible disorders of the hypothalamus, pituitary, or testis. This requires rectifying the deficit and maintaining androgenic/anabolic effects on bone,[132,482] muscle,[357] blood-forming marrow,[360,483] sexual function,[484,485] and other androgen-responsive tissues. The ideal product for long-term androgen replacement therapy should be a safe, effective, convenient, and inexpensive form of testosterone with long-acting depot properties providing steady-state blood testosterone levels as a result of reproducible, zero-order

release kinetics. Following the aim to maintain physiologic testosterone levels and resulting tissue androgen effects, androgen replacement therapy usually uses testosterone rather than synthetic androgens for reasons of safety, full-spectrum efficacy, and ease of monitoring. Synthetic steroidal and nonsteroidal androgens are likely to lack the full spectrum of testosterone tissue effects because of local amplification by 5α reductase to DHT and/or diversification to act on ERα by aromatization to estradiol.[5,124] The practical goal of androgen replacement therapy is therefore to maintain stable, physiologic testosterone levels for prolonged periods using convenient depot testosterone formulations that facilitate compliance and avoid either supranormal or excessive fluctuation of androgen levels. The adequacy of testosterone replacement therapy is important for optimal outcomes,[486] as suboptimal testosterone regimens, whether because of inadequate dosage or poor compliance, produce suboptimal bone density[487-489] compared with the maintenance of the age-specific norms achieved with adequate testosterone regimens.[486,490] Differences in testosterone-induced bone density according to type of hypogonadism[491] may be attributable to delay in onset and/or suboptimal testosterone dose in early onset androgen deficiency[492,493] leading to reduced peak bone mass achieved in early manhood. Similarly, the severity of the androgen deficiency also predicts the magnitude of the restorative effect of testosterone replacement with greatest effects early in treatment of severe androgen deficiency,[482,486] whereas only minimal effects are evident for testosterone treatment of mild androgen deficiency.[284,285] The potential for individual tailoring of testosterone replacement dose according to an individual's pharmacogenetic background of androgen sensitivity has been proposed by a study showing that the magnitude of the prostate growth response to exogenous testosterone in androgen-deficient men is inversely related to the CAG triplet (polyglutamine) repeat length in exon 1 of the AR.[190] However, this polyglutamine repeat is inversely related to ambient blood testosterone levels[494] consistent with the reciprocal relationship between repeat lengths and AR transactivational activity. Hence this polymorphism is only a weak modulator of tissue androgen sensitivity. Whether the magnitude of this pharmacogenetic effect is sufficiently large and significantly influences other androgen-sensitive end points will determine whether this approach is useful in practice.

Pharmacologic Features of Androgens

The major features of the clinical pharmacology of testosterone are its short circulating half-life and low oral bioavailability, both largely attributable to rapid hepatic conversion to biologically inactivate oxidized and glucuronidated excretory metabolites. The pharmaceutical development of practical testosterone products has been geared to overcoming these limitations. This has led to the development of parenteral depot formulations (injectable, implantable, transdermal), or products to bypass the hepatic portal system (sublingual, buccal, gut lymphatic absorption) as well as orally active synthetic androgens that resist hepatic degradation.[100,495]

Androgens are defined pharmacologically by their binding and activation of the AR.[1] Testosterone is the model androgen featuring a 19-carbon, four-ring steroid structure with two oxygens (3-keto, 17β-hydroxy) including a Δ^4 nonaromatic A ring. Testosterone derivatives (Fig. 138-2) have been developed to enhance intrinsic androgenic potency, prolong duration of action, and/or improve oral bioavailability of synthetic androgens. Major ring structural modifications of testosterone include 17β-esterification, 19-nor-methyl, 17α-alkyl, 1-methyl, 7α-methyl, and D-homoandrogens. Most synthetic androgens are 17α-alkylated analogues of testosterone developed to exploit the fact that introducing a one-carbon (methyl) or two-carbon (ethyl, ethinyl) group at the 17α position of the D ring allowed for oral bioactivity by reducing hepatic oxidative degradative metabolism. In 1998, the first nonsteroidal androgens, modified from nonsteroidal aryl propionamide anti-androgen structures, were reported,[496] followed by quinoline, tetrahydroquinoline, and hydantoin derivatives.[497]

The identification of a single gene and protein for the AR in 1988[498-500] explains the physiologic observation that, at equivalent doses, all androgens produce essentially similar effects.[501] The term "anabolic steroid" was invented during the post-WWII golden age of steroid



Figure 138-2 Pathways of testosterone action. In men, most (>95%) testosterone is produced under LH stimulation through its specific receptor, a heptahelical G-protein coupled receptor located on the surface membrane of the steroidogenic Leydig cells. The daily production of testosterone (5 to 7 mg) is disposed along one of four major pathways. The direct pathway of testosterone action is characteristic of skeletal muscle in which testosterone itself binds to and activates the AR. In such tissues there is little metabolism of testosterone to biologically active metabolites. The amplification pathway is characteristic of the prostate and hair follicle in which testosterone is converted by the type 2 5α reductase enzyme into the more potent androgen, dihydrotestosterone. This pathway produces local tissue-based enhancement of androgen action in specific tissues according to where this pathway is operative. The local amplification mechanism was the basis for the development of prostate-selective inhibitors of androgen action via 5α reductase inhibition, the forerunner being finasteride. The diversification pathway of testosterone action allows testosterone to modulate its biological effects via estrogenic effects that often differ from AR-mediated effects. The diversification pathway, characteristic of bone and brain, involves the conversion of testosterone to estradiol by the enzyme aromatase, which then interacts with the ERs α and/or β. Finally the inactivation pathway occurs mainly in the liver with oxidation and conjugation to biologically inactive metabolites that are excreted by the liver into the bile and by the kidney into the urine.

pharmacology to define an idealized androgen lacking virilizing features but maintaining myotrophic properties so that it could be used safely in children and women. Although this quest proved illusory and was abandoned after all industry efforts failed to identify such a hypothetical synthetic androgen, the obsolete term "anabolic steroid" persists mainly as a lurid descriptor in popular media despite its continuing to make a false distinction where there is no difference.[502] Better understanding of the metabolic activation of androgens via 5α-reduction and aromatization in target tissues and the tissue-specific partial agonist/antagonist properties of some synthetic androgens may lead to more physiologic concepts of tissue-specific androgen action ("specific androgen receptor modulator") governed by the physiologic processes of prereceptor androgen activation as well as postreceptor interaction with coregulator proteins analogous to the development of synthetic estrogen partial agonists with tissue specificity ("specific estrogen receptor modulator").[503] However, administration of a pure androgen incapable of aromatization may induce estrogen deficiency.[504] The potential for new clinical therapeutic indications of novel tissue-selective androgens in clinical development remains to be fully evaluated.[505]

Formulation, Route, and Dose

Unmodified Testosterone

Testosterone Implants. Implants of fused crystalline testosterone provide stable, physiologic testosterone levels for as long as 6 months after a single implantation procedure.[506] Typically, four 200-mg pellets are inserted under the skin of the lateral abdominal wall or hip using in-office minor surgery and a local anesthetic. No suture or antibiotic is required, and the pellets are fully biodegradable and thus do not require removal. This old testosterone formulation[507] includes excellent depot properties, with testosterone being absorbed by simple dissolution from a solid reservoir into extracellular fluid at a rate governed by the solubility of testosterone in the extracellular fluid, resulting in a standard 800-mg testosterone dose releasing ~5 mg per day,[508] which replicates the testosterone production rate in healthy eugonadal men.[48-50,509] The long duration of action makes it popular among younger androgen-deficient men as reflected by a high continuation rate.[510] The major limitations of this form of testosterone administration are the cumbersome implantation procedure and extrusion of a single pellet after ~5% of procedures. Extrusions are more frequent among thin men undertaking vigorous physical activities,[510] but surface washing,[511] antibiotic impregnation[512] or varying the site of implantation or track geometry[513] do not reduce the extrusion rate. Other side effects such as bleeding or infection are rare (<1%).[510] Despite its clinical advantages and popularity, this simple, nonpatented technology has limited commercial marketing appeal and, consequently, is not widely available apart from compounding chemists and niche manufacturers.[514]

Transdermal Testosterone. Delivery of testosterone across the skin has long been of interest.[152] Adhesive dermal patches and gels delivering testosterone transdermally by daily application can maintain physiologic circulating testosterone levels. The first transdermal patch was developed for scrotal application where the thin, highly vascular skin facilitates steroid absorption,[515,516] but these patches were succeeded by smaller, nonscrotal patches.[517,518] The application of patches onto less permeable nonscrotal skin (trunk, proximal limb, axilla) reduces steroid absorption and, although absorption can be enhanced by heating,[519] in practice this required inclusion of absorption enhancers that caused skin irritation[520,521] of varying severity.[522] Although skin irritation may be reduced by topical corticosteroid cream,[523] most users experience some skin reaction with ~25% having to discontinue because of dermal intolerance.[393]

Dermal testosterone[524] or DHT[525,526] gels developed in Europe are now more widely available as topical gels[484,527-532] or solution.[533] They must be applied daily on the trunk or axilla, and the volatile hydroalcoholic gel base evaporates rapidly with a short-lived stinging sensation but is relatively nonirritating to the skin, so there are few discontinuations because of adverse skin reactions.[484,534] Transdermal testosterone delivery depends on a small fraction (typically <5%) of testosterone applied to the skin in the dermal gel or solution transferring into the skin where it forms a secondary reservoir in the stratum corneum. From this depot, testosterone is gradually released into the circulation by diffusion down a concentration gradient into the bloodstream. As a large amount of testosterone remains on the skin after topical application, transfer of testosterone by direct skin contact is a risk for an intimate partner[535-537] or for children.[538-543] Serum testosterone concentrations are increased in nondosed female partners who are making direct skin contact with men using transdermal testosterone products.[544] Creating a physical barrier such as using a testosterone transdermal patch[545] or covering the application site with clothing[544,546] reduces this risk. Washing off excess gel from the application site after a short time (<30 minutes) may reduce the risk of transfer[544,546,547] but also reduces effective testosterone absorption in some[548] but not all[547] studies. Unlike transdermal patches, topical gel or solutions have considerable misuse and abuse potential.

Testosterone Microspheres. Suspensions of biodegradable microspheres, consisting of polyglycolide-lactide matrix similar to absorbable suture material and laden with testosterone, can deliver stable, physiologic levels of testosterone for 2 to 3 months after intramuscular injection.[549,550] Subsequent findings[551] suggest that the practical limitations of microsphere technology such as loading capacity, large injection volumes, and batch variability have yet to be overcome.

Oral Testosterone. Finely milled testosterone[144,552] or testosterone suspended in an oil vehicle[553,554] has low oral bioavailability requiring high daily doses (200 mg to 400 mg) to maintain physiologic testosterone levels. Such a heavy androgen load causes prominent hepatic enzyme induction[555] without hepatotoxicity,[556] and lower doses may be used for selective androgen delivery to the liver.[557,558] Although effective in small studies,[559] oral testosterone is

not commercially available and is little used. Sufficiently high oral testosterone doses (400 mg to 900 mg daily) also reduce serum SHBG,[560] which may explain the concomitant acceleration of testosterone metabolism.[144,559,561]

Buccal or sublingual delivery of testosterone is an old technology[147] designed to bypass the avid first-pass hepatic metabolism of testosterone that is inevitable with the portal route of absorption. After it is absorbed into the general circulation, however, testosterone is rapidly inactivated, reflecting its short circulating half-time. Revivals of this technology include testosterone in a sublingual cyclodextrin formulation[562] and in a buccal lozenge.[148,563] The multiple daily dosing required to maintain physiologic testosterone levels are drawbacks for long-term androgen replacement using such products, and their effectiveness and acceptability remain to be established. Like all transepithelial (nonparenteral) testosterone delivery systems, disproportionate amounts of testosterone undergo 5α-reduction during local absorption, resulting in higher blood DHT levels than those in eugonadal men.[564] Such increases in circulating DHT pose minimal risk of accelerating prostate disease because: 1) intraprostatic DHT, produced locally within the prostate, is unaffected by administration of testosterone[565,566] or DHT[567]; 2) prolonged administration (2 years) of high-dose DHT does not accelerate prostate size or growth rate in men without prostate disease[504]; and 3) prostate diseases remain rare among men with pathological androgen deficiency and men receiving testosterone replacement therapy.

Testosterone Esters

Injectable. The most widely used testosterone formulation for many decades has been the intramuscular injection of testosterone esters, formed by 17β-esterification of testosterone with fatty acids of various aliphatic and/or aromatic chain lengths, injected in a vegetable-oil vehicle.[568] This depot product relies on retarded release of the testosterone ester from the oil vehicle injection depot because esters undergo rapid hydrolysis by ubiquitous esterases to liberate free testosterone into the circulation. The pharmacokinetics and pharmacodynamics of androgen esters are therefore primarily determined by ester side-chain length, volume of oil vehicle, and site of injection via hydrophobic physicochemical partitioning of the androgen ester between the hydrophobic oil vehicle and the aqueous extracellular fluid.[569]

The short 3-carbon aliphatic ester side-chain of testosterone propionate gives the product a brief duration of action requiring injections of 25 to 50 mg at 1- to 2-day intervals for effective testosterone replacement therapy. In contrast, the 7-carbon side-chain of testosterone enanthate has a longer duration of action so that it is used at doses of 200 to 250 mg per 14 days for androgen replacement therapy in hypogonadal men,[570-572] which is long the mainstay of testosterone used in replacement therapy. Other testosterone esters (cypionate, cyclohexane carboxylate) include similar pharmacokinetics, making them pharmacologically equivalent to testosterone enanthate.[573] Similarly, mixtures of short- and longer-acting testosterone esters also have essentially the same pharmacokinetics as the longest-acting ester.

Longer-acting testosterone esters, testosterone buciclate and undecanoate, which are intended to provide depot release throughout months rather than weeks, have been developed. Testosterone buciclate (trans-4-n-butyl cyclohexane carboxylate) is an insoluble testosterone ester in an aqueous suspension that produces prolonged testosterone release because of steric hindrance of ester side-chain hydrolysis slowing the liberation of unesterified testosterone. Although the buciclate ester produces blood testosterone levels in the low-normal physiologic range for as many as 4 months after injection in nonhuman primates[574] as well as in hypogonadal[575] and eugonadal[576] men, product development has not progressed. Injectable testosterone undecanoate, an ester of an 11-carbon aliphatic fatty acid in an oil vehicle, provides a longer (~12 weeks) duration of action[577-579] now widely marketed as a long-acting injectable depot testosterone product. Because of its limited solubility in the castor oil vehicle, testosterone undecanoate is administered as a 1000-mg dose in a large (4 mL) injection volume at 12-week intervals after the first dose and one 6-week loading dose or multiple loading doses thereafter.[580] Its relatively long duration of action is also well suited to male hormonal contraception either alone in Chinese men[581] or as part of an androgen-progestin combination.[582-584] For treatment of androgen deficiency, although its longer duration of action entails fewer injections with advantages for convenience and compliance, the efficacy and safety does not differ significantly from the shorter-acting testosterone enanthate,[585] but testosterone undecanoate is not yet marketed in the United States.

Oral Testosterone Undecanoate. Oral testosterone undecanoate, a suspension of the ester in 40-mg oil-filled capsules, is administered as 160 to 240 mg in two or more daily doses.[586] The hydrophobic, long aliphatic chain ester in an oil vehicle favors preferential absorption into chylomicrons entering the gastrointestinal lymphatics and largely bypassing hepatic first-pass metabolism.[150] The original oleic oil vehicle has been replaced by newer formulations comprising either castor oil containing a lipophilic surfactant (propylene glycol laureate)[587] or a different self-emulsifying formulation.[151] Oral testosterone undecanoate is not absorbed under fasting conditions but is taken up when ingested with food[587] that contains a moderate amount (at least 19 g) of fat.[151,588] Although oral testosterone undecanoate produces a disproportionate increase in serum DHT that is unaffected by concomitant administration of an oral 5α reductase inhibitor,[589] such modest increases in circulating DHT would have no impact on prostate size or growth rate[504] and apparent risk of prostate cancer,[332,590] presumably because testosterone or DHT of extraprostatic origin fails to increase intraprostatic DHT concentrations.[565-567] Testosterone undecanoate's low and capricious oral bioavailability[591] and short duration of action, requiring multiple, high daily doses of testosterone, lead only to modest clinical efficacy compared with injectable testosterone esters.[572,592] Widely marketed except in the United States, it may cause gastrointestinal intolerance but otherwise exhibits well-established safety.[590] Its

limitations in efficacy make it a second choice,[572] unless parenteral therapy is best avoided (e.g., bleeding disorders, anticoagulation) or a low dose, as for induction of male puberty, must be provided[593,594] as a better option than the hepatotoxic alkylated androgen, oxandrolone.[595]

Synthetic Androgens

Synthetic androgens include both steroidal and nonsteroidal androgens. Synthetic steroidal androgens, most developed by 1970, comprise categories of 17α-alkylated androgens, 1-methyl androgens, and nandrolone and its derivatives.

Most oral androgens are hepatotoxic 17α-alkylated androgens (methyltestosterone, fluoxymesterone, oxymetholone, oxandrolone, ethylestrenol, stanozolol, danazol, methandrostenolone, norethandrolone), making them unacceptable for long-term androgen replacement therapy (Fig. 138-3). The 1-methyl androgen mesterolone is an orally active DHT analogue that undergoes neither amplification by 5α reduction nor aromatization, but it is free of hepatotoxicity. Mesterolone is not used for long-term androgen replacement because of the need for multiple daily dosing, its poorly defined pharmacology,[596] and suboptimal efficacy at standard dose.[483,491] For historical reasons, the other marketed 1-methyl androgen methenolone is used almost exclusively in anemia because of marrow failure,[597,598] although it has no specific pharmacologic advantage over testosterone or other androgens.

Nandrolone (19-nor testosterone) is a widely used injectable androgen in the form of aliphatic fatty acid esters in an oil vehicle mainly used for the treatment of postmenopausal osteoporosis, where it is effective at increasing bone density and reducing fracture rate[599,600] but, because of virilization side-effects, its use is restricted to women who are unable to use or are intolerant of estrogens. It is also the most popular androgen abused in sports doping and in bodybuilding. Nandrolone is a naturally occurring steroid that appears as an intermediate in the conversion of testosterone to estradiol by the aromatase enzyme[601]; however, it is not normally present in the human bloodstream. The aromatase enzyme complex undertakes two successive hydroxylations on the angular C19 methyl group of testosterone followed by a cleavage of the C10-C19 bond to release formic acid and aromatize the A ring.[602] Nandrolone represents a penultimate step of the aromatization reaction while it is bound to the enzyme complex, including the C19 methyl group excised but a still nonaromatic A ring. Paradoxically, despite being an intermediate in the aromatization reaction, after parenteral administration nandrolone is virtually not aromatized,[603,604] presumably as a poor substrate with hindered access to the human aromatase enzyme.[605] Nandrolone is susceptible to enzymatic 5α reduction with its 5α reduced metabolites exhibiting moderate androgenic activity.[606] The minimal aromatizability of nandrolone makes it suitable for treatment of osteoporosis in women in whom estrogen therapy is contraindicated because of hormone-sensitive cancers (breast, uterus) or for older women, although virilization limits its acceptability.[607]

Synthetic nandrolone derivatives 7α-methyl 19-nortestosterone (MENT),[608] 7α, 11β-dimethyl 19-nortestosterone (dimethandrolone),[609] and 11β-methyl 19-nortestosterone (11β MNT) are potent, nonhepatotoxic androgens. MENT has potential as a depot androgen[610] for androgen replacement[611] and male contraception in an androgen-progestin combination regimen,[612] whereas dimethandrolone and 11β MNT have potential for male contraception as a single orally active steroid with dual androgen and progestin activity.[613,614] As nandrolone derivatives, these synthetic androgens undergo 5α-reduction[605,615] with their 5α-reduced metabolites, have reduced AR-binding affinity,[616] and their androgenic activity does not depend on 5α-reduction.[617] Disparities in reported susceptibility to aromatization vary from minimal using a recombinant human aromatase assay,[605] whereas greater aromatization is reported using purified human or equine placental aromatase.[615,618,619] The inability of MENT to maintain bone density in androgen-deficient men[489] may be a result of underdosing rather than an intrinsic feature of this synthetic androgen, illustrating the need for thorough dose titration in different tissues for synthetic androgens that may lack the full spectrum of testosterone effects.

Nonsteroidal Androgens

The first nonsteroidal androgen was described in 1998.[496] Based on structural modifications of the aryl-propionamide nonsteroidal anti-androgens (bicalutamide, flutamide), these compounds offer the possibility of orally active, potent androgens. Subsequently, additional classes of nonsteroidal androgen based on structures including quinolines, hydantoins, tetracyclic indoles, and oxachrysensones have been reported. Lacking the classical steroid-ring structure, such androgens are not subject to androgen activation either by 5α reductase or aromatization but, if taken orally, are subject to first-pass hepatic metabolism. Such hepatic metabolism can eliminate in vivo bioactivity of analogues with potent in vitro androgenic effects,[620] whereas metabolically resistant analogues can produce potent and disproportionate androgenic effects on the liver in transit. Several novel nonsteroidal androgens demonstrate potent androgenic effects experimentally on muscle, bone, and sexual function while minimizing prostate effects in experimental animals, but none have yet completed full clinical evaluation. These tissue-selective androgen effects may be attributable to the tissue distribution of 5α-reductase[621] or more complex mechanisms involving ligand-induced receptor conformation changes and/or postreceptor coregulator interaction mechanisms comparable to those that define the tissue selectivity and agonist/antagonist specificity of nonsteroidal estrogen partial agonists.[622] These features suggest that nonsteroidal androgens include the potential for development into pharmacologic androgen therapy regimens as tissue-selective mixed or partial androgen agonists ("selective androgen receptor modulators" [SARM]).[302,623] Conversely, they are not suitable for testosterone replacement therapy where the full spectrum of testosterone effects including aromatization is required, especially for tissues such as the brain[127,138] and bone,[132] where aromatization



GENERIC NAME	YEAR OF PATENT	R (17β)	X (17α)	OTHER MODIFICATIONS
NATURAL ANDROGENS				
Testosterone		H	H	
5α-Dihydrotestosterone	1960	H	H	4,5-ane
UNMODIFIED 17β ESTERS				
Testosterone propionate	1941	$COCH_2CH_3$	H	
Testosterone cypionate	1956	$CO(CH_2)_2$—⬡	H	
Testosterone enanthate	1958	$CO(CH_2)_5CH_3$	H	
Testosterone undecanoate	1975	$CO(CH_2)_9CH_3$	H	
Testosterone buciclate	1987	CO—⬡—$(CH_2)_3CH_3$	H	
MODIFIED ANDROGENS				
Methenolone	1958	H	H	4,5-ane :1,2-ene :1-CH_3
Nandrolone	1955	H	H	19-norCH_3
Mesterolone	1962	H	H	4,5-ane :1α-CH_3
MENT (7α-methyl nandrolone)	1994	H	H	19-norCH_3 :7α-CH_3
MODIFIED 17β ESTERS				
Methenolone acetate	1958	$COCH_3$	H	4,5-ane :1,2-ene :1-CH_3
Nandrolone phenylpropionate	1959	$CO(CH_2)_2$—⬡	H	19-norCH_3
Nandrolone decanoate	1961	$CO(CH_2)_8CH_3$	H	19-norCH_3
17α ALKYLATION				
Methyltestosterone	1945	H	CH_3	
Fluoxymesterone	1957	H	CH_3	9α-F :11β-OH
Methandrostenolone	1959	H	CH_3	1,2-ene
Oxandrolone	1964	H	CH_3	4,5-ane :C2-replaced by O
Oxymetholone	1959	H	CH_3	4,5-ane :2-methyleneOH
Stanozolol	1962	H	CH_3	4,5-ane :[2,3-c]pyrazole :2,3-ene
Danazol	1962	H	C≡CH	2,3-ene :[2,3-d]isoxazole}
Norethandrolone	1955	H	CH_2CH_3	19-norCH_3
Ethylestrenol	1959	H	CH_2CH_3	19-norCH_3 :3-H_2

Figure 138-3 **Testosterone and its derivatives.** Listed are the androgens in most common clinical use and their structural and chemical relationship to testosterone.

is a prominent feature of testosterone action.[124] The clinical efficacy, safety, and role of nonsteroidal androgens have yet to be defined fully and none are marketed. Whether the hepatotoxicity of anti-androgens[624,625] will also be a feature of nonsteroidal androgens remains to be determined.

Choice of Preparation

The choice of testosterone product for androgen replacement therapy depends on physician experience and patient preference, involving factors such as convenience, availability, familiarity, cost, and tolerance of frequent injections versus daily application. Testosterone in various forms is favored as superior to synthetic androgens for all androgen replacement therapy applications by virtue of their long record of safety and efficacy, ease of dose titration and blood level monitoring, as well as the possibility that synthetic androgens lack the full spectrum of testosterone effects through prereceptor tissue activational mechanisms (5α reduction, aromatization). The hepatotoxicity of synthetic 17α-alkylated androgens[349,350] makes them unsuitable for long-term androgen replacement therapy.

Crossover studies indicate that patients prefer testosterone products that maintain stable blood levels and smoother clinical effects. This is best achieved by testosterone products that form effective depots for sustained release, such as long-acting testosterone implants (6 monthly)[572] and injectable testosterone undecanoate (3 monthly)[626,627] or shorter-acting daily transdermal gels.[485] These are an improvement over the previous standard of intramuscular injections of older testosterone esters (enanthate, mixed esters) in an oil vehicle every 2 to 3 weeks,[570,572,573] which produce characteristically wide fluctuations in testosterone levels and corresponding roller-coaster symptomatic effects. A high rate of discontinuation among men commencing testosterone gel treatment[628] may reflect the now widespread but inappropriate prescription of testosterone for older men without pathological androgen deficiency.

There are few well-established formulation or route-dependent differences between various testosterone products after adequate doses are administered. As with estrogen replacement,[629,630] testosterone effects on SHBG act as manifestations of hepatic overdose[631] so that oral ingestion of either 17α-alkylated androgens[632] or oral testosterone undecanoate[572] causes prominent lowering of blood SHBG levels because of prominent first-pass hepatic effects. By contrast, nonoral, noninjectable testosterone depot products (transdermal, implants) have minimal effects on blood SHBG.[506,550,572,575,626] The more convenient and popular depot testosterone products, which maintain steady-state delivery patterns,[485,506,572,626,627] are supplanting the older, short-term (2 to 3 week) injectable testosterone esters (enanthate, mixed esters) as the mainstays of androgen replacement therapy.

Side Effects of Androgen Therapy

Serious adverse effects from androgen replacement therapy using physiologic testosterone doses for appropriate indications are rare. This corresponds to the observation that testosterone is the only hormone without a well-defined, spontaneously occurring clinical syndrome of hormone excess in men. However, supraphysiologic doses of synthetic androgens in pharmacologic androgen therapy or the massive doses of androgen abusers as well as unphysiologic use of androgens in children or women may produce unwanted androgenic side effects. Oral 17α alkylated androgens also provide the risk of a wide range of hepatic adverse effects. Virtually all androgenic side effects are rapidly reversible on cessation of treatment apart from inappropriate virilization in children or women in whom voice deepening and terminal body hair may be irreversible.

Steroidal Effects

Androgen replacement therapy activates physical and mental activity to enhance mood, behavior, and libido, thereby reversing their impairment during androgen deficiency.[633] In otherwise healthy men, however, who are receiving additional testosterone at doses equivalent to testosterone replacement doses, mood or behavior changes are not evident[362,634-640] or are minimal.[584] Even among healthy young men having very high androgen doses, there are few mood or behavior changes[403,641-644] except for a small minority (~5%) of paid clinical trial volunteers who display a hypomanic reaction, reversible on androgen discontinuation.[403] However, such adverse behavioral reactions were not observed in larger studies of testosterone administration to unpaid healthy men in hormonal contraception studies.[581,584,645,646] The higher prevalence of adverse behavioral effects reported among androgen abusers may be related not only to the massive androgen doses, but also to high levels of background psychological disturbance,[442] drug habituation,[472] and anticipation,[647] which predispose to behavioral disturbances reported during this form of drug abuse.[633,648]

Excessive or undesirable androgenic effects may be experienced during androgen therapy because of intrinsic androgenic effects in inappropriate settings (e.g., virilization in women or children). In a few untreated, late-diagnosed older men with pathological androgen deficiency, initiation of androgen treatment with standard doses may produce an unfamiliar and even intolerable increase in libido and erection frequency. Usually adequate advice to men and their partners before starting treatment is sufficient, but if such reactions are experienced, reduced starting dose with more gradual acclimatization to full dose coupled with counseling may be helpful.

Seborrhea and acne are commonly associated with high androgen levels in either the steep rise in endogenous testosterone during puberty or among androgen abusers. In contrast to the predominantly facial distribution of adolescent acne, androgen-induced acne occurring well after puberty is characteristically truncal in distribution and provides a useful clinical clue to androgen abuse.[649] Acne is unusual during testosterone replacement therapy, being mainly restricted to a few susceptible individuals during at the start of treatment with shorter-acting intramuscular testosterone esters, probably related to their generation of transient supraphysiologic testosterone concentrations in the days after injection.[483,570] Acne is rare with depot

testosterone products that maintain steady-state physiologic blood testosterone levels. Androgen-induced acne is usually adequately managed with topical measures and/or broad-spectrum antibiotics, if required, with either dose reduction or a switch to steady-state delivery (gel, long-acting injectable) that avoids supraphysiologic peak blood testosterone concentrations. Increased body hair and temporal hair loss or balding may also be seen even with physiologic testosterone replacement in susceptible men.

Modest weight gain (up to 5 kg) reflecting anabolic effects on muscle mass is also common. Gynecomastia is a feature of androgen deficiency but may appear during androgen replacement therapy, especially during use of aromatizable androgens such as testosterone that increase circulating estradiol levels at times when androgenic effects are inadequate (e.g., a too low or infrequent dose or unreliable compliance with treatment).

Obstructive sleep apnea causes a mild lowering of blood testosterone concentrations that is rectified by effective continuous positive airway pressure treatment.[650] Although testosterone treatment has precipitated obstructive sleep apnea[651] and has potential adverse effects on sleep in older men,[652] the prevalence of obstructive sleep apnea precipitated by testosterone treatment remains unclear. The risk is rare in younger androgen-deficient men, but is higher among older men with the steeply rising background prevalence with age of obstructive sleep apnea. Hence, screening for obstructive sleep apnea by asking about daytime sleepiness and partner reports of loud and irregular snoring, especially among overweight men with large collar size, is wise for older men starting testosterone treatment but is not routinely required for young men with classic androgen deficiency.

Hepatotoxicity

Hepatotoxicity is a well-recognized but uncommon side effect of 17α-alkylated androgens,[349] whereas the occurrence of liver disorders in patients using non-17α alkylated androgens such as testosterone, nandrolone, and 1-methyl androgens (methenolone, mesterolone) do not occur other than by chance.[350] This is consistent with the evidence of direct toxic effects on liver cells of alkylated but not nonalkylated androgens.[653] The risk of 17α alkylated androgen-induced hepatotoxicity is unrelated to the indication for use, although the association with certain underlying conditions may be related to the intensity of diagnostic surveillance.[350] It is possible, but unproven, that the risks are dose-dependent, although relatively few cases are reported among women using low-dose methyl-testosterone,[654,655] whereas the clinical management of children using the alkylated androgen oxandrolone often omits liver function tests. However, even if the risks are dose-dependent, the therapeutic margin is narrow. By contrast, the rates of hepatotoxicity among androgen abusers who typically use supraphysiologic, often massive, doses remain difficult to quantify because of underreporting of the extent of illicit use and dosage, but abnormal liver function tests are common in androgen abusers when checked incidentally as part of other health evaluations.

Biochemical hepatotoxicity may involve either a cholestatic or hepatitic pattern and usually abates with the cessation of steroid ingestion. Elevation of blood transaminases without gamma-glutamyl transferase may be attributable to rhabdomyolysis rather than to hepatotoxicity if confirmed by increased creatinine kinase.[656] Major hepatic abnormalities are related to the use of 17-alkylated androgens, including peliosis hepatis (blood-filled cysts)[657] and hepatic rupture, adenoma, angiosarcoma,[658,659] and carcinoma; however, these risks do not apply to testosterone or other nonalkylated androgens such as nandrolone or 1-methyl androgens. Prolonged use of 17α-alkylated androgens, if unavoidable, requires regular clinical examination together with biochemical monitoring of hepatic function, the latter not required for nonalkylated androgens. If biochemical abnormalities are detected, treatment with 17α-alkylated androgens should cease and safer androgens may be substituted without concern. Where structural lesions are suspected, radionuclide scan, ultrasonography, or abdominal computed tomography or magnetic resonance scan should precede hepatic biopsy, during which severe bleeding may be provoked in peliosis hepatis. Because equally effective and safer alternatives exist, the hepatotoxic 17α-alkylated androgens should not be used for long-term androgen replacement therapy. By contrast, pharmacologic androgen therapy often uses 17α alkylated androgens rather than the nonhepatotoxic alternatives for historical reasons. In these situations, the risk-benefit analysis needs to be judged according to the clinical circumstances.

Formulation-Related Effects

Complications related to testosterone products may be related to dosage, mode of administration, or idiosyncratic reactions to constituents. Intramuscular injections of oil vehicle may cause local pain, bleeding, or bruising, and, rarely, coughing fits or fainting resulting from oil microembolization[660,661] as a minor variant of accidental self-injection oil embolism.[662] Inadvertent subcutaneous administration of the oil vehicle is highly irritating and may cause pain, inflammation, or even dermal necrosis. Allergy to the vegetable oil vehicle (sesame, castor, arachis) used in testosterone ester injections is very rare, and even patients allergic to peanuts usually tolerate arachis (peanut) oil. Self-injection by bodybuilders of large volumes of sesame or other oils may cause exuberant local injection site reactions[663] or even oil embolism.[662] Long-term fibrosis at intramuscular injection sites might be expected but is rarely evident and has not been reported. Oral testosterone undecanoate frequently causes gastrointestinal intolerance because of the oil suspension vehicle in capsules. Testosterone implants may be associated with extrusion of implants or bleeding, infection, or scarring at implant sites.[510] Parenteral injection of testosterone undecanoate[626] or biodegradable microspheres[551] involves a large injection volume that may cause discomfort. Transdermal patches applied to the trunk cause skin irritation in most men, some with quite severe burnlike lesions,[522] with a significant minority (~20%) unable to continue use. Skin irritation may be reduced in prevalence or ameliorated by concurrent use of topical corticosteroid

cream at the application site,[523] whereas transdermal testosterone gels are rarely irritating.[484] Topical testosterone gels cause virilization via transfer of androgens through topical skin-to-skin contact with children[538-543] or sexual partners.[535,536] These problems can be avoided by covering the application site with clothing or by washing off excess gel after a short time.[547]

Monitoring of Androgen Replacement Therapy

Monitoring of androgen replacement therapy primarily involves clinical observations to optimize androgen effects including ensuring the continuation of treatment and surveillance for side effects. After testosterone dosage is well established, androgen replacement therapy requires only limited, judicious use of biochemical testing or hormone assays to verify adequacy of dosage when in doubt or when following changes of product or dosage. Testosterone and its esters at conventional doses for replacement therapy are sufficiently safe not to require routine biochemical monitoring of liver, kidney, or electrolytes.

Clinical monitoring depends on serial observation of improvement in the key presenting features of androgen deficiency. Androgen-deficient men as a group may report subjective improvement in one or more of a variety of symptoms (some only recognized in retrospect) including energy, well-being, psychosocial drive, initiative, and assertiveness as well as sexual activity (especially libido and ejaculation frequency), increased truncal and facial hair growth, and muscular strength and endurance. Individual men will become familiar with their own leading androgen deficiency symptom(s), and these appear in predictable sequence and at consistent blood testosterone thresholds toward the end of any treatment cycle.[269,664] Symptoms of genuine androgen deficiency are alleviated quickly, typically within 3 weeks, reaching a plateau within 2 to 3 months,[665] whereas symptoms that persist or recur after 3 months may represent placebo responses reflecting the nonspecificity of androgen deficiency symptoms and the unusually prominent expectations of testosterone treatment. Objective and sensitive measures of androgen action are highly desirable but are not available for most androgen-responsive tissues.[666] The main biochemical measures available for monitoring of androgenic effects include hemoglobin and trough reproductive hormone (testosterone, LH, FSH) levels. In androgen-deficient men, hemoglobin typically increases by ~10% (or up to 20 g/L) with standard testosterone doses.[360,483,667] Excessive hemoglobin responses (hematocrit ≥0.54, or ≥0.50 with higher risk of cardiovascular or cerebrovascular ischemia) occur as a rare (~1%) idiosyncratic reaction that is more frequent at older age,[360] which explains the higher prevalence of polycythemia in older testosterone-treated men.[668] Testosterone-induced polycythemia is dose dependent[360,669] and is related to the supraphysiologic peak blood testosterone levels observed with shorter-acting testosterone ester injections,[483] trough blood testosterone during treatment with injectable testosterone,[669] and predicted by higher pretreatment hematocrit,[504] although it can occur in older men even with transdermal products.[670] Such androgen-induced secondary erythrocytosis is characteristically negative for *JAK2* mutations, distinguishing it from primary polycythemia rubra vera,[671] and it usually resolves with reducing testosterone dose and/or switching to more steady-state testosterone delivery systems (implants, injectable testosterone undecanoate, or transdermal gel),[672] and only rarely is venesection and/or anticoagulation required.

During monitoring of testosterone therapy, circulating testosterone and gonadotropin levels must be considered in relation to the time since last testosterone dose. Trough levels (immediately before next scheduled dose) may be helpful in establishing the adequacy of depot testosterone regimens. In men with hypergonadotropic hypogonadism, the negative feedback regulation of pituitary LH secretion means that plasma LH levels are elevated in proportion to the degree of androgen deficiency so that in severe androgen deficiency, virtually castrate LH levels may be present. Similarly, during monitoring of testosterone therapy, blood LH levels provide a sensitive and specific index of tissue testosterone effects,[506,570] especially with steady-state depot testosterone products. Suppression of LH into the eugonadal range indicates adequate androgen replacement therapy, whereas persistent nonsuppression after the first few months of treatment is an indication of inadequate dose or pattern of testosterone levels. In hypogonadotropic hypogonadism, however, impaired hypothalamic-pituitary function diminishes circulating LH levels regardless of androgen effects, so blood LH levels do not reflect tissue androgenic effects. Blood testosterone levels are not helpful for the monitoring of oral testosterone undecanoate because of its capricious pharmacokinetics, whereas pharmacologic androgen therapy using any synthetic androgens would lower endogenous blood testosterone levels. Serial evaluation of bone density (especially vertebral trabecular bone) by dual photon absorptiometry at 1- to 2-year intervals may be helpful as a time-integrated measure to verify the adequacy of tissue androgen effects.[303,486]

Although chronic androgen deficiency protects against prostate disease,[110,673,674] prostate size of androgen-deficient men receiving androgen replacement therapy is restored to, but does not exceed, age-appropriate norms.[675,676] Even prolonged (2 years) high doses of exogenous DHT did not significantly increase age-related prostate size or growth rate in middle-aged men without known prostate disease.[504] Between-subject variability in response to testosterone replacement is partly explained by genetic sensitivity to testosterone, which is inversely related to the length of the CAG triplet (polyglutamine) repeat polymorphism in exon 1 of the AR.[190] Furthermore, because neither endogenous blood testosterone nor circulating levels of other androgen predict subsequent development of prostate cancer,[332] maintaining physiologic testosterone concentrations should ensure no higher rates of prostate disease than in eugonadal men of similar age.[677]

The potential long-term risks for cardiovascular disease of androgen replacement and pharmacologic androgen therapy remain uncertain. Although men have two to three times the prevalence,[311] as well as earlier onset and more severe atherosclerotic cardiovascular disease, than women, the precise role of blood testosterone and

of androgen treatment in this marked gender disparity is still poorly understood.[262] Although in observational studies, low blood testosterone concentration is associated with cardiovascular disease, and testosterone effects include vasodilation and amelioration of coronary ischemia as well as potentially deleterious effects, it is not possible to predict the net clinical risk-benefit of androgen replacement therapy on cardiovascular disease.[262] Hence, during androgen replacement therapy, it is prudent to aim at maintaining physiologic testosterone concentrations, and surveillance of cardiovascular and prostate disease should be comparable with, and no more intensive than, that for eugonadal men of equivalent age.[677] The effects of pharmacologic androgen therapy, in which the androgen dose is not necessarily restricted to eugonadal limits, on cardiovascular and prostate disease are still more difficult to predict, and surveillance then depends on the nature, severity, and life expectancy of the underlying disease.

Contraindications and Precautions for Androgen Replacement Therapy

Contraindications to androgen replacement therapy are prostate or breast cancer, because these tumors may be androgen responsive, and pregnancy, in which transplacental passage of androgens may disturb fetal sexual differentiation, notably risking virilization of a female fetus.

The Nobel Prize-winning recognition in the 1940s that prostate cancer was androgen dependent led to castration being since that time the main treatment for advanced prostate cancer, where it prolongs life but is not curative. This approach led to the long-held concern about testosterone treatment for men with advanced prostate cancer[238] including the fear of relapse, based, however, largely on anecdotal observations.[678,679] Studies have challenged this belief as intermittent rather than sustained androgen blockade,[680] and rapid androgen cycling,[681] androgen priming,[682,683] or even testosterone administration[684,685] have all shown promising beneficial empirical results. Furthermore, the increasing diagnosis of organ-confined prostate cancer detected by PSA screening among younger men with pathological androgen deficiency requires different considerations including the continuation of testosterone replacement therapy following curative treatment of the prostate cancer with careful monitoring.[686-688] This is consistent with the fact that endogenous circulating androgens (testosterone, dihydrotestosterone) do not predict subsequent prostate cancer,[332] and even prolonged (2-year) administration of high doses of exogenous DHT does not accelerate midlife prostate growth rate in middle-aged men without prostate disease,[504] presumably because exogenous DHT does not increase intraprostatic androgens.[567] Hence local, organ-confined prostate cancer following treatment with curative intent may be an exception to the otherwise absolute contraindication to testosterone for men with a diagnosis of advanced prostate cancer.

Precautions and/or careful monitoring of androgen use are required in: 1) initiating treatment in older men with newly diagnosed androgen deficiency who may experience unfamiliar and intolerable changes in libido; 2) competitive athletes who may be disqualified or men working in security-related industries where urine drug screening is required; 3) women of reproductive age, especially those who use their voice professionally, who may become irreversibly virilized; 4) prepubertal children in whom inappropriate androgen treatment presents risks of precocious sexual development, virilization, and premature epiphyseal closure with compromised final adult height; 5) patients with bleeding disorders or those undergoing anticoagulation or antiplatelet treatment when parenteral administration may cause severe bruising or bleeding; 6) sex steroid–sensitive epilepsy or migraine; and 7) older and especially obese men with subclinical obstructive sleep apnea. Some traditional warnings about risks of androgen treatment, which appear on older product information labels, appear to be rarely or never observed in modern clinical practice. An example of this is hypercalcemia, originally described during pharmacologic androgen therapy for advanced breast cancer with metastases,[689] although direct causation was not well established,[690] but this not been reported with androgen use for other indications. Similarly, fluid overload from sodium and fluid retention resulting from cardiac or renal failure or severe hypertension is rare and is probably confined to high-dose pharmacologic androgen therapy,[689] whereas controlled clinical trials suggest androgens may improve cardiac function and quality of life,[393] rather than having detrimental effects in men with chronic heart failure.

- For your free Expert Consult eBook with bibliographic citations as well as the ability to take notes, highlight important content, search the full text, and more, visit http://www.ExpertConsult.Inkling.com.

REFERENCES

1. Quigley CA, DeBellis A, Marschke KB, El-Awady MK, Wilson EM, French FF. Androgen receptor defects: Historical, clinical and molecular perspectives. *Endocr Rev*. 1995;16:271–321.
2. Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. *Front Neuroendocrinol*. 2008;29:169–181.
3. Michels G, Hoppe UC. Rapid actions of androgens. *Front Neuroendocrinol*. 2008;29:182–198.
4. Gonzalez-Montelongo MC, Marin R, Gomez T, Diaz M. Androgens are powerful non-genomic inducers of calcium sensitization in visceral smooth muscle. *Steroids*. 2010;75:533–538.
5. Handelsman DJ. Mechanisms of action of testosterone—Unraveling a Gordian knot. *N Engl J Med*. 2013;369:1058–1059.
6. Kochakian CD, ed. *Anabolic-Androgenic Steroids*. Berlin: Springer-Verlag; 1976.
7. Nieschlag E, Behre HM, eds. *Testosterone: Action, Deficiency, Substitution*. 4th ed. Cambridge: Cambridge University Press; 2012.
8. Hall PF. Testicular steroid synthesis: Organization and regulation. In: Knobil E, Neill J, eds. *The Physiology of Reproduction*. New York: Raven Press; 1988:975–998.
9. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocr Rev*. 2011;32:81–151.
10. Neaves WB, Johnson L, Porter JC, Parker CR, Petty CS. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. *J Clin Endocrinol Metab*. 1984;55:756–763.
11. Miller WL. The syndrome of 17,20 lyase deficiency. *J Clin Endocrinol Metab*. 2012;97:59–67.
12. Labrie F. Adrenal androgens and intracrinology. *Semin Reprod Med*. 2004;22:299–309.
13. Oesterling JE, Epstein JI, Walsh PC. The inability of adrenal androgens to stimulate the adult human prostate: An autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. *J Urol*. 1986;136:1030–1034.
14. Young J, Couzinet B, Nahoul K, et al. Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. *J Clin Endocrinol Metab*. 1997;82:2578–2585.
15. Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: Pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. *J Clin Endocrinol Metab*. 1998;83:1928–1934.
16. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. *J Clin Endocrinol Metab*. 2005;90:3847–3853.
17. Gallegos AM, Atshaves BP, Storey SM, et al. Gene structure, intracellular localization, and functional roles of sterol carrier protein-2. *Prog Lipid Res*. 2001;40:498–563.
18. Miller WL. Steroidogenic acute regulatory protein (StAR): A novel mitochondrial cholesterol transporter. *Biochim Biophys Acta*. 2007;1771:663–676.
19. Papadopoulos V. In search of the function of the peripheral-type benzodiazepine receptor. *Endocr Res*. 2004;30:677–684.
20. Jarow JP, Zirkin BR. The androgen microenvironment of the human testis and hormonal control of spermatogenesis. *Ann N Y Acad Sci*. 2005;1061:208–220.
21. Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: Results of a meta-analysis. *J Clin Epidemiol*. 1991;44:671–684.
22. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. *Endocr Rev*. 2005;26:833–876.
23. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: The European Male Aging Study. *J Clin Endocrinol Metab*. 2008;93:2737–2745.
24. Sartorius G, Spasevska S, Idan A, et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: The Healthy Man Study. *Clin Endocrinol (Oxf)*. 2012;77:755–763.
25. Handelsman DJ, Staraj S. Testicular size: The effects of aging, malnutrition and illness. *J Androl*. 1985;6:144–151.
26. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachussetts Male Aging Study. *J Clin Endocrinol Metab*. 1991;73:1016–1025.
27. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study. *J Clin Endocrinol Metab*. 2002;87:589–598.
28. Andersson AM, Jensen TK, Juul A, Petersen JH, Jorgensen T, Skakkebaek NE. Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys. *J Clin Endocrinol Metab*. 2007;92:4696–4705.
29. Travison TG, Araujo AB, Hall SA, McKinlay JB. Temporal trends in testosterone levels and treatment in older men. *Curr Opin Endocrinol Diabetes Obes*. 2009;16:211–217.
30. Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. *Clin Chem*. 2003;49:1381–1395.
31. Sikaris K, McLachlan RI, Kazlauskas R, de Kretser D, Holden CA, Handelsman DJ. Reproductive hormone reference intervals for healthy fertile young men: Evaluation of automated platform assays. *J Clin Endocrinol Metab*. 2005;90:5928–5936.
32. Vermeulen A, Desylpere JP, Kaufman JM. Influence of antiopioids on luteinizing hormone pulsatility in aging men. *J Clin Endocrinol Metab*. 1989;68:68–72.
33. Deslypere JP, Kaufman JM, Vermeulen T, Vogelaers D, Vandalem JL, Vermeulen A. Influence of age on pulsatile luteinizing hormone release and responsiveness of the gonadotrophs to sex hormone feedback in men. *J Clin Endocrinol Metab*. 1987;64:68–73.
34. Veldhuis JD, Urban RJ, Lizarralde G, Johnson ML, Iranmanesh A. Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging men. *J Clin Endocrinol Metab*. 1992;75:707–713.
35. Liu PY, Pincus SM, Takahashi PY, et al. Aging attenuates both the regularity and joint synchrony of LH and testosterone secretion in normal men: Analyses via a model of graded GnRH receptor blockade. *Am J Physiol Endocrinol Metab*. 2006;290:E34–E41.
36. Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD. Amplified nocturnal luteinizing hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men: Possible Leydig cell desensitization to endogenous LH signaling—A clinical research center study. *J Clin Endocrinol Metab*. 1995;80:3025–3031.
37. Mulligan T, Iranmanesh A, Kerzner R, Demers LW, Veldhuis JD. Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy aging male gonadotropic axis. *Eur J Endocrinol*. 1999;141:257–266.
38. Liu PY, Takahashi PY, Roebuck PD, Iranmanesh A, Veldhuis JD. Aging in healthy men impairs recombinant human luteinizing hormone (LH)-stimulated testosterone secretion monitored under a two-day intravenous pulsatile LH clamp. *J Clin Endocrinol Metab*. 2005;90:5544–5550.
39. Regadera J, Nistal M, Paniagua R. Testis, epididymis, and spermatic cord in elderly men: Correlation of angiographic and histologic studies with systemic arteriosclerosis. *Arch Pathol Lab Med*. 1985;109:663–667.
40. Veldhuis JD, Keenan DM, Iranmanesh A. Mechanisms of ensemble failure of the male gonadal axis in aging. *J Endocrinol Invest*. 2005;28:8–13.
41. Veldhuis JD, Keenan DM, Liu PY, Iranmanesh A, Takahashi PY, Nehra AX. The aging male hypothalamic-pituitary-gonadal axis: Pulsatility and feedback. *Mol Cell Endocrinol*. 2009;299:14–22.
42. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. *Lancet*. 2000;355:1491–1498.
43. Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. *J Clin Endocrinol Metab*. 2001;86:4686–4692.
44. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. *N Engl J Med*. 2006;355:1647–1659.

45. Baird DT, Horton R, Longcope C, Tait JF. Steroid dynamics under steady-state conditions. *Recent Prog Horm Res*. 1969;25: 611–664.
46. Gurpide E. *Tracer Methods in Hormone Research*. New York: Springer; 1975.
47. Setchell BP. *The Mammalian Testis*. London: Paul Elek; 1978.
48. Southren AL, Gordon GG, Tochimoto S. Further studies of factors affecting metabolic clearance rate of testosterone in man. *J Clin Endocrinol Metab*. 1968;28:1105–1112.
49. Santner S, Albertson B, Zhang GY, et al. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. *J Clin Endocrinol Metab*. 1998;83:2104–2109.
50. Wang C, Catlin DH, Starcevic B, et al. Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: Influence of ethnicity and age. *J Clin Endocrinol Metab*. 2004;89:2936–2941.
51. Ishimaru T, Edmiston WA, Pages L, Horton R. Splanchnic extraction and conversion of testosterone and dihydrotestosterone in man. *J Clin Endocrinol Metab*. 1978;46:528–533.
52. Longcope C, Sato K, McKay C, Horton R. Aromatization by splanchnic tissue in men. *J Clin Endocrinol Metab*. 1984;58:1089–1093.
53. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. *Clin Endocrinol (Oxf)*. 2003;58:710–717.
54. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. *J Clin Endocrinol Metab*. 1983;56:1278–1281.
55. Keenan DM, Takahashi PY, Liu PY, et al. An ensemble model of the male gonadal axis: Illustrative application in aging men. *Endocrinology*. 2006;147:2817–2828.
56. Petra P, Stanczyk FZ, Namkung PC, Fritz MA, Novy ML. Direct effect of sex-steroid binding protein (SBP) of plasma on the metabolic clearance rate of testosterone in the rhesus macaque. *J Steroid Biochem Mol Biol*. 1985;22:739–746.
57. Vanbillemont G, Bogaert V, De Bacquer D, et al. Polymorphisms of the SHBG gene contribute to the interindividual variation of sex steroid hormone blood levels in young, middle-aged and elderly men. *Clin Endocrinol (Oxf)*. 2009;70:303–310.
58. Ohlsson C, Wallaschofski H, Lunetta KL, et al. Genetic determinants of serum testosterone concentrations in men. *PLoS genetics*. 2011;7:e1002313.
59. Jin G, Sun J, Kim ST, et al. Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. *Hum Mol Genet*. 2012;21:5222–5228.
60. Xita N, Tsatsoulis A. Genetic variants of sex hormone-binding globulin and their biological consequences. *Mol Cell Endocrinol*. 2010;316:60–65.
61. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. *J Clin Endocrinol Metab*. 1981;53:58–68.
62. Fournier T, Medjoubi NN, Porquet D. Alpha-1-acid glycoprotein. *Biochim Biophys Acta*. 2000;1482:157–171.
63. Hammond GL, Wu TS, Simard M. Evolving utility of sex hormone-binding globulin measurements in clinical medicine. *Curr Opin Endocrinol Diabetes Obes*. 2012;19:183–189.
64. Luppa PB, Thaler M, Schulte-Frohlinde E, et al. Unchanged androgen-binding properties of sex hormone-binding globulin in male patients with liver cirrhosis. *Clin Chem Lab Med*. 2006;44:967–973.
65. Selva DM, Hammond GL. Human sex hormone-binding globulin is expressed in testicular germ cells and not in sertoli cells. *Horm Metab Res*. 2006;38:230–235.
66. Diaz L, Queipo G, Carino C, Nisembaum A, Larrea F. Biologically active steroid and thyroid hormones stimulate secretion of sex hormone-binding globulin by human term placenta in culture. *Arch Med Res*. 1997;28:29–36.
67. Hogeveen KN, Cousin P, Pugeat M, Dewailly D, Soudan B, Hammond GL. Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. *J Clin Invest*. 2002;109:973–981.
68. Pardridge WM. Plasma protein-mediated transport of steroid and thyroid hormones. *Am J Physiol*. 1987;252:E157–E164.
69. Mendel CM. The free hormone hypothesis: A physiologically based mathematical model. *Endocr Rev*. 1989;10:232–274.
70. Ekins R. Measurement of free hormones in blood. *Endocr Rev*. 1990;11:5–46.
71. Queipo G, Deas M, Arranz C, Carino C, Gonzalez R, Larrea F. Sex hormone-binding globulin stimulates chorionic gonadotrophin secretion from human cytotrophoblasts in culture. *Hum Reprod*. 1998;13:1368–1373.
72. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. *J Steroid Biochem Mol Biol*. 1999;69:481–485.
73. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate. *Steroids*. 1999;64:100–106.
74. Kahn SM, Li YH, Hryb DJ, et al. Sex hormone-binding globulin influences gene expression of LNCaP and MCF-7 cells in response to androgen and estrogen treatment. *Adv Exp Med Biol*. 2008;617:557–564.
75. Hamada A, Sissung T, Price DK, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. *Clin Cancer Res*. 2008;14:3312–3318.
76. Hammes A, Andreassen TK, Spoelgen R, et al. Role of endocytosis in cellular uptake of sex steroids. *Cell*. 2005;122:751–762.
77. Adams JS. "Bound" to work: The free hormone hypothesis revisited. *Cell*. 2005;122:647–649.
78. Poole CN, Roberts MD, Dalbo VJ, Sunderland KL, Kerksick CM. Megalin and androgen receptor gene expression in young and old human skeletal muscle before and after three sequential exercise bouts. *Journal of Strength and Conditioning Research / National Strength & Conditioning Association*. 2011;25:309–317.
79. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. *Clin Cancer Res*. 2008;14:3823–3831.
80. Ellis GB, Desjardins C. Male rats secrete luteinizing hormone and testosterone episodically. *Endocrinology*. 1982;110:1618–1627.
81. Coquelin A, Desjardins C. Luteinizing hormone and testosterone secretion in young and old male mice. *Am J Physiol*. 1982;243:E257–E263.
82. Shackleton C. Clinical steroid mass spectrometry: A 45-year history culminating in HPLC-MS/MS becoming an essential tool for patient diagnosis. *J Steroid Biochem Mol Biol*. 2010;121:481–490.
83. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. *J Clin Endocrinol Metab*. 2007;92:405–413.
84. Herold DA, Fitzgerald RL. Immunoassays for testosterone in women: Better than a guess? *Clin Chem*. 2003;49:1250–1251.
85. Umstot ES, Baxter JE, Andersen RN. A theoretically sound and practicable equilibrium dialysis method for measuring percentage of free testosterone. *J Steroid Biochem*. 1985;22:639–648.
86. Swinkels LM, Ross HA, Benraad TJ. A symmetric dialysis method for the determination of free testosterone in human plasma. *Clin Chim Acta*. 1987;165:341–349.
87. Hammond GL, Nisker JA, Jones LA, Siiteri PK. Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. *J Biol Chem*. 1980;255:5023–5026.
88. Vlahos I, MacMahon W, Sgoutas D, Bowers W, Thompson J, Trawick W. An improved ultrafiltration method for determining free testosterone in serum. *Clinical Chemistry*. 1982;28:2286–2291.
89. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. *J Steroid Biochem*. 1982;16:801–810.
90. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab*. 1999;84:3666–3672.
91. Rosner W. An extraordinarily inaccurate assay for free testosterone is still with us. *J Clin Endocrinol Metab*. 2001;86:2903.
92. Fritz KS, McKean AJ, Nelson JC, Wilcox RB. Analog-based free testosterone test results linked to total testosterone concentrations, not free testosterone concentrations. *Clin Chem*. 2008;54:512–516.

93. Kapoor P, Luttrell BM, Williams D. The free androgen index is not valid for adult males. *J Steroid Biochem Mol Biol*. 1993;45: 325–326.
94. Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: With illustrative examples from male and female populations. *Steroids*. 2009;74:512–519.
95. Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. *Eur J Endocrinol*. 2005;152:471–478.
96. Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free testosterone formulae in men. *Clin Endocrinol (Oxf)*. 2010;73: 382–388.
97. Sartorius G, Ly LP, Sikaris K, McLachlan R, Handelsman DJ. Predictive accuracy and sources of variability in calculated free testosterone estimates. *Ann Clin Biochem*. 2009;46:137–143.
98. Egleston BL, Chandler DW, Dorgan JF. Validity of estimating non-sex hormone-binding globulin bound testosterone and oestradiol from total hormone measurements in boys and girls. *Ann Clin Biochem*. 2010;47:233–241.
99. Giton F, Fiet J, Guechot J, et al. Serum bioavailable testosterone: Assayed or calculated? *Clin Chem*. 2006;52:474–481.
100. Van Eenoo P, Delbeke FT. Metabolism and excretion of anabolic steroids in doping control—new steroids and new insights. *J Steroid Biochem Mol Biol*. 2006;101:161–178.
101. Kumar N, Crozat A, Li F, Catterall JF, Bardin CW, Sundaram K. 7alpha-methyl-19-nortestosterone, a synthetic androgen with high potency: Structure-activity comparisons with other androgens. *J Steroid Biochem Mol Biol*. 1999;71:213–222.
102. Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. *Mol Cell Endocrinol*. 1992;88:15–22.
103. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM. Specificity of ligand-dependent androgen receptor stabilization: Receptor domain interactions influence ligand dissociation and receptor stability. *Mol Endocrinol*. 1995;9:208–218.
104. McRobb L, Handelsman DJ, Kazlauskas R, Wilkinson S, McLeod MD, Heather AK. Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay. *J Steroid Biochem Mol Biol*. 2008;110:39–47.
105. Russell DW, Wilson JD. Steroid 5 alpha-reductase: Two genes/two enzymes. *Annu Rev Biochem*. 1994;63:25–61.
106. Thigpen AE, Davis DL, Milatovich A, et al. Molecular genetics of steroid 5a-reductase 2 deficiency. *Journal of Clinical Investigations*. 1992;90:799–809.
107. Cai LQ, Fratiani CM, Gautier T, Imperato-McGinley J. Dihydrotestosterone regulation of semen in males pseudohermaphrodites with 5-a reductase deficiency. *J Clin Endocrinol Metab*. 1994;79:409–414.
108. Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J. Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. *J Clin Endocrinol Metab*. 2006;91:3017–3023.
109. Imperato-McGinley J, Peterson RE, Gautier T, Sturla E. Androgens and the evolution of male gender identity among male pseudohemaphrodites with 5-a reductase deficiency. *N Engl J Med*. 1979;300:1233–1237.
110. Imperato-McGinley J, Gautier T, Zirinsky K, et al. Prostate visualization studies in males homozygous and heterozygous for 5-a reductase deficiency. *J Clin Endocrinol Metab*. 1992;75:1022–1026.
111. Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. *Mol Cell Endocrinol*. 2002;198:51–59.
112. Steers WD. 5alpha-reductase activity in the prostate. *Urology*. 2001;58:17–24. discussion.
113. Frick J, Aulitzky W. Physiology of the prostate. *Infection*. 1991;19(suppl 3):S115–S118.
114. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. *Clin Pharmacol Ther*. 1998;64:636–647.
115. Miller LR, Partin AW, Chan DW, et al. Influence of radical prostatectomy on serum hormone levels. *J Urol*. 1998;160:449–453.
116. Toorians AW, Kelleher S, Gooren LJ, Jimenez M, Handelsman DJ. Estimating the contribution of the prostate to blood dihydrotestosterone. *J Clin Endocrinol Metab*. 2003;88:5207–5211.
117. Zhu YS, Katz MD, Imperato-McGinley J. Natural potent androgens: Lessons from human genetic models. *Baillieres Clin Endocrinol Metab*. 1998;12:83–113.
118. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med*. 2003;349:215–224.
119. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med*. 2010;362: 1192–1202.
120. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. *J Natl Cancer Inst*. 2007;99:1375–1383.
121. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman Jr CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. *Cancer Prev Res (Phila)*. 2008;1:174–181.
122. Kim J, Amos CI, Logothetis C. 5alpha-Reductase inhibitors for prostate-cancer prevention. *N Engl J Med*. 2011;365:2340.
123. Simpson ER, Zhao Y, Agarwal VR, et al. Aromatase expression in health and disease. *Recent Prog Horm Res*. 1997;52:185–213. discussion 214.
124. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. *N Engl J Med*. 2013;369:1011–1022.
125. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S. Organization of the human aromatase p450 (CYP19) gene. *Semin Reprod Med*. 2004;22:5–9.
126. Naftolin F. Brain aromatization of androgens. *J Reprod Med*. 1994;39:257–261.
127. Roselli CF. Brain aromatase: Roles in reproduction and neuroprotection. *J Steroid Biochem Mol Biol*. 2007;106:143–150.
128. Jones ME, Boon WC, Proietto J, Simpson ER. Of mice and men: The evolving phenotype of aromatase deficiency. *Trends Endocrinol Metab*. 2006;17:55–64.
129. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. *Proceedings of the National Academy of Sciences USA*. 1993;90:11162–11166.
130. Couse JE, Mahato D, Eddy EM, Korach KS. Molecular mechanism of estrogen action in the male: Insights from the estrogen receptor null mice. *Reprod Fertil Dev*. 2001;13:211–219.
131. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. *J Clin Endocrinol Metab*. 2004;89: 5898–5907.
132. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. *Endocr Rev*. 2004;25:389–425.
133. Vandenput L, Swinnen JV, Boonen S, et al. Role of the androgen receptor in skeletal homeostasis: The androgen-resistant testicular feminized male mouse model. *J Bone Miner Res*. 2004;19:1462–1470.
134. Chesnut 3rd CH, Ivey JL, Gruber HE, et al. Stanozolol in postmenopausal osteoporosis: Therapeutic efficacy and possible mechanisms of action. *Metabolism*. 1983;32:571–580.
135. Need AG, Nordin BEC, Chatterton BE. Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic steroid nandrolone decanoate. *Osteoporos Int*. 1993;3(suppl 1): S218–S222.
136. Venken K, De Gendt K, Boonen S, et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: A study in the androgen receptor knockout mouse model. *J Bone Miner Res*. 2006;21:576–585.
137. Callewaert F, Venken K, Ophoff J, et al. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. *FASEB J*. 2009;23:232–240.
138. Zuloaga DG, Puts DA, Jordan CL, Breedlove SM. The role of androgen receptors in the masculinization of brain and behavior: What we've learned from the testicular feminization mutation. *Horm Behav*. 2008;53:613–626.

139. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. *Curr Drug Metab*. 2008;9:310–322.
140. Chouinard S, Yueh MF, Tukey RH, et al. Inactivation by UDP-glucuronosyltransferase enzymes: The end of androgen signaling. *J Steroid Biochem Mol Biol*. 2008;109:247–253.
141. Xue Y, Sun D, Daly A, et al. Adaptive evolution of UGT2B17 copy-number variation. *Am J Hum Genet*. 2008;83:337–346.
142. Jakobsson J, Ekstrom L, Inotsume N, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. *J Clin Endocrinol Metab*. 2006;91:687–693.
143. Schulze JJ, Lundmark J, Garle M, Skilving I, Ekstrom L, Rane A. Doping test results dependent on genotype of uridine diphosphoglucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. *J Clin Endocrinol Metab*. 2008;93:2500–2506.
144. Johnsen SG, Bennet EP, Jensen VG. Therapeutic effectiveness of oral testosterone. *Lancet*. 1974;ii1473–1475.
145. Frey H, Aakvag A, Saanum D, Falch J. Bioavailability of testosterone in males. *Eur J Clin Pharmacol*. 1979;16:345–349.
146. Parkes AS. Effective absorption of hormones. *Br Med J*. 1938: 371–373.
147. Lisser H, Escamilla RF, Curtis LE. Testosterone therapy of male eunuchoids. III Sublingual administration of testosterone compounds. *J Clin Endocrinol*. 1942;2:351–360.
148. Korbonits M, Slawik M, Cullen D, et al. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. *J Clin Endocrinol Metab*. 2004;89:2039–2043.
149. Wang C, Eyre DR, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men—A clinical research center study. *J Clin Endocrinol Metab*. 1996;81:3654–3662.
150. Shackleford DM, Faassen WA, Houwing N, et al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. *J Pharmacol Exp Ther*. 2003;306:925–933.
151. Yin AY, Htun M, Swerdloff RS, et al. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation. *J Androl*. 2012;33:190–201.
152. Foss GL. Clinical administration of androgens. *Lancet*. 1939;i502–504.
153. Bousfield GR, Butnev VY, Gotschall RR, Baker VL, Moore WT. Structural features of mammalian gonadotropins. *Mol Cell Endocrinol*. 1996;125:3–19.
154. Gromoll J, Eiholzer U, Nieschlag E, Simoni M. Male hypogonadism caused by homozygous deletion of exon 10 of the luteinizing hormone (LH) receptor: Differential action of human chorionic gonadotropin and LH. *J Clin Endocrinol Metab*. 2000;85:2281–2286.
155. O'Shaughnessy PJ, Baker P, Sohnius U, Haavisto AM, Charlton HM, Huhtaniemi I. Fetal development of Leydig cell activity in the mouse is independent of pituitary gonadotroph function. *Endocrinology*. 1998;139:1141–1146.
156. Sisk CL, Foster DL. The neural basis of puberty and adolescence. *Nat Neurosci*. 2004;7:1040–1047.
157. Veldhuis JD. Neuroendocrine facets of human puberty. *Neurobiol Aging*. 2003;24(suppl 1):S93–S119. discussion S21–S22.
158. Terasawa E, Fernandez DL. Neurobiological mechanisms of the onset of puberty in primates. *Endocr Rev*. 2001;22:111–151.
159. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. *Proc Natl Acad Sci U S A*. 2003;100:10972–10976.
160. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. *N Engl J Med*. 2003;349:1614–1627.
161. Wu FC, Borrow SM, Nicol K, Elton R, Hunter WM. Ontogeny of pulsatile gonadotrophin secretion and pituitary responsiveness in male puberty in man: A mixed longitudinal and cross-sectional study. *J Endocrinol*. 1989;123:347–359.
162. Silventoinen K, Haukka J, Dunkel L, Tynelius P, Rasmussen F. Genetics of pubertal timing and its associations with relative weight in childhood and adult height: The Swedish Young Male Twins Study. *Pediatrics*. 2008;121:e885–e891.
163. Pedersen-White JR, Chorich LP, Bick DP, Sherins RJ, Layman LC. The prevalence of intragenic deletions in patients with idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. *Mol Hum Reprod*. 2008;14:367–370.
164. Delemarre-van de Waal HA. Secular trend of timing of puberty. *Endocr Dev*. 2005;8:1–14.
165. Ong KK, Ahmed ML, Dunger DB. Lessons from large population studies on timing and tempo of puberty (secular trends and relation to body size): The European trend. *Mol Cell Endocrinol*. 2006;254-255:8–12.
166. Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP. The timing of normal puberty and the age limits of sexual precocity: Variations around the world, secular trends, and changes after migration. *Endocr Rev*. 2003;24:668–693.
167. Gluckman PD, Hanson MA. Changing times: The evolution of puberty. *Mol Cell Endocrinol*. 2006:254–255. 26–31.
168. Veldhuis JD, Keenan DM, Pincus SM. Regulation of complex pulsatile and rhythmic neuroendocrine systems: The male gonadal axis as a prototype. *Prog Brain Res*. 2010;181:79–110.
169. Chin WW, Boime I, eds. *Glycoprotein Hormones: Structure, Synthesis and Biologic Function*. Serono Symposia, USA: Norwell; 1990.
170. Boime I, Ben-Menahem D. Glycoprotein hormone structure-function and analog design. *Recent Prog Horm Res*. 1999;54: 271–288. discussion 88–89.
171. Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. *Endocr Rev*. 2002;23:141–174.
172. Rosa C, Amr S, Birken S, Wehmann R, Nisula B. Effect of desialylation of human chorionic gonadotropin on its metabolic clearance rate in humans. *J Clin Endocrinol Metab*. 1984;59: 1215–1219.
173. Muyan M, Furuhashi M, Sugahara T, Boime I. The carboxy-terminal region of the beta-subunits of luteinizing hormone and chorionic gonadotropin differentially influence secretion and assembly of the heterodimers. *Mol Endocrinol*. 1996;10: 1678–1687.
174. Bouloux PM, Handelsman DJ, Jockenhovel F, et al. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. *Hum Reprod*. 2001;16:1592–1597.
175. Joshi L, Murata Y, Wondisford FE, Szkudlinski MW, Desai R, Weintraub BD. Recombinant thyrotropin containing a beta-subunit chimera with the human chorionic gonadotropin-beta carboxy-terminus is biologically active, with a prolonged plasma half-life: Role of carbohydrate in bioactivity and metabolic clearance. *Endocrinology*. 1995;136:3839–3848.
176. Fares F, Ganem S, Hajouj T, Agai E. Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin. *Endocrinology*. 2007;148:5081–5087.
177. Saunders PT. Germ cell-somatic cell interactions during spermatogenesis. *Reprod Suppl*. 2003;61:91–101.
178. Rudolfsson SH, Wikstrom P, Jonsson A, Collin O, Bergh A. Hormonal regulation and functional role of vascular endothelial growth factor a in the rat testis. *Biol Reprod*. 2004;70:340–347.
179. Schnorr JA, Bray MJ, Veldhuis JD. Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men. *J Clin Endocrinol Metab*. 2001;86: 2600–2606.
180. Pitteloud N, Dwyer AA, DeCruz S, et al. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: Evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. *J Clin Endocrinol Metab*. 2008;93:784–791.
181. Wilson JD. The role of 5alpha-reduction in steroid hormone physiology. *Reprod Fertil Dev*. 2001;13:673–678.
182. Simpson ER. Aromatase: biologic relevance of tissue-specific expression. *Semin Reprod Med*. 2004;22:11–23.
183. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. *Nat Rev Drug Discov*. 2004;3:950–964.
184. Shi Y. Orphan nuclear receptors in drug discovery. *Drug Discov Today*. 2007;12:440–445.

185. Adachi M, Takayanagi R, Tomura A, et al. Androgen-insensitivity syndrome as a possible coactivator disease. *N Engl J Med*. 2000;343:856–862.
186. McEwan IJ, Lavery D, Fischer K, Watt K. Natural disordered sequences in the amino terminal domain of nuclear receptors: Lessons from the androgen and glucocorticoid receptors. *Nucl Recept Signal*. 2007;5. e001.
187. Rajender S, Singh L, Thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene. *Asian J Androl*. 2007;9: 147–179.
188. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. *Int J Androl*. 2003;26:76–83.
189. Simanainen U, Brogley M, Gao YR, et al. Length of the human androgen receptor glutamine tract determines androgen sensitivity in vivo. *Mol Cell Endocrinol*. 2011;342:81–86.
190. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: A longitudinal pharmacogenetic study. *J Clin Endocrinol Metab*. 2003;88:2049–2054.
191. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. *J Clin Endocrinol Metab*. 2007;92:3844–3853.
192. Zeegers MP, Kiemeney LA, Nieder AM, Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?. *Cancer Epidemiol Biomarkers Prev*. 2004;13:1765–1771.
193. Davis-Dao CA, Tuazon ED, Sokol RZ, Cortessis VK. Male infertility and variation in CAG repeat length in the androgen receptor gene: A meta-analysis. *J Clin Endocrinol Metab*. 2007;92:4319–4326.
194. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. *Nat Genet*. 2001;29:306–309.
195. Palazzolo I, Gliozzi A, Rusmini P, et al. The role of the polyglutamine tract in androgen receptor. *J Steroid Biochem Mol Biol*. 2008;108:245–253.
196. Thomas Jr PS, Fraley GS, Damian V, et al. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. *Hum Mol Genet*. 2006;15:2225–2238.
197. Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): A study of 223 Japanese patients. *Brain*. 2006;129:1446–1455.
198. Ross CA, Poirier MA. Opinion: What is the role of protein aggregation in neurodegeneration? *Nat Rev Mol Cell Biol*. 2005;6:891–898.
199. Adachi H, Waza M, Katsuno M, Tanaka F, Doyu M, Sobue G. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. *Neuropathol Appl Neurobiol*. 2007;33:135–151.
200. Palazzolo I, Stack C, Kong L, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. *Neuron*. 2009;63:316–328.
201. Rinaldi C, Bott LC, Chen KL, et al. IGF-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. *Mol Med*. 2012;18:1261–8126.
202. Katsuno M, Banno H, Suzuki K, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): A multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2010;9:875–884.
203. Banno H, Katsuno M, Suzuki K, Tanaka F, Sobue G. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA). *Cell Tissue Res*. 2012;349:313–320.
204. Prescott J, Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. *Cancer Lett*. 2006;231:12–19.
205. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: An overview. *Endocr Rev*. 2002;23:175–200.
206. Smith CL, O'Malley BW. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. *Endocr Rev*. 2004;25:45–71.
207. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations database: 2012 update. *Hum Mutat*. 2012;33:887–894.
208. Sarpel U, Palmer SK, Dolgin SE. The incidence of complete androgen insensitivity in girls with inguinal hernias and assessment of screening by vaginal length measurement. *J Pediatr Surg*. 2005;40:133–136. discussion 6–7.
209. Hiort O, Holterhus PM, Horter T, et al. Significance of mutations in the androgen receptor gene in males with idiopathic infertility. *J Clin Endocrinol Metab*. 2000;85:2810–2815.
210. Belgorosky A, Rivarola MA. Sex hormone binding globulin response to testosterone. An androgen sensitivity test. *Acta Endocrinol (Copenh)*. 1985;109:130–138.
211. Sinnecker GH, Hiort O, Nitsche EM, Holterhus PM, Kruse K. Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group. *Eur J Pediatr*. 1997;156:7–14.
212. Cheikhelard A, Morel Y, Thibaud E, et al. Long-term followup and comparison between genotype and phenotype in 29 cases of complete androgen insensitivity syndrome. *J Urol*. 2008;180:1496–1501.
213. Marcus R, Leary D, Schneider DL, Shane E, Favus M, Quigley CA. The contribution of testosterone to skeletal development and maintenance: Lessons from the androgen insensitivity syndrome. *J Clin Endocrinol Metab*. 2000;85:1032–1037.
214. Danilovic DL, Correa PH, Costa EM, Melo KF, Mendonca BB, Arnhold IJ. Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene. *Osteoporos Int*. 2007;18:369–374.
215. Han TS, Goswami D, Trikudanathan S, Creighton SM, Conway GS. Comparison of bone mineral density and body proportions between women with complete androgen insensitivity syndrome and women with gonadal dysgenesis. *Eur J Endocrinol*. 2008;159:179–185.
216. Wisniewski AB, Migeon CJ, Meyer-Bahlburg HF, et al. Complete androgen insensitivity syndrome: Long-term medical, surgical, and psychosexual outcome. *J Clin Endocrinol Metab*. 2000;85:2664–2669.
217. Hines M, Ahmed SF, Hughes IA. Psychological outcomes and gender-related development in complete androgen insensitivity syndrome. *Arch Sex Behav*. 2003;32:93–101.
218. Minto CL, Liao KL, Conway GS, Creighton SM. Sexual function in women with complete androgen insensitivity syndrome. *Fertil Steril*. 2003;80:157–164.
219. Brinkmann L, Schuetzmann K, Richter-Appelt H. Gender assignment and medical history of individuals with different forms of intersexuality: Evaluation of medical records and the patients' perspective. *J Sex Med*. 2007;4:964–980.
220. Kohler B, Kleinemeier E, Lux A, et al. Satisfaction with genital surgery and sexual life of adults with XY disorders of sex development: results from the German clinical evaluation study. *J Clin Endocrinol Metab*. 2012;97:577–588.
221. Ahmed SF, Cheng A, Dovey L, et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. *J Clin Endocrinol Metab*. 2000;85:658–665.
222. Deeb A, Mason C, Lee YS, Hughes IA. Correlation between genotype, phenotype and sex of rearing in 111 patients with partial androgen insensitivity syndrome. *Clin Endocrinol (Oxf)*. 2005;63:56–62.
223. Migeon CJ, Wisniewski AB, Gearhart JP, et al. Ambiguous genitalia with perineoscrotal hypospadias in 46,XY individuals: Long-term medical, surgical, and psychosexual outcome. *Pediatrics*. 2002;110:e31.
224. Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. *Hum Mutat*. 2004;23:527–533.
225. Rodien P, Mebarki F, Mowszowicz I, et al. Different phenotypes in a family with androgen insensitivity caused by the same M780I point mutation in the androgen receptor gene. *J Clin Endocrinol Metab*. 1996;81:2994–2998.
226. Boehmer AL, Brinkmann O, Bruggenwirth H, et al. Genotype versus phenotype in families with androgen insensitivity syndrome. *J Clin Endocrinol Metab*. 2001;86:4151–4160.
227. Kohler B, Lumbroso S, Leger J, et al. Androgen insensitivity syndrome: Somatic mosaicism of the androgen receptor in seven families and consequences for sex assignment and genetic counseling. *J Clin Endocrinol Metab*. 2005;90:106–111.

228. Boehmer AL, Brinkmann AO, Nijman RM, et al. Phenotypic variation in a family with partial androgen insensitivity syndrome explained by differences in 5alpha dihydrotestosterone availability. *J Clin Endocrinol Metab*. 2001;86:1240–1246.
229. MacLean HE, Favaloro JM, Warne GL, Zajac JD. Double-strand DNA break repair with replication slippage on two strands: A novel mechanism of deletion formation. *Hum Mutat*. 2006;27:483–489.
230. Rogowski W. Genetic screening by DNA technology: A systematic review of health economic evidence. *Int J Technol Assess Health Care*. 2006;22:327–337.
231. Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse K. Inherited and de novo androgen receptor gene mutations: Investigation of single-case families. *J Pediatr*. 1998;132:939–943.
232. Yeh SH, Chiu CM, Chen CL, et al. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. *Int J Cancer*. 2007;120:1610–1617.
233. Hiort O, Naber SP, Lehners A, et al. The role of androgen receptor gene mutations in male breast carcinoma. *J Clin Endocrinol Metab*. 1996;81:3404–3407.
234. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: Incidence and clinical significance. *Drug Saf*. 2000;23:381–390.
235. Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. *J Urol*. 2008;180: 921–927.
236. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. *Cancer Res*. 2003;63:149–153.
237. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. *J Cell Biochem*. 2004;91:3–12.
238. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Cancer Res*. 1941;1:293–297.
239. Labrie F, Cusan L, Gomez JL, et al. Comparable amounts of sex steroids are made outside the gonads in men and women: Strong lesson for hormone therapy of prostate and breast cancer. *J Steroid Biochem Mol Biol*. 2009;113:52–56.
240. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. *J Clin Oncol*. 2008;26:4563–4571.
241. Anonymous. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. *Lancet*. 2000;355:1491–1498.
242. Pezaro CJ, Mukherji D, De Bono JS. Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. *Drug Discov Today*. 2012;17:221–226.
243. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*. 2012;367:1187–1197.
244. Meikle AW. The interrelationships between thyroid dysfunction and hypogonadism in men and boys. *Thyroid*. 2004;14(suppl 1):S17–S25.
245. Payne KL, Loidl NM, Lim CF, Topliss DJ, Stockigt JR, Barlow JW. Modulation of T3-induced sex hormone-binding globulin secretion by human hepatoblastoma cells. *Eur J Endocrinol*. 1997;137: 415–420.
246. Isojarvi J. Disorders of reproduction in patients with epilepsy: Antiepileptic drug related mechanisms. *Seizure*. 2008;17: 111–119.
247. Reis RM, de Angelo AG, Sakamoto AC, Ferriani RA, Lara LA. Altered sexual and reproductive functions in epileptic men taking carbamazepine. *J Sex Med*. 2013;10:493–499.
248. Wheeler MJ, Toone BK, ADannatt Fenwick PB, Brown S. Metabolic clearance rate of testosterone in male epileptic patients on anti-convulsant therapy. *J Endocrinol*. 1991;129: 465–468.
249. Death AK, McGrath KC, Handelsman DJ. Valproate is an antiandrogen and anti-progestin. *Steroids*. 2005;70:946–953.
250. Green JRB, Goble HL, Edwards CRW, Dawson AM. Reversible insensitivity to androgens in men with untreated gluten enteropathy. *Lancet*. 1977;i:280–282.
251. Farthing MJR, Rees LH, Edwards CRW, Dawson AM. Male gonadal dysfunction in coeliac disease: 2. Sex hormones. *Gut*. 1983;24:127–135.
252. Frydman M, Kauschansky A, Bonne-Tamir B, Nassar F, Homburg R. Assessment of the hypothalamic-pituitary-testicular function in male patients with Wilson's disease. *J Androl*. 1991;12: 180–184.
253. Herrick AL, McColl KE, Wallace AM, Moore MR, Goldberg A. Elevation of hormone-binding globulins in acute intermittent porphyria. *Clin Chim Acta*. 1990;187:141–148.
254. Iturriaga H, Lioi X, Valladares L. Sex hormone-binding globulin in non-cirrhotic alcoholic patients during early withdrawal and after longer abstinence. *Alcohol Alcohol*. 1999;34:903–909.
255. Handelsman DJ, Strasser S, McDonald JA, Conway AJ, McCaughan GW. Hypothalamic-pituitary testicular function in end-stage non-alcoholic liver disease before and after liver transplantation. *Clin Endocrinol (Oxf)*. 1995;43:331–337.
256. Hamilton JB, Mestler GE. Mortality and survival: Comparison of eunuchs with intact men and women in a mentally retarded population. *J Gerontol*. 1969;24:395–411.
257. Nieschlag E, Nieschlag S, Behre HM. Lifespan and testosterone. *Nature*. 1993;366:215.
258. Jenkins JS. The voice of the castrato. *Lancet*. 1998;351:1877–1880.
259. Eyben FE, Graugaard C, Vaeth M. All-cause mortality and mortality of myocardial infarction for 989 legally castrated men. *Eur J Epidemiol*. 2005;20:863–869.
260. Min KJ, Lee CK, Park HN. The lifespan of Korean eunuchs. *Curr Biol*. 2012;22:R792–793.
261. Bojesen A, Juul S, Birkebaek N, Gravholt CH. Increased mortality in Klinefelter syndrome. *J Clin Endocrinol Metab*. 2004;89:3830–3834.
262. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. *Endocr Rev*. 2003;24:313–340.
263. Liu PY, Handelsman DJ. Androgen therapy in non-gonadal disease. In: Nieschlag E, Behre HM, eds. *Testosterone: Action, Deficiency and Substitution*. 3rd ed. Berlin: Springer-Verlag; 2004:445–495.
264. Zuraw BL. Clinical practice. Hereditary angioedema. *N Engl J Med*. 2008;359:1027–1036.
265. Longhurst H, Cicardi M. Hereditary angio-oedema. *Lancet*. 2012;379:474–481.
266. Handelsman DJ. Update in andrology. *J Clin Endocrinol Metab*. 2007;92:4505–4511.
267. Coffee B, Keith K, Albizua I, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. *Am J Hum Genet*. 2009;85:503–514.
268. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: A national registry study. *J Clin Endocrinol Metab*. 2003;88:622–626.
269. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. *J Clin Endocrinol Metab*. 2004;89:3813–3817.
270. Schaison G, Young J, Pholsena M, Nahoul K, Couzinet B. Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 1993;77:1545–1549.
271. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley Jr WF. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab*. 2002;87:4128–4136.
272. Wang C, Tso SC, Todd D. Hypogonadotropic hypogonadism in severe beta-thalassemia: Effect of chelation and pulsatile gonadotropin-releasing hormone therapy. *J Clin Endocrinol Metab*. 1989;68:511–516.
273. Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: Predictors of fertility outcome. *J Clin Endocrinol Metab*. 2009;94:801–808.
274. Handelsman DJ, Goebel C, Idan A, Jimenez M, Trout G, Kazlauskas R. Effects of recombinant human LH and hCG on serum and urine LH and androgens in men. *Clin Endocrinol (Oxf)*. 2009;71:417–428.

275. Barrio R, de Luis D, Alonso M, Lamas A, Moreno JC. Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. *Fertil Steril*. 1999;71:244–248.
276. Belanger A, Candas B, Dupont A, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. *J Clin Endocrinol Metab*. 1994;79: 1086–1090.
277. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. *J Clin Endocrinol Metab*. 2006;91: 1336–1344.
278. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. *J Clin Endocrinol Metab*. 2007;92:549–555.
279. Andersson AM, Jorgensen N, Frydelund-Larsen L, Rajpert-De Meyts E, Skakkebaek NE. Impaired Leydig cell function in infertile men: A study of 357 idiopathic infertile men and 318 proven fertile controls. *J Clin Endocrinol Metab*. 2004;89:3161–3167.
280. Howell SJ, Radford JA, Adams JE, Shalet SM. The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. *Clin Endocrinol (Oxf)*. 2000;52:609–616.
281. Howell SJ, Radford JA, Smets EM, Shalet SM. Fatigue, sexual function and mood following treatment for haematological malignancy: The impact of mild Leydig cell dysfunction. *Br J Cancer*. 2000;82:789–793.
282. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. *Cancer*. 2001;91:1297–1303.
283. Somali M, Mpatakoias V, Avramides A, et al. Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases. *Gynecol Endocrinol*. 2005;21:18–26.
284. Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. *Clin Endocrinol (Oxf)*. 2001;55: 315–324.
285. Merza Z, Blumsohn A, Mah PM, et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. *Int J Androl*. 2006;29: 381–391.
286. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. *J Clin Endocrinol Metab*. 2001;86:724–731.
287. Travison TG, Shackelton R, Araujo AB, et al. The natural history of symptomatic androgen deficiency in men: Onset, progression, and spontaneous remission. *J Am Geriatr Soc*. 2008;56: 831–839.
288. Deslypere JP, Vermeulen A. Aging and tissue androgens. *J Clin Endocrinol Metab*. 1981;53:430–434.
289. Deslypere JP, Vermeulen A. Influence of age on steroid concentration in skin and striated muscle in women and in cardiac muscle and lung tissue in men. *J Clin Endocrinol Metab*. 1985;60:648–653.
290. Mohr BA, Guay AT, O'Donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: Results from the Massachusetts Male Ageing Study. *Clin Endocrinol (Oxf)*. 2005;62:64–73.
291. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: A meta-analysis study. *J Sex Med*. 2011;8:272–283.
292. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: A systematic review and meta-analysis of observational studies. *Int J Epidemiol*. 2011;40:189–207.
293. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: A meta-analysis. *Heart*. 2011;97:870–875.
294. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: A systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2011;96:3007–3019.
295. Toma M, McAlister FA, Coglianese EE, et al. Testosterone supplementation in heart failure: A meta-analysis. *Circulation Heart Failure*. 2012;5:315–321.
296. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. *J Clin Endocrinol Metab*. 2012;97: 2050–2058.
297. Wu FC. Caveat emptor: Does testosterone treatment reduce mortality in men? *J Clin Endocrinol Metab*. 2012;97:1884–1886.
298. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: Potential benefits and risks. *J Am Geriatr Soc*. 2003;51:101–115.
299. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. *J Clin Endocrinol Metab*. 2001;86:4078–4088.
300. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: A prospective, randomized, double blind study. *J Clin Endocrinol Metab*. 2002;87:1467–1472.
301. Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. *J Clin Endocrinol Metab*. 2002;87:3125–3135.
302. Bhasin S, Calof OM, Storer TW, et al. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. *Nat Clin Pract Endocrinol Metab*. 2006;2:146–159.
303. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. *Clin Endocrinol (Oxf)*. 2005;63:280–293.
304. Tracz MJ, Sideras K, Bolona ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. *J Clin Endocrinol Metab*. 2006;91:2011–2016.
305. Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, Acha AA, Ostir GV. Androgen treatment and muscle strength in elderly men: A meta-analysis. *J Am Geriatr Soc*. 2006;54: 1666–1673.
306. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: Results of a meta-analysis. *Clin Endocrinol (Oxf)*. 2005;63:381–394.
307. Bolona ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: A systematic review and meta-analysis of randomized placebo-controlled trials. *Mayo Clin Proc*. 2007;82:20–28.
308. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. *J Gerontol A Biol Sci Med Sci*. 2005;60:1451–1457.
309. Liverman CT, Blazer DG, eds. *Testosterone and Aging: Clinical Research Directions*. Washington, DC: Institute of Medicine: The National Academies Press; 2004.
310. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal Results from the Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288:321–333.
311. Kalin MF, Zumoff B. Sex hormones and coronary disease: A review of the clinical studies. *Steroids*. 1990;55:330–352.
312. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. *Circulation*. 2007;116:2694–2701.
313. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. *J Clin Endocrinol Metab*. 2008;93:68–75.
314. Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. *Circulation*. 2005;112:332–340.

315. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. *Arch Intern Med*. 2007;167:1252–1260.
316. Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. *Arch Intern Med*. 2007;167:2249–2254.
317. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. *N Engl J Med*. 2010;363:109–122.
318. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trials. *BMC Med*. 2013;11:108.
319. Handelsman DJ. An old emperor finds new clothing: Rejuvenation in our time. *Asian J Androl*. 2011;13:125–129.
320. Zhang Y, Ouyang P, Post WS, et al. Sex-steroid hormones and electrocardiographic QT-interval duration: Findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. *Am J Epidemiol*. 2011;174:403–411.
321. Carnes CA, Dech SJ. Effects of dihydrotestosterone on cardiac inward rectifier K(+) current. *Int J Androl*. 2002;25:210–214.
322. Liu XK, Katchman A, Whitfield BH, et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. *Cardiovasc Res*. 2003;57:28–36.
323. Fulop L, Banyasz T, Szabo G, et al. Effects of sex hormones on ECG parameters and expression of cardiac ion channels in dogs. *Acta Physiol*. 2006;188:163–171.
324. Ridley JM, Shuba YM, James AF, Hancox JC. Modulation by testosterone of an endogenous hERG potassium channel current. *J Physiol Pharmacol*. 2008;59:395–407.
325. Wu ZY, Chen K, Haendler B, McDonald TV, Bian JS. Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-a-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2. *Endocrinology*. 2008;149:5061–5069.
326. Charbit B, Christin-Maitre S, Demolis JL, Soustre E, Young J, Funck-Brentano C. Effects of testosterone on ventricular repolarization in hypogonadic men. *Am J Cardiol*. 2009;103:887–890.
327. Pecori Giraldi F, Toja PM, Filippini B, et al. Increased prevalence of prolonged QT interval in males with primary or secondary hypogonadism: a pilot study. *Int J Androl*. 2010;33:e132–e138.
328. van Noord C, Rodenburg EM, Stricker BH. Invited commentary: Sex-steroid hormones and QT-interval duration. *Am J Epidemiol*. 2011;174:412–415.
329. Sieveking DP, Lim P, Chow RW, et al. A sex-specific role for androgens in angiogenesis. *J Exp Med*. 2010;207:345–352.
330. Wu FC, von Eckardstein A. Androgens and coronary artery disease. *Endocr Rev*. 2003;24:183–217.
331. Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA. Mortality in patients with Klinefelter syndrome in Britain: A cohort study. *J Clin Endocrinol Metab*. 2005;90:6516–6522.
332. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. *J Natl Cancer Inst*. 2008;100:170–183.
333. Conway AJ, Handelsman DJ, Lording DW, Stuckey B, Zajac JD. Use, misuse and abuse of androgens: The Endocrine Society of Australia consensus guidelines for androgen prescribing. *Med J Aust*. 2000;172:220–224.
334. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. *J Androl*. 2009;30:1–9.
335. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2010;95:2536–2559.
336. Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. *Med J Aust*. 2012;196:642–645.
337. Gan E, Pattman S, Pearce S, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. *Clin Endocrinol (Oxf)*. 2013.
338. Nigro N, Christ-Crain M. Testosterone treatment in the aging mal e: Myth or reality? *Swiss Med Wkly*. 2012;142:w13539.
339. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for a standardized monitoring plan. *J Androl*. 2003;24:299–311.
340. Tan RS, Salazar JA. Risks of testosterone replacement therapy in ageing men. *Expert Opin Drug Saf*. 2004;3:599–606.
341. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. *JAMA Intern Med*. 2013;173:1465–1466.
342. Handelsman DJ. Global trends in testosterone prescribing 2000-11: Expanding the spectrum of prescription drug misuse. *Med J Aust*. 2013;199:548–551.
343. Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. *J Sex Med*. 2009;6:1165–1170.
344. Nieschlag E. Male hormonal contraception. *Handb Exp Pharmacol*. 2010:197–223.
345. Handelsman DJ. Androgen therapy in non-gonadal disease. In: Nieschlag E, Behre HM, eds. *Testosterone: Action, Deficiency and Substitution*. 4th ed. Cambridge: Cambridge University Press; 2011:372–407.
346. Teruel JL, Aguilera A, Marcen R, Antolin JN, Otero GG, Ortuno J. Androgen therapy for anaemia of chronic renal failure. *Scand J Urol Nephrol*. 1996;30:403–408.
347. Gascon A, Belvis JJ, Berisa F, Iglesias E, Estopinan V, Teruel JL. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. *Geriatr Nephrol Urol*. 1999;9:67–72.
348. Navarro JF, Mora C, Macia M, Garcia J. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. *Kidney Int*. 2002;61:1537–1544.
349. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic-androgenic steroids. *Semin Liver Dis*. 1987;7:230–236.
350. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. *Am J Hematol*. 2004;77:257–267.
351. Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: Safety of long-term stanozolol therapy. *J Allergy Clin Immunol*. 2007;120:654–658.
352. Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: A current state-of-the-art review, V: Attenuated androgens for the treatment of hereditary angioedema. *Ann Allergy Asthma Immunol*. 2008;100:S19–S22.
353. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: A long-term survey of 118 patients. *Ann Allergy Asthma Immunol*. 2008;100:153–161.
354. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. *N Engl J Med*. 1996;335:1–7.
355. Elashoff JD, Jacknow AD, Shain SG, Braunstein GD. Effects of anabolic-androgenic steroids on muscular strength. *Ann Intern Med*. 1991;115:387–393.
356. Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. *J Clin Endocrinol Metab*. 2003;88:1478–1485.
357. Storer TW, Woodhouse L, Magliano L, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. *J Am Geriatr Soc*. 2008;56:1991–1999.
358. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. *J Clin Endocrinol Metab*. 2005;90:678–688.
359. Coviello AD, Lakshman K, Mazer NA, Bhasin S. Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. *J Clin Endocrinol Metab*. 2006;91:4669–4675.
360. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. *J Clin Endocrinol Metab*. 2008;93:914–919.

361. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. *J Clin Endocrinol Metab*. 2002;87:136–143.
362. Gray PB, Singh AB, Woodhouse LJ, et al. Dose-dependent effects of testosterone on sexual function, mood and visuospatial cognition in older men. *J Clin Endocrinol Metab*. 2005;90:3838–3846.
363. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. *Am J Clin Nutr*. 1989;50:444–447.
364. Moyle GJ, Schoelles K, Fahrbach K, et al. Efficacy of selected treatments of HIV wasting: A systematic review and meta-analysis. *J Acquir Immune Defic Syndr*. 2004;37(suppl 5):S262–S276.
365. Johns K, Beddall MJ, Corrin RC. Anabolic steroids for the treatment of weight loss in HIV-infected individuals. *Cochrane Database Syst Rev*. 2005. CD005483.
366. Bolding G, Sherr L, Maguire M, Elford J. HIV risk behaviours among gay men who use anabolic steroids. *Addiction*. 1999;94:1829–1835.
367. Lambert CP, Sullivan DH, Freeling SA, Lindquist DM, Evans WJ. Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: A randomized controlled trial. *J Clin Endocrinol Metab*. 2002;87:2100–2106.
368. Mulligan K, Zackin R, Von Roenn JH, et al. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: A randomized, double-blind, placebo-controlled, multicenter trial. *J Clin Endocrinol Metab*. 2007;92:563–570.
369. Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: An Endocrine Society Clinical Practice guideline. *J Clin Endocrinol Metab*. 2006;91:3697–3710.
370. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. *N Engl J Med*. 1999;341:1013–1020.
371. Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in primary adrenal insufficiency: A randomized, controlled trial. *J Clin Endocrinol Metab*. 2008;93:400–409.
372. Johannsson G, Burman P, Wiren L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: A placebo-controlled trial. *J Clin Endocrinol Metab*. 2002;87:2046–2052.
373. Lovas K, Gebre-Medhin G, Trovik TS, et al. Replacement of dehydroepiandrosterone in adrenal failure: No benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. *J Clin Endocrinol Metab*. 2003;88:1112–1118.
374. Miller KK, Biller BM, Beauregard C, et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: A randomized, double-blind, placebo-controlled study. *J Clin Endocrinol Metab*. 2006;91:1683–1690.
375. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *N Engl J Med*. 2000;343:682–688.
376. Davis S, Papalia MA, Norman RJ, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: A randomized trial. *Ann Intern Med*. 2008;148:569–577.
377. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. *Cochrane Database Syst Rev*. 2005. CD004509.
378. Greenblatt RB, Barfield WE, Garner JF, Calk GL, Harrod JP. Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause. *J Clin Endocrinol Metab*. 1950;10:1547–1558.
379. Sherwin BB, Gelfand MM. The role of androgens in the maintenance of sexual functioning in oophorectomized women. *Psychosom Med*. 1987;49:397–409.
380. Urman B, Pride SM, Yuen BH. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. *Obstet Gynecol*. 1991;77:1124–1131.
381. Gerritsma EJ, Brocaar MP, Hakkesteegt MM, Birkenhager JC. Virilization of the voice in post-menopausal women due to the anabolic steroid nandrolone decanoate (Decadurabolin). The effects of medication for one year. *Clin Otolaryngol Allied Sci*. 1994;19:79–84.
382. Baker J. A report on alterations to the speaking and singing voices of four women following hormonal therapy with virilizing agents. *J Voice*. 1999;13:496–507.
383. Davis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. *Maturitas*. 1995;21:227–236.
384. Braunstein GD. Safety of testosterone treatment in postmenopausal women. *Fertil Steril*. 2007;88:1–17.
385. Miller KK, Grieco KA, Klibanski A. Testosterone administration in women with anorexia nervosa. *J Clin Endocrinol Metab*. 2005;90:1428–1433.
386. Choi HH, Gray PB, Storer TW, et al. Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. *J Clin Endocrinol Metab*. 2005;90:1531–1541.
387. Gordon C, Wallace DJ, Shinada S, et al. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. *Rheumatology (Oxford)*. 2008;47:334–338.
388. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. *Chest*. 1998;114:19–28.
389. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2004;170:870–878.
390. Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. *Respir Med*. 2004;98:906–913.
391. Weisberg J, Wanger J, Olson J, et al. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. *Chest*. 2002;121:1070–1078.
392. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: Prevalence and detrimental impact on survival. *Circulation*. 2006;114:1829–1837.
393. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. *Eur Heart J*. 2006;27:57–64.
394. Handelsman DJ, Dong Q. Ontogenic regression: A model of stress and reproduction. In: Sheppard K, Boublik JH, Funder JW, eds. *Stress and Reproduction*. New York: Raven Press; 1992:333–345.
395. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. *Arch Intern Med*. 1996;156:1173–1177.
396. Crawford BA, Liu PY, Kean M, Bleasel J, Handelsman DJ. Randomised, placebo-controlled trial of androgen effects on bone and muscle in men requiring long-term systemic glucocorticoid therapy. *J Clin Endocrinol Metab*. 2003;88:3167–3176.
397. Jeschke MG, Finnerty CC, Suman OE, Kulp G, Mlcak RP, Herndon DN. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn. *Ann Surg*. 2007;246:351–360. discussion 360–362.
398. Bulger EM, Jurkovich GJ, Farver CL, Klotz P, Maier RV. Oxandrolone does not improve outcome of ventilator dependent surgical patients. *Ann Surg*. 2004;240:472–478. discussion 478–480.
399. Vandekerckhove P, Lilford R, Vail A, Hughes E. Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. *Cochrane Database Syst Rev*. 2000. CD000150.
400. Hoberman JM, Yesalis CE. The history of synthetic testosterone. *Sci Am*. 1995;272:76–81.
401. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: A secret program of the German Democratic Republic government. *Clin Chem*. 1997;43:1262–1279.
402. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. *Am J Physiol Endocrinol Metab*. 2001;281:E1172–E1181.
403. Pope Jr HG, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: A randomized controlled trial. *Arch Gen Psychiatry*. 2000;57:133–140. discussion 55–56.
404. Kanayama G, Hudson JI, Pope Jr HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: A looming public health concern? *Drug Alcohol Depend*. 2008;98:1–12.

405. Parkinson AB, Evans NA. Anabolic androgenic steroids: A survey of 500 users. *Med Sci Sports Exerc*. 2006;38:644–651.
406. Buckley WE, Yesalis CE, Freidl KE, Anderson WA, Streit AL, Wright JE. Estimated prevalence of anabolic steroid use among male high school students. *JAMA*. 1988;260:3441–3445.
407. Nilsson S. Androgenic anabolic steroid use among male adolescents in Falkenberg. *Eur J Clin Pharmacol*. 1995;48:9–11.
408. Handelsman DJ, Gupta L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian secondary school students. *Int J Androl*. 1997;20:159–164.
409. Lambert MI, Titlestad SD, Schwellnus MP. Prevalence of androgenic-anabolic steroid use in adolescents in two regions of South Africa. *S Afr Med J*. 1998;88:876–880.
410. Ferenchick GS. Validity of self-report in identifying anabolic steroid use among weightlifters. *J Gen Intern Med*. 1996;11:554–556.
411. Pope HG, Kouri EM, Powell KF, Campbell C, Katz DL. Anabolic-androgenic steroid use among 133 prisoners. *Compr Psychiatry*. 1996;37:322–327.
412. Isacsson G, Garle M, Ljung EB, Asgard U, Bergmen U. Anabolic steroids and violent crime—An epidemiological study at a jail in Stockholm, Sweden. *Compr Psychiatry*. 1998;39:203–205.
413. Catlin DH, Ahrens BD, Kucherova Y. Detection of norbolethone, an anabolic steroid never marketed, in athletes' urine. *Rapid Commun Mass Spectrom*. 2002;16:1273–1275.
414. Death AK, McGrath KC, Kazlauskas R, Handelsman DJ. Tetrahydrogestrinone is a potent androgen and progestin. *J Clin Endocrinol Metab*. 2004;89:2498–2500.
415. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang YC, Hatton CK. Tetrahydrogestrinone: Discovery, synthesis, and detection. *Rapid Commun Mass Spectrom*. 2004;18:1245–1249.
416. Sekera MH, Ahrens BD, Chang YC, Starcevic B, Georgakopoulos C, Catlin DH. Another designer steroid: Discovery, synthesis, and detection of 'madol' in urine. *Rapid Commun Mass Spectrom*. 2005;19:781–784.
417. Handelsman DJ, Heather A. Androgen abuse in sports. *Asian J Androl*. 2008;10:403–415.
418. vandenBerg P, Neumark-Sztainer D, Cafri G, Wall M. Steroid use among adolescents: Longitudinal findings from Project EAT. *Pediatrics*. 2007;119:476–486.
419. McCabe SE, Brower KJ, West BT, Nelson TF, Wechsler H. Trends in non-medical use of anabolic steroids by U.S. college students: Results from four national surveys. *Drug Alcohol Depend*. 2007;90:243–251.
420. Holma PK. Effects of an anabolic steroid (metandienone) on spermatogenesis. *Contraception*. 1977;15:151–162.
421. Knuth UA, Maniera H, Nieschlag E. Anabolic steroids and semen parameters in bodybuilders. *Fertil Steril*. 1989;52:1041–1047.
422. Turek PJ, Williams RH, Gilbaugh JH, Lipshultz LI. The reversibility of anabolic steroid-induced azoospermia. *J Urol*. 1995;153:1628–1630.
423. Sorensen M, Ingerslev HJ. Azoospermia in two bodybuilders taking anabolic steroids. *Ugeskr Laeger*. 1995;157:1044–1045.
424. Gazvani MR, Buckett W, Luckas MJ, Aird IA, Hipkin LJ, Lewis-Jones DI. Conservative management of azoospermia following steroid abuse. *Hum Reprod*. 1997;12:1706–1708.
425. Reyes RJ, Zicchi S, Hamed H, Chaudary MA, Fentiman IS. Surgical correction of gynaecomastia in bodybuilders. *Br J Clin Pract*. 1995;49:177–179.
426. Friedl KE. Reappraisal of health risks associated with use of high doses of oral and injectable androgenic steroids. *NIDA Res Monogr*. 1990;102:142–177.
427. Sklarek HM, Mantovani RP, Erens E, Heisler D, Niederman MS, Fein AM. AIDS in a bodybuilder using anabolic steroids [letter]. *N Engl J Med*. 1984;311:1701.
428. Nemechek PM. Anabolic steroid users—Another potential risk group for HIV infection [letter]. *N Engl J Med*. 1991;325:357.
429. Henrion R, Mandelbrot L, Delfieu D. HIV contamination after injections of anabolic steroids (letter). *Presse Med*. 1992;21:218.
430. Rich JD, Dickinson BP, Merriman NA, Flanigan TP. Hepatitis C virus infection related to anabolic-androgenic steroid injection in a recreational weight lifter [letter]. *Am J Gastroenterol*. 1998;93:1598.
431. Aitken C, Delalande C, Stanton K. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. *Drug Alcohol Depend*. 2002;65:303–308.
432. Rich JD, Dickinson BP, Feller A, Pugatch D, Mylonakis E. The infectious complications of anabolic-androgenic steroid injection. *Int J Sports Med*. 1999;20:563–566.
433. Khankhanian NK, Hammers YA. Exuberant local tissue reaction to intramuscular injection of nandrolone decanoate (Deca-Durabolin)—a steroid compound in sesame seed oil base—mimicking soft tissue malignant tumors: A case report and review of the literature. *Mil Med*. 1992;157:670–674.
434. Evans NA. Local complications of self administered anabolic steroid injections. *Br J Sports Med*. 1997;31:349–350.
435. Freeman BJ, Rooker GD. Spontaneous rupture of the anterior cruciate ligament after anabolic steroids. *Br J Sports Med*. 1995;29:274–275.
436. Daniels JM, van Westerloo DJ, de Hon OM, Frissen PH. Rhabdomyolysis in a bodybuilder using steroids. *Ned Tijdschr Geneeskd*. 2006;150:1077–1080.
437. Lepori M, Perren A, Gallino A. The popliteal-artery entrapment syndrome in a patient using anabolic steroids. *N Engl J Med*. 2002;346:1254–1255.
438. Sahraian MA, Mottamedi M, Azimi AR, Moghimi B. Androgen-induced cerebral venous sinus thrombosis in a young body builder: Case report. *BMC Neurol*. 2004;4:22.
439. Liljeqvist S, Hellden A, Bergman U, Soderberg M. Pulmonary embolism associated with the use of anabolic steroids. *Eur J Intern Med*. 2008;19:214–215.
440. Alaraj AM, Chamoun RB, Dahdaleh NS, Haddad GF, Comair YG. Spontaneous subdural haematoma in anabolic steroids dependent weight lifters: Reports of two cases and review of literature. *Acta Neurochir (Wien)*. 2005;147:85–87. discussion 87–88.
441. Petersson A, Garle M, Granath F, Thiblin I. Convulsions in users of anabolic androgenic steroids: Possible explanations. *J Clin Psychopharmacol*. 2007;27:723–725.
442. Pope HG, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. *Am J Psychiatry*. 1988;145:487–490.
443. Bahrke MS, Yesalis CE, Wright JE. Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among male. An update. *Sports Med*. 1996;22:367–390.
444. Rockhold RW. Cardiovascular toxicity of anabolic steroids. *Annu Rev Pharmacol Toxicol*. 1993;33:497–520.
445. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. *Med Sci Sports Exerc*. 1995;27:1252–1262.
446. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. *Prog Cardiovasc Dis*. 1998;41:1–15.
447. Dhar R, Stout CW, Link MS, Homoud MK, Weinstock J, Estes 3rd NA. Cardiovascular toxicities of performance-enhancing substances in sports. *Mayo Clin Proc*. 2005;80:1307–1315.
448. Furlanello F, Serdoz LV, Cappato R, De Ambroggi L. Illicit drugs and cardiac arrhythmias in athletes. *Eur J Cardiovasc Prev Rehabil*. 2007;14:487–494.
449. Larkin GL. Carcinoma of the prostate. *N Engl J Med*. 1991;324:1892.
450. Roberts JT, Essenhigh DM. Adenocarcinoma of prostate in 40 year old body-builder. *Lancet*. 1986;2:742.
451. Nakata S, Hasumi M, Sato J, Ogawa A, Yamanaka H. Prostate cancer associated with long-term intake of patent medicine containing methyltestosterone: A case report. *Hinyokika Kiyo—Acta Urologica Japonica*. 1997;43:791–793.
452. Hartgens F, Cheriex EC, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. *Int J Sports Med*. 2003;24:344–351.
453. Chung T, Kelleher S, Liu PY, Conway AJ, Kritharides L, Handelsman DJ. Effects of testosterone and nandrolone on cardiac function: A randomized, placebo-controlled study. *Clin Endocrinol (Oxf)*. 2007;66:235–245.
454. Jin B, Turner L, Walters WAW, Handelsman DJ. Androgen or estrogen effects on the human prostate. *J Clin Endocrinol Metab*. 1996;81:4290–4295.
455. Palatini P, Giada F, Garavelli G, et al. Cardiovascular effects of anabolic steroids in weight-trained subjects. *J Clin Pharmacol New Drugs*. 1996;36:1132–1140.
456. Krieg A, Scharhag J, Albers T, Kindermann W, Urhausen A. Cardiac tissue Doppler in steroid users. *Int J Sports Med*. 2007;28:638–643.

457. D'Andrea A, Caso P, Salerno G, et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: A Doppler myocardial and strain imaging analysis. *Br J Sports Med*. 2007;41:149–155.
458. Lane HA, Grace F, Smith JC, et al. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. *Eur J Clin Invest*. 2006;36:483–488.
459. Nottin S, Nguyen LD, Terbah M, Obert P. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. *Am J Cardiol*. 2006;97:912–915.
460. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? *Heart*. 2004;90:496–501.
461. Climstein M, O'Shea P, Adams KJ, DeBeliso M. The effects of anabolic-androgenic steroids upon resting and peak exercise left ventricular heart wall motion kinetics in male strength and power athletes. *J Sci Med Sport*. 2003;6:387–397.
462. Grace F, Sculthorpe N, Baker J, Davies B. Blood pressure and rate pressure product response in males using high-dose anabolic androgenic steroids (AAS). *J Sci Med Sport*. 2003;6:307–312.
463. Karila TA, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppala TA. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone. *Int J Sports Med*. 2003;24:337–343.
464. Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, Celermajer DS. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. *J Am Coll Cardiol*. 2001;37:224–230.
465. Di Bello V, Giorgi D, Bianchi M, et al. Effects of anabolic-androgenic steroids on weight-lifters' myocardium: An ultrasonic videodensitometric study. *Med Sci Sports Exerc*. 1999;31:514–521.
466. Dickerman RD, Schaller F, Zachariah NY, McConathy WJ. Left ventricular size and function in elite bodybuilders using anabolic steroids. *Clin J Sports Med*. 1997;7:90–93.
467. Di Bello V, Pedrinelli R, Giorgi D, et al. Ultrasonic videodensitometric analysis of two different models of left ventricular hypertrophy. Athlete's heart and hypertension. *Hypertension*. 1997;29:937–944.
468. Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: A review. *Fundam Clin Pharmacol*. 2005;19:27–44.
469. Sarna S, Sahi T, Koskenvuo M, Kaprio J. Increased life expectancy of world class male athletes. *Med Sci Sports Exerc*. 1993;25:237–244.
470. Sarna S, Kaprio J, Kujala UM, Koskenvuo M. Health status of former elite athletes. The Finnish experience. *Aging (Milano)*. 1997;9:35–41.
471. Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. *Int J Sports Med*. 2000;21:225–227.
472. Kashkin KB, Kleber HD. Hooked on hormones? An anabolic steroid addiction hypothesis. *JAMA*. 1989;262:3166–3170.
473. Fingerhood MI, Sullivan JT, Testa M, Jasinski DR. Abuse liability of testosterone. *J Psychopharmacol (Oxf)*. 1997;11:59–63.
474. Gill GV. Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin. *Postgrad Med J*. 1998;74:45–46.
475. Boyadjiev NP, Georgieva KN, Massaldjieva RI, Gueorguiev SI. Reversible hypogonadism and azoospermia as a result of anabolic-androgenic steroid use in a bodybuilder with personality disorder. A case report. *J Sports Med Phys Fitness*. 2000;40:271–274.
476. Torres-Calleja J, Gonzalez-Unzaga M, DeCelis-Carrillo R, Calzada-Sanchez L, Pedron N. Effect of androgenic anabolic steroids on sperm quality and serum hormone levels in adult male bodybuilders. *Life Sci*. 2001;68:1769–1774.
477. Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. *Fertil Steril*. 2003;79(suppl 3):1659–1661.
478. Drakeley A, Gazvani R, Lewis-Jones I. Duration of azoospermia following anabolic steroids. *Fertil Steril*. 2004;81:226.
479. Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. *J Urol*. 2000;164:1891–1894.
480. Kaku H, Saika T, Tsushima T, et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. *Prostate*. 2006;66:439–444.
481. Goldberg L, MacKinnon DP, Elliot DL, Moe EL, Clarke G, Cheong J. The adolescents training and learning to avoid steroids program: Preventing drug use and promoting health behaviors. *Arch Pediatr Adolesc Med*. 2000;154:332–338.
482. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. *J Clin Endocrinol Metab*. 1997;82:2386–2390.
483. Jockenhovel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. *Eur J Med Res*. 1997;2:293–298.
484. Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. *J Clin Endocrinol Metab*. 2000;85:2839–2853.
485. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. *J Clin Endocrinol Metab*. 2004;89:2085–2098.
486. Aminorroaya A, Kelleher S, Conway AJ, Ly LP, Handelsman DJ. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. *Eur J Endocrinol*. 2005;152:881–886.
487. Wong FH, Pun KK, Wang C. Loss of bone mass in patients with Klinefelter's syndrome despite sufficient testosterone replacement. *Osteoporos Int*. 1993;3:3–7.
488. Ishizaka K, Suzuki M, Kageyama Y, Kihara K, Yoshida K. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement. *Asian J Androl*. 2002;4:117–121.
489. Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K. Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. *J Clin Endocrinol Metab*. 2003;88:2784–2793.
490. Zacharin MR, Pua J, Kanumakala S. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism. *Clin Endocrinol (Oxf)*. 2003;58:691–695.
491. Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhovel F. Osteoporosis in male hypogonadism: Responses to androgen substitution differ among men with primary and secondary hypogonadism. *Horm Res*. 2003;60:21–28.
492. Finkelstein JS, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. *J Clin Endocrinol Metab*. 1996;81:1152–1155.
493. Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A. Osteopenia in men with a history of delayed puberty. *N Engl J Med*. 1992;326:600–604.
494. Huhtaniemi IT, Pye SR, Limer KL, et al. Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. *J Clin Endocrinol Metab*. 2009;94:277–284.
495. Kicman AT. Pharmacology of anabolic steroids. *Br J Pharmacol*. 2008;154:502–521.
496. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD. Discovery of nonsteroidal androgens. *Biochem Biophys Res Commun*. 1998;244:1–4.
497. Thevis M, Schanzer W. Mass spectrometry of selective androgen receptor modulators. *J Mass Spectrom*. 2008;43:865–876.
498. Lubahn D, Joseph DR, Sullivan PM, Williard HF, French FS, Wilson EM. Cloning of the human androgen receptor complementary DNA and localisation to the X-chromosome. *Science*. 1988;240:327–330.
499. Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. *Science*. 1988;240:324–326.
500. Trapman J, Klaassen P, Kuiper GG, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. *Biochem Biophys Res Commun*. 1988;153:241–248.
501. Wilson JD. The use and misuse of androgens. *Metabolism*. 1980;29:1278–1295.
502. Handelsman DJ. Commentary: Androgens and "anabolic steroids": The one-headed janus. *Endocrinology*. 2011;152:1752–1754.
503. Negro-Vilar A. Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millennium. *J Clin Endocrinol Metab*. 1999;84:3459–3462.

504. Idan A, Griffiths KA, Harwood DT, et al. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: A randomized, placebo-controlled trial. *Ann Intern Med*. 2010;153:621–632.
505. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. *Curr Opin Clin Nutr Metab Care*. 2009;12:232–240.
506. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. *J Clin Endocrinol Metab*. 1990;71:216–222.
507. Deansley R, Parkes AS. Further experiments on the administration of hormones by the subcutaneous implantation of tablets. *Lancet*. 1938;ii:606–608.
508. Kelleher S, Howe C, Conway AJ, Handelsman DJ. Testosterone release rate and duration of action of testosterone pellet implants. *Clin Endocrinol (Oxf)*. 2004;60:420–428.
509. Vierhapper H, Nowotny P, Waldhausl W. Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone. *Metabolism*. 2003;52:230–232.
510. Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ. Analysis of testosterone implants for androgen replacement therapy. *Clin Endocrinol (Oxf)*. 1997;47:311–316.
511. Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ. Extrusion of testosterone pellets: A randomized controlled clinical study. *Clin Endocrinol*. 1999;51:469–471.
512. Kelleher S, Conway AJ, Handelsman DJ. A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. *Eur J Endocrinol*. 2002;146:513–518.
513. Kelleher S, Conway AJ, Handelsman DJ. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. *Clin Endocrinol*. 2001;55:531–536.
514. Cavender RK, Fairall M. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: A single-site retrospective safety analysis. *J Sex Med*. 2009;6:3177–3192.
515. Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. *Lancet*. 1986;2:943–946.
516. Findlay JC, Place VA, Snyder PJ. Transdermal delivery of testosterone. *J Clin Endocrinol Metab*. 1987;64:266–268.
517. Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. *J Clin Endocrinol Metab*. 1992;74:623–628.
518. Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. *Clin Endocrinol (Oxf)*. 1997;47:727–737.
519. Shomaker TS, Zhang J, Ashburn MA. A pilot study assessing the impact of heat on the transdermal delivery of testosterone. *J Clin Pharmacol*. 2001;41:677–682.
520. Jordan Jr WP, Atkinson LE, Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: An investigational system and a marketed product. *Clin Ther*. 1998;20:80–87.
521. Jordan Jr WP. Allergy and topical irritation associated with transdermal testosterone administration: A comparison of scrotal and nonscrotal transdermal systems. *Am J Contact Dermat*. 1997;8:108–113.
522. Bennett NJ. A burn-like lesion caused by a testosterone transdermal system. *Burns*. 1998;24:478–480.
523. Wilson DE, Kaidbey K, Boike SC, Jorkasky DK. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. *Clin Ther*. 1998;20:299–306.
524. Guerin JF, Rollet J. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. *Int J Androl*. 1988;11:187–199.
525. Fiet J, Morville R, Chemana D, et al. Percutaneous absorption of 5a-dihydrotestosterone in man. I Plasma androgen and gonadotrophin levels in normal adult men after percutaneous administration of 5a-dihydrotestosterone. *Int J Androl*. 1982;5:586–594.
526. Chemana D, Morville R, Fiet J, et al. Percutaneous absorption of 5a-dihydrotestosterone in man. II Percutaneous administration of 5a-dihydrotestosterone in hypogonadal men with idiopathic haemochromatosis: Clinical, metabolic and hormonal effectiveness. *Int J Androl*. 1982;5:595–606.
527. Wang C, Iranmanesh A, Berman N, et al. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men—A clinical research center study. *J Clin Endocrinol Metab*. 1998;83:2749–2757.
528. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. *J Clin Endocrinol Metab*. 2000;85:4500–4510.
529. Rolf C, Kemper S, Lemmnitz G, Eickenberg U, Nieschlag E. Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men. *Eur J Endocrinol*. 2002;146:673–679.
530. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. *J Clin Endocrinol Metab*. 2003;88:2673–2681.
531. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. *BJU Int*. 2003;91:69–74.
532. Kuhnert B, Byrne M, Simoni M, et al. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. *Eur J Endocrinol*. 2005;153:317–326.
533. Wang C, Ilani N, Arver S, McLachlan RI, Soulis T, Watkinson A. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. *Clin Endocrinol (Oxf)*. 2011;75:836–843.
534. Muram D, Melby T, Alles Kingshill E. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men. *Curr Med Res Opin*. 2012;28:761–766.
535. Delanoe D, Fougeyrollas B, Meyer L, Thonneau P. Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. *Lancet*. 1984;i:276.
536. Moore N, Paux G, Noblet C, Andrejak M. Spouse-related drug side-effects. *Lancet*. 1988;1:468.
537. de Ronde W. Hyperandrogenism after transfer of topical testosterone gel: Case report and review of published and unpublished studies. *Hum Reprod*. 2009;24:425–428.
538. Yu YM, Punyasavatsu N, Elder D, D'Ercole AJ. Sexual development in a two-year-old boy induced by topical exposure to testosterone. *Pediatrics*. 1999;104:e23.
539. Bhowmick SK, Ricke T, Rettig KR. Sexual precocity in a 16-month-old boy induced by indirect topical exposure to testosterone. *Clin Pediatr (Phila)*. 2007;46:540–543.
540. Brachet C, Vermeulen J, Heinrichs C. Children's virilization and the use of a testosterone gel by their fathers. *Eur J Pediatr*. 2005;164:646–647.
541. Svoren BM, Wolfsdorf JI. Sexual development in a 21 month-old boy caused by testosterone contamination of a topical hydrocortisone cream. *J Pediatr Endocrinol Metab*. 2005;18:507–510.
542. Kunz GJ, Klein KO, Clemons RD, Gottschalk ME, Jones KL. Virilization of young children after topical androgen use by their parents. *Pediatrics*. 2004;114:282–284.
543. Franklin SL, Geffner ME. Precocious puberty secondary to topical testosterone exposure. *J Pediatr Endocrinol Metab*. 2003;16:107–110.
544. Stahlman J, Britto M, Fitzpatrick S, et al. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: Effects of clothing barrier on testosterone absorption. *Curr Med Res Opin*. 2012;28:291–301.
545. Mazer N, Fisher D, Fischer J, Cosgrove M, Bell D, Eilers B. Transfer of transdermally applied testosterone to clothing: A comparison of a testosterone patch versus a testosterone gel. *J Sex Med*. 2005;2:227–234.
546. Stahlman J, Britto M, Fitzpatrick S, et al. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel. *Curr Med Res Opin*. 2012;28:281–290.
547. Rolf C, Knie U, Lemmnitz G, Nieschlag E. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. *Clin Endocrinol (Oxf)*. 2002;56:637–641.
548. de Ronde W, Vogel S, Bui HN, Heijboer AC. Reduction in 24-hour plasma testosterone levels in subjects who showered 15 or 30 minutes after application of testosterone gel. *Pharmacotherapy*. 2011;31:248–252.

549. Burris AS, Ewing LL, Sherins RJ. Initial trial of slow-release testosterone microspheres in hypogonadal men. *Fertil Steril*. 1988;50:493–497.
550. Bhasin S, Swerdloff RS, Steiner B, et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. *J Clin Endocrinol Metab*. 1992;74:75–83.
551. Amory JK, Anawalt BD, Blaskovich PD, Gilchriest J, Nuwayser ES, Matsumoto AM. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. *J Androl*. 2002;23:84–91.
552. Page ST, Bremner WJ, Clark RV, et al. Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism. *J Androl*. 2008;29:222–227.
553. Amory JK, Bremner WJ. Oral testosterone in oil plus dutasteride in men: A pharmacokinetic study. *J Clin Endocrinol Metab*. 2005;90:2610–2617.
554. Amory JK, Page ST, Bremner WJ. Oral testosterone in oil: Pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. *J Androl*. 2006;27:72–78.
555. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. Enzyme induction by oral testosterone. *Clin Pharmacol Ther*. 1976;20:233–237.
556. Johnsen S. Long-term oral testosterone and liver function. *Lancet*. 1978;1:50.
557. Birzniece V, Meinhardt UJ, Handelsman DJ, Ho KK. Testosterone stimulates extra-hepatic but not hepatic fat oxidation (Fox): Comparison of oral and transdermal testosterone administration in hypopituitary men. *Clin Endocrinol (Oxf)*. 2009;71:715–721.
558. Birzniece V, Umpleby MA, Poljak A, Handelsman DJ, Ho KK. Oral low-dose testosterone administration induces whole-body protein anabolism in postmenopausal women: A novel liver-targeted therapy. *Eur J Endocrinol*. 2013;169:321–327.
559. Daggett PR, Wheeler MJ, Nabarro JD. Oral testosterone, a reappraisal. *Horm Res*. 1978;9:121–129.
560. Lee A, Rubinow K, Clark RV, et al. Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism. *J Androl*. 2012;33:420–426.
561. Amory JK, Bush MA, Zhi H, et al. Oral testosterone with and without concomitant inhibition of 5alpha-reductase by dutasteride in hypogonadal men for 28 days. *J Urol*. 2011;185:626–632.
562. Salehian B, Wang C, Alexander G, et al. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: Comparison to testosterone enanthate—A clinical research center study. *J Clin Endocrinol Metab*. 1995;80:3567–3575.
563. Dobs AS, Hoover DR, Chen MC, Allen R. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: A pilot study. *J Clin Endocrinol Metab*. 1998;83:33–39.
564. Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. *J Sex Med*. 2005;2:213–226.
565. Mostaghel EA, Lin DW, Amory JK, et al. Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: A randomized, controlled trial. *J Clin Endocrinol Metab*. 2012;97:2809–2817.
566. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: A randomized controlled trial. *JAMA*. 2006;296:2351–2361.
567. Page ST, Lin DW, Mostaghel EA, et al. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. *J Clin Endocrinol Metab*. 2011;96:430–437.
568. Junkman K. Long-acting steroids in reproduction. *Recent Prog Horm Res*. 1957;13:380–419.
569. Minto C, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: Effects of ester, injection site and volume. *J Pharmacol Exp Ther*. 1997;281:93–102.
570. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. *J Clin Endocrinol Metab*. 1980;51:1335–1339.
571. Cantrill JA, Dewis P, Large DM, Newman M, Anderson DC. Which testosterone replacement therapy? *Clin Endocrinol (Oxf)*. 1984;24:97–107.
572. Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ. A randomised clinical trial of testosterone replacement therapy in hypogonadal men. *Int J Androl*. 1988;11:247–264.
573. Behre HM, Wang C, Handelsman DJ, Nieschlag E. Pharmacology of testosterone preparations. In: Nieschlag E, Behre HM, eds. *Testosterone: Action Deficiency Substitution*. 3rd ed. Cambridge: Cambridge University Press; 2004:405–444.
574. Weinbauer GF, Marshall GR, Nieschlag E. New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months. *Acta Endocrinol*. 1986;113:128–132.
575. Behre HM, Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: Pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. *J Clin Endocrinol Metab*. 1992;75:1204–1210.
576. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E. Potential of testosterone buciclate for male contraception: Endocrine differences between responders and nonresponders. *J Clin Endocrinol Metab*. 1995;80:2394–2403.
577. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. *J Androl*. 1998;19:761–768.
578. Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. *Clin Endocrinol (Oxf)*. 1999;51:757–763.
579. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: A phase II study. *J Androl*. 2002;23:419–425.
580. Schubert M, Minnemann T, Hubler D, et al. Intramuscular testosterone undecanoate: Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. *J Clin Endocrinol Metab*. 2004;89:5429–5434.
581. Gu YQ, Wang XH, Xu D, et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. *J Clin Endocrinol Metab*. 2003;88:562–568.
582. Gu YQ, Tong JS, Ma DZ, et al. Male hormonal contraception: Effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. *J Clin Endocrinol Metab*. 2004;89:2254–2262.
583. Qoubaitary A, Meriggiola C, Ng CM, et al. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. *J Androl*. 2006;27:853–867.
584. Mommers E, Kersemaekers WM, Elliesen J, et al. Male hormonal contraception: A double-blind, placebo-controlled study. *J Clin Endocrinol Metab*. 2008;93:2572–2580.
585. Jockenhovel F, Minnemann T, Schubert M, et al. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. *Eur J Endocrinol*. 2009;160:815–819.
586. Kohn FM, Schill WB. A new oral testosterone undecanoate formulation. *World J Urol*. 2003;21:311–315.
587. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS. Important effect of food on the bioavailability of oral testosterone undecanoate. *Pharmacotherapy*. 2003;23:319–325.
588. Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB. The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. *Clin Endocrinol (Oxf)*. 2007;66:579–585.
589. Roth MY, Dudley RE, Hull L, et al. Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5alpha-reductase by finasteride. *Int J Androl*. 2011;34:541–547.
590. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. *J Androl*. 1994;15:212–215.
591. Tauber U, Schroder K, Dusterberg B, Matthes H. Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. *Eur J Drug Metab Pharmacokinet*. 1986;11:145–149.
592. Ahmed SF, Tucker P, Mayo A, Wallace AM, Hughes IA. Randomized, crossover comparison study of the short-term effect of oral testosterone undecanoate and intramuscular testosterone depot on linear growth and serum bone alkaline phosphatase. *J Pediatr Endocrinol Metab*. 2004;17:941–950.

593. Butler GE, Sellar RE, Walker RF, Hendry M, Kelnar CJH, Wu FCW. Oral testosterone undecanoate in the management of delayed puberty in boys: Pharmacokinetics and effects on sexual maturation and growth. *J Clin Endocrinol Metab*. 1992;75:37–44.
594. Brown DC, Butler GE, Kelnar CJ, Wu FC. A double blind, placebo controlled study of the effects of low dose testosterone undecanoate on the growth of small for age, prepubertal boys. *Arch Dis Child*. 1995;73:131–135.
595. Albanese A, Kewley GD, Long A, Pearl KN, Robins DG, Stanhope R. Oral treatment for constitutional delay of growth and puberty in boys: A randomised trial of an anabolic steroid or testosterone undecanoate. *Arch Dis Child*. 1994;71:315–317.
596. Luisi M, Franchi E. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. *J Endocrinol Invest*. 1980;3:305–308.
597. Androgen therapy of aplastic anaemia—A prospective study of 352 cases. *Scand J Haematol*. 1979;22:343–356.
598. Shimoda K, Shide K, Kamezaki K, et al. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: Retrospective analysis of 39 patients in Japan. *Int J Hematol*. 2007;85:338–343.
599. Gennari C, AgnusDei D, Gonnelli S, Nardi P. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: A double-blind placebo-controlled study. *Maturitas*. 1989;11:187–197.
600. Frisoli Jr A, Chaves PH, Pinheiro MM, Szejnfeld VL. The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: A double-blind, randomized, placebo-controlled clinical trial. *J Gerontol A Biol Sci Med Sci*. 2005;60:648–653.
601. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. *Endocr Rev*. 1994;15:342–355.
602. Hong Y, Yu B, Sherman M, Yuan YC, Zhou D, Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. *Mol Endocrinol*. 2007;21:401–414.
603. Hobbs CJ, Jones RE, Plymate SR. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. *J Clin Endocrinol Metab*. 1996;81:1582–1585.
604. Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. *Hum Reprod*. 2001;16:2570–2577.
605. Attardi BJ, Pham TC, Radler LC, Burgenson J, Hild SA, Reel JR. Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase. *J Steroid Biochem Mol Biol*. 2008;110:214–222.
606. Lemus AE, Enriquez J, Garcia GA, Grillasca I, Perez-Palacios G. 5alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency. *J Steroid Biochem Mol Biol*. 1997;60:121–129.
607. Geusens P. Nandrolone decanoate: Pharmacological properties and therapeutic use in osteoporosis. *Clin Rheumatol*. 1995;14:32–39.
608. Sundaram K, Kumar N. 7alpha-methyl-19-nortestosterone (MENT): The optimal androgen for male contraception and replacement therapy. *Int J Androl*. 2000;23(suppl 2):13–15.
609. Cook CE, Kepler JA. 7alpha,11beta-Dimethyl-19-nortestosterone: A potent and selective androgen response modulator with prostate-sparing properties. *Bioorg Med Chem Lett*. 2005;15:1213–1216.
610. Suvisaari J, Sundaram K, Noe G, et al. Pharmacokinetics and pharmacodynamics of 7a-methyl-19-nortestosterone after intramuscular administration in healthy men. *Hum Reprod*. 1997;12:967–973.
611. Sundaram K, Kumar N, Bardin CW. 7 alpha-Methyl-19-nortestosterone: An ideal androgen for replacement therapy. *Recent Prog Horm Res*. 1994;49:373–376.
612. Sundaram K, Kumar N, Bardin CW. 7a-Methyl-nortestosterone (MENT): The optimal androgen for male contraception. *Ann Med*. 1993;25:199–205.
613. Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: A new potent orally active androgen with progestational activity. *Endocrinology*. 2006;147:3016–3026.
614. Attardi BJ, Engbring JA, Gropp D, Hild SA. Development of dimethandrolone 17beta-undecanoate (DMAU) as an oral male hormonal contraceptive: Induction of infertility and recovery of fertility in adult male rabbits. *J Androl*. 2011;32:530–540.
615. Sundaram K, Kumar N, Monder C, Bardin CW. Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens. *J Steroid Biochem Mol Biol*. 1995;53:253–257.
616. Toth M, Zakar T. Relative binding affinities of testosterone, 19-nortestosterone and their 5 alpha-reduced derivatives to the androgen receptor and to other androgen-binding proteins: A suggested role of 5 alpha-reductive steroid metabolism in the dissociation of "myotropic" and "androgenic" activities of 19-nortestosterone. *J Steroid Biochem*. 1982;17:653–660.
617. Attardi BJ, Hild SA, Koduri S, et al. The potent synthetic androgens, dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone, do not require 5alpha-reduction to exert their maximal androgenic effects. *J Steroid Biochem Mol Biol*. 2010;122:212–218.
618. LaMorte A, Kumar N, Bardin CW, Sundaram K. Aromatization of 7 alpha-methyl-19-nortestosterone by human placental microsomes in vitro. *J Steroid Biochem Mol Biol*. 1994;48:297–304.
619. Moslemi S, Dintinger T, Dehennin L, Silberzahn P, Gaillard JL. Different in vitro metabolism of 7 alpha-methyl-19-nortestosterone by human and equine aromatases. *Eur J Biochem*. 1993;214:569–576.
620. Yin D, Xu H, He Y, Kirkovsky LI, Miller DD, Dalton JT. Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. *J Pharmacol Exp Ther*. 2002;304:1323–1333.
621. Gao W, Dalton JT. Ockham's razor and selective androgen receptor modulators (SARMs): Are we overlooking the role of 5alpha-reductase? *Mol Interv*. 2007;7:10–13.
622. Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: Mechanisms of efficiency and resistance. *Adv Exp Med Biol*. 2008;630:206–219.
623. Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). *Drug Discov Today*. 2007;12:241–248.
624. Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: A review of the literature. *Urol Int*. 2004;73:289–295.
625. Manso G, Thole Z, Salgueiro E, Revuelta P, Hidalgo A. Spontaneous reporting of hepatotoxicity associated with antiandrogens: Data from the Spanish pharmacovigilance system. *Pharmacoepidemiol Drug Saf*. 2006;15:253–259.
626. Minnemann T, Schubert M, Hubler D, et al. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. *Aging Male*. 2007;10:155–158.
627. Saad F, Kamischke A, Yassin A, et al. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. *Asian J Androl*. 2007;9:291–297.
628. Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: A retrospective medical claims analysis. *J Sex Med*. 2013;10:1401–1409.
629. Stege R, Frohlander N, Carlstrom K, Pousette A, von Schoultz B. Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: Effects of parenteral and oral estrogen therapy. *Prostate*. 1987;10:333–338.
630. Serin IS, Ozcelik B, Basbug M, Aygen E, Kula M, Erez R. Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels. *Eur J Obstet Gynecol Reprod Biol*. 2001;99:222–225.
631. von Schoultz B, Carlstrom K. On the regulation of sex-hormone-binding globulin. A challenge of an old dogma and outlines of an alternative mechanism. *J Steroid Biochem Mol Biol*. 1989;32:327–334.
632. Small M, Beastall GH, Semple CG, Cowan RA, Forbes CD. Alterations of hormone levels in normal males given the anabolic steroid stanozolol. *Clin Endocrinol (Oxf)*. 1984;21:49–55.
633. Christiansen K. Behavioural correlates of testosterone. In: Nieschlag E, Behre HM, eds. *Testosterone: Action Deficiency Substitution*. 3rd ed. Cambridge: Cambridge University Press; 2004:125–172.

634. Anderson RA, Bancroft J, Wu FCW. The effects of exogenous testosterone on sexuality and mood of normal men. *J Clin Endocrinol Metab*. 1992;75:1503–1507.
635. Buena F, Peterson MA, Swerdloff RS, et al. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. *Fertil Steril*. 1993;59:1118–1123.
636. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. *J Clin Endocrinol Metab*. 1994;79:561–567.
637. Tricker R, Casaburi R, Storer TW, et al. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men—A clinical research center study. *J Clin Endocrinol Metab*. 1996;81:3754–3758.
638. O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. *Physiol Behav*. 2002;75:557–566.
639. O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: A double-blind, placebo-controlled, cross-over study. *J Clin Endocrinol Metab*. 2004;89:2837–2845.
640. Meriggiola MC, Cerpolini S, Bremner WJ, et al. Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men. *Hum Reprod*. 2006;21:2033–2040.
641. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR. Neuropsychiatric effects of anabolic steroids in male normal volunteers. *JAMA*. 1993;269:2760–2764.
642. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. *Biol Psychiatry*. 1999;45:254–260.
643. Daly RC, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. *Psychoneuroendocrinology*. 2003;28:317–331.
644. Schmidt PJ, Berlin KL, Danaceau MA, et al. The effects of pharmacologically induced hypogonadism on mood in healthy men. *Arch Gen Psychiatry*. 2004;61:997–1004.
645. WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. *Fertil Steril*. 1996;65:821–829.
646. WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. *Lancet*. 1990;336:955–959.
647. Bjorkvist K, Nygren T, Bjorklund AC, Bjorkvist SE. Testosterone intake and aggressiveness: Real effect or anticipation? *Aggress Behav*. 1994;20:17–26.
648. Archer J. The influence of testosterone on human aggression. *Br J Psychiatry*. 1991;82:1–28.
649. Melnik B, Jansen T, Grabbe S. Abuse of anabolic-androgenic steroids and bodybuilding acne: An underestimated health problem. *J Dtsch Dermatol Ges*. 2007;5:110–117.
650. Grunstein RR, Handelsman DJ, Lawrence SJ, Blackwell C, Caterson ID, Sullivan CE. Hypothalamic dysfunction in sleep apnea: Reversal by nasal continuous positive airways pressure. *J Clin Endocrinol Metab*. 1989;68:352–358.
651. Sandblom RE, Matsumoto AM, Scoene RB, et al. Obstructive sleep apnea induced by testosterone administration. *N Engl J Med*. 1983;308:508–510.
652. Liu PY, Yee BJ, Wishart SM, et al. The short-term effects of high dose testosterone on sleep, breathing and function in older men. *J Clin Endocrinol Metab*. 2003;88:3605–3613.
653. Welder AA, Robertson JW, Melchert RB. Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures. *J Pharmacol Toxicol Methods*. 1995;33:187–195.
654. Gitlin N, Korner P, Yang HM. Liver function in postmenopausal women on estrogen-androgen hormone replacement therapy: A meta-analysis of eight clinical trials. *Menopause*. 1999;6:216–224.
655. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: A review of the safety literature, 1941 to 1996. *Clin Ther*. 1997;19:383–404. discussion 367–368.
656. Pertusi R, Dickerman RD, McConathy WJ. Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: Hepatitis or rhabdomyolysis? *J Am Osteopath Assoc*. 2001;101:391–394.
657. Tsokos M, Erbersdobler A. Pathology of peliosis. *Forensic Sci Int*. 2005;149:25–33.
658. Falk H, Thomas LB, Popper H, Ishak KG. Hepatic angiosarcoma associated with androgenic-anabolic steroids. *Lancet*. 1979;2:1120–1123.
659. Daneshmend TK, Bradfield JW. Hepatic angiosarcoma associated with androgenic-anabolic steroids. *Lancet*. 1979;2:1249.
660. Mackey MA, Conway AJ, Handelsman DJ. Tolerability of intramuscular injections of testosterone ester in an oil vehicle. *Hum Reprod*. 1995;10:862–865.
661. Gu Y, Liang X, Wu W, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. *J Clin Endocrinol Metab*. 2009;94:1910–1915.
662. Bhagat R, Holmes IH, Kulaga A, Murphy F, Cockcroft DW. Self-injection with olive oil. A cause of lipoid pneumonia. *Chest*. 1995;107:875–876.
663. Darsow U, Bruckbauer H, Worret WI, Hofmann H, Ring J. Subcutaneous oleomas induced by self-injection of sesame seed oil for muscle augmentation. *J Am Acad Dermatol*. 2000;42:292–294.
664. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. *J Clin Endocrinol Metab*. 2006;91:4335–4343.
665. Jockenhovel F, Minnemann T, Schubert M, et al. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood. *Aging Male*. 2009;12:113–118.
666. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. *Endocr Rev*. 1987;8:1–28.
667. Palacios A, Campfield LA, McClure RD, Steiner B, Swerdloff RS. Effect of testosterone enanthate on hematopoesis in normal men. *Fertil Steril*. 1983;40:100–104.
668. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. *J Am Geriatr Soc*. 1995;43:899–901.
669. Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ, Liu PY. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. *Eur J Endocrinol*. 2010;162:385–390.
670. Viallard JF, Marit G, Mercie P, Leng B, Reiffers J, Pellegrin JL. Polycythaemia as a complication of transdermal testosterone therapy. *Br J Haematol*. 2000;110:237–238.
671. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2012;87:285–293.
672. Siddique H, Smith JC, Corrall RJ. Reversal of polycythaemia induced by intramuscular androgen replacement using transdermal testosterone therapy. *Clin Endocrinol (Oxf)*. 2004;60:143–145.
673. Wu JP, Gu FL. The prostate 41-65 years post castration. *Chin Med J (Engl)*. 1987;100:271–272.
674. Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA. Cancer incidence and mortality in men with Klinefelter syndrome: A cohort study. *J Natl Cancer Inst*. 2005;97:1204–1210.
675. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. *Clin Endocrinol (Oxf)*. 1994;40:341–349.
676. Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. *Clin Endocrinol (Oxf)*. 2001;54:437–445.
677. Handelsman DJ. The safety of androgens: Prostate and cardiovascular disease. In: Wang C, ed. *Male Reproductive Function*. Boston: Kluwer Academic Publishers; 1998:173–190.
678. Fowler Jr JE, Whitmore Jr WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. *J Urol*. 1981;126:372–375.
679. Fowler Jr JE, Whitmore Jr WF. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. *Cancer*. 1982;49:1373–1377.
680. Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: Clinical experience and practical applications. *Urol Clin North Am*. 2006;33:167–179. vi.
681. Feltquate D, Nordquist L, Eicher C, et al. Rapid androgen cycling as treatment for patients with prostate cancer. *Clin Cancer Res*. 2006;12:7414–7421.

682. Manni A, Bartholomew M, Caplan R, et al. Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome. *J Clin Oncol*. 1988;6: 1456–1466.
683. Santen RJ, Manni A, English HF, Heitjan D. Androgen-primed chemotherapy-experimental confirmation of efficacy. *J Steroid Biochem Mol Biol*. 1990;37:1115–1120.
684. Szmulewitz R, Mohile S, Posadas E, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. *Eur Urol*. 2009;56:97–103.
685. Morris MJ, Huang D, Kelly WK, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. *Eur Urol*. 2009;56:237–244.
686. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. *J Urol*. 2004;172:920–922.
687. Rhoden EL, Averbeck MA, Teloken PE. Androgen replacement in men undergoing treatment for prostate cancer. *J Sex Med*. 2008;5:2202–2208.
688. Morgentaler A. Testosterone therapy in men with prostate cancer: Scientific and ethical considerations. *J Urol*. 2009;181:972–979.
689. Hormones in advanced cancer. *Br Med J*. 1971;2:760–763.
690. Muggia FM. Overview of cancer-related hypercalcemia: Epidemiology and etiology. *Semin Oncol*. 1990;17:3–9.